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1. Abstract of the dissertation 
 
Spinal cord injury (SCI) is characterized by axonal damage, neural degeneration, formation of 
cystic cavities, and upregulation of a plethora of inhibitory as well as inflammatory molecules. 
To protect the surrounding tissue from further damage, fibroblasts and reactive astrocytes form 
an impenetrable barrier lining the lesion site. This environment impedes endogenous 
regeneration of axotomized neurons and glial cells. In addition to being exposed to extrinsic 
inhibitors of axonal regeneration after SCI, neurons in the mammalian central nervous system 
(CNS) intrinsically lack the capacity for spontaneous axonal regeneration. To restore neural 
tissue integrity and provide a favorable environment for injured axons to regenerate, an 
appropriate substrate is needed. An optimal substrate for neuroregeneration should have a 
neural identity and fulfill several functions including physical support and guidance, trophic and 
metabolic support, maintenance of tissue homeostasis, and modulation of neuronal outgrowth 
and network activity. Astrocytes represent the most suitable cell population to fulfill this task. 
Induced pluripotent stem cells (iPSCs), which show many homologies to embryonic stem cells 
(ESCs), represent an ethically acceptable means to obtain large amounts of astrocytes in vitro 
for autologous transplantation. 
In the present study, populations of immature astrocytes with caudal identity were generated 
from three human pluripotent stem cell (PSC) lines, whereby terminal in vitro differentiation 
was performed according to previously published studies using the inductors of astrocytic 
maturation CNTF, BMP2/4 and FGF1 to allow for comparative analysis of specific astrocytic 
subtypes and for selection of a pro-regenerative cell population. 
In accordance with previously published findings, morphological and functional differences 
among astrocytic populations were observed in the present study. Compared to astrocytes 
differentiated with FBS only, astrocytes differentiated with BMP2/4 exhibited a significantly 
increased cell size and a complex cytoarchitecture, decreased expression of the NSC marker 
Sox2, increased production of potentially growth-inhibitory extracellular matrix (ECM) 
components and of the growth-promoting neurotrophic factor BDNF, and limited ability to 
induce neurite outgrowth in co-cultures with primary dorsal root ganglion (DRG) neurons. 
Astrocytes differentiated with FGF1 were, in contrast, significantly smaller, mainly had a bipolar 
morphology and retained expression of the NSC marker Sox2, indicative of a rather immature 
phenotype. On the other side, differentiation with FBS alone or in combination with CNTF led to 
astrocytes that produced the pro-regenerative ECM component laminin, which was reflected in 
a strong growth-promoting effect on primary DRG neurons. Importantly, clear differences 
across the three used pluripotent stem cell (PSC) lines were observed; in particular, differences 
in the electrophysiological response pattern elicited by stimulation with adenosine triphosphate 
(ATP) indicated that astrocytic lines with a similar phenotypic profile have distinct 
characteristics. After transplantation into the intact and injured spinal cord of Fischer 344 rats, 
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some of these phenotypical characteristics observed in vitro were maintained in vivo. This is 
indicative of a stable phenotype of pre-differentiated astrocytes, which allows the selection of 
an astrocytic subtype in vitro to maximize the pro-regenerative effect of cell transplantation 
after SCI. However, the present study also sheds light on the risks associated with the use of 
human iPSCs as appreciable cell survival in the injured spinal cord was associated with a 
predisposition of grafted cells to form tumors. This was particularly evident in the intact spinal 
cord.  
In summary, the present study provides a comparative overview over astrocytic features and 
pinpoints inclusion or exclusion criteria for transplantation after SCI. These criteria can be used 
to estimate the pro-regenerative ability of astrocytic populations and to predict the potential of 
PSC-derived progeny to form tumors. 
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1. Zusammenfassung der Dissertation 
 
Traumatische Verletzungen des Rückenmarks führen zu axonalem Schäden, Verlust von 
neuralem Gewebe, zur Entstehung von Zysten und zur Hochregulierung von zahlreichen 
inhibitorischen und inflammatorischen Molekülen. Um das umliegende Gewebe vor 
zusätzlichen bzw. sekundären Schäden zu schützen bilden Fibroblasten und reaktive Astrozyten 
eine undurchdringliche Barriere um die Läsionsstelle herum. Dieses Milieu erschwert die 
endogene Regeneration beschädigter Neurone und glialen Zellen. In der Folge der Verletzung 
sind beschädigte Neurone des zentralen Nervensystems (ZNS) von Säugetieren extrinsischen 
Inhibitoren axonaler Regeneration ausgesetzt. Darüber hinaus fehlt den Neuronen die 
intrinsische Fähigkeit spontan zu regenerieren. Um die Integrität des neuralen Gewebes 
wiederherzustellen und um die Regeneration von beschädigten Neuronen durch ein 
Wachstumsförderndes Milieus zu begünstigen ist die Unterstützung durch ein entsprechendes 
Substrat notwendig. Ein optimales Substrat für die Neuroregeneration sollte einen neuralen 
Phänotyp aufweisen und verschiedene Funktionen, wie die physische, trophische und 
metabolische Unterstützung, die Regulierung axonaler Wegfindung, die Aufrechterhaltung der 
Gewebe-Homöostase sowie die Modulierung von neuronalem Wachstum und Netzwerk-
Aktivität, erfüllen. Aufgrund dieser Anforderungen stellen Astrozyten eine optimale 
Zellpopulation dar, um diese Aufgaben zu erfüllen. Induzierte pluripotente Stammzellen (iPSZ), 
die zahlreiche Gemeinsamkeiten mit embryonalen Stammzellen (ESZ) aufweisen, stellen eine 
ethisch vertretbare Möglichkeit dar, Astrozyten für autologe Transplantation in ausreichender 
Zahl in vitro zu generieren. 
Basierend auf bereits veröffentlichten Studien wurden hier Populationen von Astrozyten mit 
kaudalem Phänotyp aus drei humanen pluripotenten Stammzell- (PSZ)-Linien generiert. Ihre in 
vitro End-Differenzierung wurde dabei mit den Induktoren der astrozytären Reifung CNTF, 
BMP2/4 und FGF1 durchgeführt. Dadurch ergibt sich die Möglichkeit eines komparativen 
Vergleiches der daraus entstandenen astrozytären Subtypen und der Selektion einer pro-
regenerativen Zellpopulation.  
In Einklang mit der vorhandenen Fachliteratur wurden morphologische und funktionelle 
Unterschiede beobachtet. Astrozyten die mit BMP2/4 differenziert wurden zeigten signifikant 
erhöhte Zellgröße und komplexere Zytoarchitektur, niedrigere Expression des neuralen 
Stammzell (NSZ) Markers Sox2, erhöhte Produktion von potentiell wachstumshemmenden 
Komponenten der extrazellulären Matrix (EZM) und des wachstumsfördernden neurotrophen 
Faktors BDNF, so wie eine beschränkte Fähigkeit, Neuritenwachstum in co-Kulturen mit 
primären Spinalganglion Neuronen zu fördern. Mit FGF1 differenzierte Astrozyten waren 
demgegenüber signifikant kleiner, bipolar in ihrer Morphologie und zeigten Expression den NSZ 
Markers Sox2, was auf einen nicht ausdifferenzierten Phänotyp hinweist. Differenzierung mit 
FBS alleine oder in Kombination mit CNTF, wiederum, führte zu Astrozyten, welche die pro-
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regenerative EZM Komponente Laminin produzierten, was sich in einem starken 
wachstumsfördernden Effekt widerspiegelte. Zwischen den drei pluripotenten Stammzell- (PSZ) 
Linien wurden signifikante Unterschiede beobachtet, vor allem in Bezug auf ihre 
elektrophysiologischen Reaktionen auf Stimulation mit Adenosintriphosphat (ATP). Diese 
Diskrepanzen deuten darauf hin, dass astrozytäre Linien trotz eines ähnlichen phänotypischen 
Profils einen individuellen elektrophysiologischen Charakter aufweisen. Nach Transplantation in 
das intakte und verletzte Rückenmark von Fischer 344 Ratten wurden einige der in vitro 
beobachteten Eigenschaften beibehalten, was darauf hinweist, dass prä-differenzierte 
Astrozyten einen stabilen Phänotyp haben. Diese Eigenschaft ermöglicht die frühe Selektion 
eines geeigneten astrozytären Subtyps in vitro, der den pro-regenerativen Effekt der 
Zelltransplantation infolge eines Rückenmarktraume maximieren kann. Auf der anderen Seite 
bestätigt diese Studie auch Risiken, die im Zusammenhang mit der Anwendung von iPSZ stehen. 
Ein beträchtliches Zellüberleben im verletzten Rückenmark korrelierte demnach mit der 
Prädisposition der transplantierten Zellen, Tumore zu erzeugen.  Dieser Zusammenhang war vor 
allem im intakten Rückenmark deutlich ausgeprägt. 
Zusammenfassend verschafft diese Studie einen komparativen Überblick über astrozytäre 
Eigenschaften und über Einschluss-/Ausschlusskriterien für Transplantation nach 
Rückenmarktrauma. Diese Kriterien sind geeignet, die wachstumsfördernde Fähigkeit von 
astrozytäre Subtypen einzuschätzen und das tumorigene Potential von PSZ Tochterzellen 
vorherzusehen/zu prognostizieren. 
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2. Introduction  
 
2.1. Spinal cord injury: clinical state 
 
2.1.1. Injury of the spinal cord 
 
Injury of the spinal cord can be caused by compression, contusion or penetration of the spinal 
cord and leads to massive degeneration of neural tissue, formation of liquid-filled cysts and 
cavities, and the accumulation of cellular debris and inflammatory cells. Degeneration of 
neurons and glia and the disruption of ascending, descending and intraspinal projections result 
in the loss of sensory, motor and autonomic function [1]. Under these conditions functional 
recovery is only possible if spared projections take over the function of degenerated axons by 
creating new connections. This process is called regeneration if new connections are formed by 
an injured neuron, which extends an axon from its cut end, from its shaft (formation of new 
branches) or from a non-injured branch, while sprouting refers to new connections formed by 
non-injured neurons [2]. Sprouting is a compensatory mechanism which occurs in response to 
injury of other axons. To protect the surrounding tissue from further damage infiltrating 
meningeal cells and reactive astrocytes form an impenetrable barrier lining the lesion site [3]. 
The formation of liquid-filled cysts, the upregulation of inflammatory and inhibitory molecules 
and the confinement of the lesion environment by the glial scar represent an impermeable 
environment that prevents endogenous regeneration of axotomized neurons and lost glial cells 
[4].  
 
2.1.2. Incidence of spinal cord injury and impact on society 
 
Spinal cord injury (SCI) mostly results from a traumatic event, commonly traffic / motor vehicle 
crashes, falls, sports accidents and violence. The resulting disruption of sensory, motor and 
autonomic function has a high impact on the patient’s quality of life, as it affects both the 
physical and the psychological well-being. In addition, it represents a substantial financial 
burden for patients, their family and the community. No treatment is currently available to fully 
restore function, therefore health care resources are needed on a long-term or even life-long 
basis, including hospitalization, rehabilitation, prevention or care of secondary complications, 
medication and personal assistance [5-8]. A 2013 World Health Organization (WHO) report 
estimated that global non-traumatic and traumatic SCI incidence is likely to be between 40 and 
80 cases per million, which means a yearly world-wide incidence of 250,000 to 500,000 patients 
[8]. Comparative studies throughoutly analyzing the world-wide economic impact of SCI are 
currently not available, however an estimation of mean costs that a SCI patient has to cover in 
the USA amounts to $138,000-476,000 within the first year and $38,000-169,000 in following 
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years depending on location and severity of injury. Accordingly, as an example, lifetime health 
care of a 25 year old and of a 50 year old SCI patients amounts up to $3 million and up to $1,7 
million, respectively [7, 9]. Interestingly, SCI incidence has decreased or been stable in 
developed countries, likely due to development of preventive strategies based on epidemiology, 
whereas it has increased in developing and middle to low-income countries, where there is lack 
of information about SCI epidemiology [5]. 
 
2.1.3. Current state of clinical intervention 
 
To date, no therapeutical approach is available for the full restoration of sensorimotor and 
autonomic dysfunction after SCI. After complete SCI, sensorimotor and autonomic function 
controlled by spinal cord segments below the lesion site is irreversibly lost. In incomplete SCI, 
spontaneous and/or compensatory functional recovery can be partially addressed by 
rehabilitation procedures. Rehabilitation is meant to train the body to “re-learn” to perform a 
specific task either by stimulating the restoration of former circuits or inducing novel circuits or 
by adaptive or compensatory mechanisms. The former are based on plasticity of the nervous 
system, which is capable of re-organizing after injury both at a physiological and at a 
morphological level. For incomplete SCI patients, rehabilitative training is the most effective 
approach to direct and enhance plasticity, thereby inducing some sensorimotor recovery. Such 
training uses specific tasks to stimulate and facilitate neuroplasticity specifically related to a lost 
function (e.g. treadmill training for walking; reach & grasp training for everyday hand use). 
Rehabilitative training is only undertaken after examination of the patient to assess if certain 
physiological requirements are met, i.e. if the basis for functional improvement is provided. 
Rehabilitation is, however, costly: long-term training with a high amount of movement-
repetitions is intensive both for the patient and for the physiotherapists, and complex robotic 
devices, which are necessary for standardized training paradigms, are expensive and generally 
not available for everyday use [10]. In addition, rehabilitation has no effect on irreversibly 
injured circuits. 
Pre-clinical and clinical research has therefore been focusing on understanding why CNS 
function is irreversibly lost and on designing approaches to enhance CNS regeneration. 
 
2.2. Failure in central nervous system regeneration: key players 
 
The peripheral nervous system (PNS) retains the ability to regenerate axons after injury, 
whereas central nervous system axons (CNS) do not regenerate. At the beginning of the 20th 
century it was generally assumed that CNS neurons are completely unable to regenerate [11]. 
However, subsequent studies demonstrated that the CNS branches of dorsal root ganglion 
(DRG) neurons were capable of intraspinal regenerative sprouting after partial denervation of 
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the spinal cord in cats [12]. Nevertheless, CNS regeneration remained controversial for several 
decades [13], until it was demonstrated that transected CNS axons are able to re-grow into 
bridges of peripheral nerves transplanted into the rodent spinal cord [14, 15]. This led to the 
hypothesis that the inhibitory nature of the CNS environment is responsible for the failure of 
CNS neurons to regenerate [16]. However, CNS neurons display a lower growth potential than 
PNS neurons on a permissive substrate [17], suggesting that cell-intrinsic mechanisms and the 
inhibitory CNS environment both represent a barrier to CNS regeneration. It is now generally 
accepted that cell-intrinsic and extrinsic properties account for the differences in the capacity to 
regenerate between CNS and PNS neurons. 
 
2.2.1. Extrinsic inhibitors of axonal regeneration 
 
Axonal regeneration and plasticity in the CNS are hampered by a whole range of soluble growth-
inhibitory molecules, which accumulate at the site of injury, including CNS-myelin-derived 
inhibitors, ephrins, semaphorins and proteoglycans [4, 18, 19]. The cellular and molecular 
responses that contribute to the inhibitory environment after CNS injury have been subject of 
numerous investigations, and means to overcome growth-inhibition have moved from in vitro 
neurite-growth assays to several pre-clinical and clinical studies to date. 
 
2.2.1.1. Fibroglial scar and proteoglycans 
 
Immediately upon SCI, a sealing cellular barrier composed of reactive fibroblasts, macrophages 
and hypertrophic astrocytes arises within and at the edge of the injury site.  This results in 
stabilization of the injured CNS tissue by restoration of physical and chemical integrity and by 
limiting the breakdown of the blood brain barrier (BBB) to impede further infiltration of non-
CNS cells/molecules and infections and excessive subsequent secondary tissue damage [3, 20]. 
In fact, ablation of glial scar formation results in invasion of inflammatory cells into the lesion 
site, an increase in lesion volume, decreased neuroregeneration and functional deterioration 
[21-25]. However, the fibroglial scar constitutes a physical and molecular obstacle to 
regenerating axons due to the upregulation of a growth-inhibitory extracellular matrix (ECM). 
One class of molecules strongly upregulated in the ECM of CNS injury sites are chondroitin-
sulphate-proteoglycans (CSPGs) [26-28]. In the 90’s, in vitro studies in which non-growth-
permissive astrocytic lines were treated with inhibitors of proteoglycan synthesis established a 
clear link between CSPG secretion and inhibition of neurite growth [29, 30], whereas in vivo 
studies demonstrated that upregulation of CSPGs in the scar tissue contribute to failure of 
axonal regeneration [31, 32].  In concomitance, digestion of glycosaminoglycan (GAG) side 
chains of CSPGs with the bacterial enzyme chondroitinase ABC (ChABC) attenuated their 
growth-inhibitory activity both in vitro and in vivo [33, 34], suggesting that CSPG digestion could 
be of therapeutic value.  
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2.2.1.2. Modulation of the extracellular matrix: chondroitinase ABC 
 
Early pre-clinical studies performed in rodents demonstrated that administration of ChABC after 
SCI promotes regeneration of ascending and descending lesioned projections, enhances 
sprouting and connectivity of spared pathways, modulates the immune response and 
neuroprotection and leads to partial recovery of sensorimotor function [35-45]. Few studies 
were performed in cats and squirrel monkeys [46, 47], however studies in larger animals are 
necessary to assess safety, efficacy and dosage of the treatment before moving to a clinical 
setting. In addition, clinical translation of ChABC treatment remains challenging due to the rapid 
loss of enzymatic activity at body temperature and consequent lack of appropriate delivery 
methods [48]. 
 
2.2.1.3. Myelin-associated inhibitors 
 
CNS myelin was identified as potent inhibitor of neurite growth more than 30 years ago, when it 
was shown that CNS axons can regenerate in peripheral nerve transplants [14, 15], whereas PNS 
neurons displayed more limited neurite extension when exposed to CNS myelin [16, 49]. Nogo-A 
was identified as one myelin component, which largely accounts for its inhibitory activity [50, 
51]. However, myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein 
(OMgp) and the CNS myelin lipid sulfatide also have potent inhibitory activity. All myelin 
inhibitors bind to a common receptor (NgR) in a complex with Lingo-1 and TROY or p75. 
Activation of NgR induces axonal cytoskeletal rearrangements and exerts further inhibitory 
functions via a signaling pathway involving the small Rho GTPase RhoA and the Rho associated 
protein kinase (ROCK) [4].  
 
2.2.1.4. Pre-clinical and clinical trials targeting Nogo-A 
 
In 1988 the monoclonal antibody IN-1, raised against the two inhibitory antigens (NI-35 and NI-
250) known as Nogo-A, was applied intratechally after SCI in rats, leading to enhanced sprouting 
and longitudinal axonal elongation [16]. Subsequent studies targeted Nogo-A in vivo by means 
of different anti-Nogo antibodies, the NgR blocking peptide NEP1-40, soluble NgR fusion 
proteins (NgR-Fc) or by genetic ablation, confirming across different animal species including 
non-human primates enhanced sprouting, some regeneration and functional recovery [52-63]. 
Based on this solid and very promising pre-clinical evidence, Nogo-A antibodies were produced 
by Novartis and applied in a Phase I clinical study which started in 2006 within the European 
Multicenter Study about Spinal Cord Injury (EMSCI) (clinicaltrials.gov ID: NCT00406016). 
However, results from this clinical study are not published yet. Anti-Nogo-A, also known as 
Ozanezumab, was also applied in more recent Phase I clinical trials targeting amyotrophic lateral 
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sclerosis (ALS) patients [64], multiple sclerosis (MS) patients (clinicaltrials.gov ID: NCT01435993; 
clinicaltrials.gov ID: NCT01424423)  and patients with traumatic brain injury (TBI) 
(clinicaltrials.gov ID: NCT02229643), results have not been published and Phase II trials are yet 
to be started.  
 
2.2.1.5. Inhibitory molecules 
 
In addition to CSPGs and CNS myelin-associated inhibitory molecules, other classes of potent 
growth-inhibitory molecules are upregulated after SCI within and around the lesion site, which 
are known to be crucial axon guidance cues during neurodevelopment: semaphorins, ephrins 
and Eph receptor tyrosine kinase family members, Wnts and Netrins [65-68]. Members of the 
Ephrin and Eph receptor families are expressed at the injury site by reactive astrocytes, 
fibroblasts and oligodendrocytes, indicating that no single cell type accounts for the inhibitory 
lesion environment, and were shown to affect cell survival and restrict axonal growth and 
regeneration after SCI [63, 69-74]. Inhibition of the ephrin/Eph receptor signaling by fusion 
proteins or blocking peptides was shown to promote axonal regeneration [72, 75]. 
Semaphorins, on the other side are expressed by infiltrating meningeal fibroblasts [76]. 
Inhibition of Sema3A resulted in improved regeneration, preservation of injured axons, 
Schwann-cell mediated myelination, decrease in apoptosis and functional recovery after SCI [77, 
78].  
Based on these pre-clinical results, modulation of the lesion environment, i.e. modulation of 
proteoglycans, myelin-associated molecules and developmentally relevant growth-inhibitory 
molecules, represents a promising therapeutical approach to increase regeneration after SCI.  
 
2.2.1.6. Delivery of neurotrophic factors to promote regeneration and 
sprouting 
 
Besides the growth-inhibitory environment of the injured spinal cord, absence of a permissive 
growth-substrate or growth-stimulating cues contribute the regenerative failure. Therefore, 
besides manipulating the extracellular environment of the injured CNS to reduce its inhibitory 
effect, chemoattractive cues, which promote axon-growth, are necessary to induce robust 
regeneration.  
Both during neurodevelopment and after injury of the PNS, neurotrophic factors play an 
important role in neuronal survival, axonal growth and target innervation. Several families of 
trophic factors including members of the neurotrophin family (nerve growth factor, NGF; brain-
derived neurotrophic factor, BDNF; neurotrophin-3, NT-3; neurotrophin-4/5, NT-4/5), GDNF-
family ligands (Glial cell line-derived neurotrophic factor, GDNF; neurturin, NRTN; artemin; 
persephin), neuropoietic cytokines (ciliary neurotrophic factor, CNTF; leukemia inhibitory factor, 
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LIF) and others have therefore been investigated for their influence on neuronal survival and 
axon growth after SCI.  
After injury of the spinal cord, BDNF and NT-3 have been shown to counteract atrophy of 
injured tracts and to support cell survival [79-81]. In addition, they encourage growth of injured 
axons [82-84]. Numerous pre-clinical studies used genetically modified cells such as fibroblasts 
[84-94], Schwann cells [82, 95], bone marrow stromal cells [96, 97], olfactory ensheathing cells 
[98-100], neural precursor cells [91, 101] or peripheral nerve grafts [102] as “biological mini-
pumps” to continuously produce the desired neurotrophic factors, such as BDNF and NT-3, after 
transplantation to the injured spinal cord. Although these studies showed robust axonal growth 
into the lesion site filled with neurotrophic factor producing cells, axons rarely exited the graft 
to extend into the host spinal cord due to the inhospitable environment and lack of 
chemoattractive cues. Only in the presence of a growth stimulus distal to the cell graft axons 
extend beyond the lesion site. Using virus-based in vivo gene delivery (lentivirus or adeno-
associated virus, AAV), neurotrophic factor gradients can be generated within the distal host 
tissue, allowing for bridging axonal regeneration [103-106].  
Although neurotrophic factor delivery represents a promising means to boost 
neuroregeneration, appropriate and safe techniques for localized and regulatable delivery have 
to be developed to allow for clinical translation. 
 
2.2.2. Intrinsic factors regulating axonal regeneration  
 
Injured CNS axons are incapable of regenerating not only due to environmental cues, but also 
due to their intrinsic properties. The growth capacity of CNS axons declines during development 
as connections mature and synapses are formed. This decline is accompanied by the down-
regulation of growth-associated genes. Transcriptional and epigenetic mechanisms, local 
protein translation, retrograde and anterograde axonal transport and cytoskeletal dynamics 
have been identified as intrinsic key regulators of axon regeneration. 
 
2.2.2.1. Calcium transients and activation of cAMP 
 
After axonal injury, influx of calcium into the axoplasm is one of the first consequences. This 
transient intracellular calcium wave propagating from the injured axon to the cell soma seems 
to be crucial for resealing the axonal membrane, protein synthesis, cytoskeleton 
rearrangement, assembly of the growth cone and the activation of intracellular signaling 
cascades. Calcium influx lead to increased cyclic cAMP levels, which promote growth cone 
assembly [107] and to activate signaling pathways to overcome myelin-associated signals [108-
110]. In fact, injection of a cell-permeable cyclic adenosine monophosphate (cAMP) analogue 
(dibutyryl-cAMP; db-cAMP) into DRG neurons enhanced the regeneration of injured dorsal 
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column axons [111-113]. An alternative method to enhance cAMP levels is subcutaneous 
application of the BBB-permeable drug Rolipram, an inhibitor of the cAMP-degrading enzyme 
phosphodiesterase (PDE) 4. Delivery of Rolipram after injury of the spinal cord led to enhanced 
regeneration, attenuation of the glial scar and significant increase in functional recovery in 
several pre-clinical studies [114-118], however clinical trials are still not reported.  
 
2.2.2.2. Epigenetic regulation of regeneration-associated genes 
 
When calcium waves reach the soma of DRG neurons, it leads to activation of PKCµ and 
consequent export of histone deacetylase 5 (HDAC5) from the nucleus. As a result, increased 
histone acetylation contributes to the activation of pro-regenerative gene expression in DRG 
neurons. In particular, increased acetylation of histone 4 (H4) in promoter regions of 
regeneration-associated genes (RAGs) leads to their increased expression. Several transcription 
factors including JUN, KLF4, KLF5, c-Fos, ATF3 and Gadd45g, as well as Smad1, Sprr1, Galanin, 
NPY and VIP, which have been associated with the injury-induced response and axon growth, 
have been found to be HDAC5-regulated [119, 120]. Independently, the histone 
acetyltransferase CBP/p300 regulates RAG expression via histone 3 (H3) acetylation of p53, 
GAP-43 and Sprr1 [121]. These findings suggest that epigenetic regulation of RAG expression 
may be targeted to promote regeneration after CNS trauma. 
 
2.2.2.3. Growth cone and microtubule dynamics 
 
Injured PNS neurons maintain stable microtubuli at the backbone and have dynamic microtubuli 
at the tip of their growth cone, whereas injured CNS axons form a retraction bulb with a 
disorganized network of microtubuli, a rather static structure that can persist for years after 
spinal cord injury [122]. After nuclear export, HDAC5-mediated deacetylation of microtubuli at 
the axon tip of DRG neurons increases their dynamics and reorganization. This is a prerequisite 
for the formation and motility of a growth cone, which are necessary for growth initiation and 
axonal extension [119, 123]. On the other side, selective inhibition of HDAC6 and the 
consequent increase in acetylated, stable microtubuli enhanced survival after oxidative stress 
and growth of CNS neurons on non-permissive substrate [124], indicating that microtubule 
stability might have divergent effects on axon regeneration. Nevertheless, some efforts have 
been made to pharmacologically stabilize microtubuli and promote growth cone formation and 
dynamics via administration of Taxol, an approved and commercially available drug. Moderate 
stabilization of microtubuli via application of low doses of Taxol prevented the formation of 
retraction bulbs, decrease axonal degeneration in vivo and enable CNS neurons to overcome the 
growth inhibitory effect of myelin in vitro [125]. In vivo, Taxol-mediated stabilization of the 
microtubule network led to a reduction of the fibrotic scar and of CSPG levels, and to moderate 
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increase in regeneration and functional recovery [126], which was partially replicated in a 
subsequent study [127]. Delivery of a Taxol derivative, Epothilone B, led to a decrease in glial 
scarring, and promoted regeneration and functional recovery [122]. Taken together, despite 
some convincing pre-clinical evidence, additional studies are needed to define the dose, time 
window of treatment and maximum benefit before moving towards clinical translation. 
 
2.2.2.4. Transcriptional networks and other signaling cascades 
 
Because CNS neurons fail to effectively activate RAGs [128], means to promote CNS axon 
growth by gene-delivery of RAGs or by manipulating pathways that lead to the upregulation of 
RAGs have been explored in numerous studies.  The pro-regenerative potential of transcription 
factors that might have a broad effects by influencing expression of several genes have been 
studied including SMAD1 [129], CREB [130], STAT3/SOCS3 [131], ATF3 [132] and c-JUN [133].  
Among these, STAT3 and c-JUN are perhaps the ones with the strongest indication for a pro-
regenerative effect; however none of these experiments promoted extensive long-distance 
regeneration in the spinal cord.  
Besides positive regulators of gene expression, intrinsic inhibitors of axon growth which 
negatively influence protein translation contribute to the CNS regenerative failure. The activity 
of mechanistic target of rapamycin (mTOR), a regulator of protein translation, is strongly 
influenced by phosphatase and tensin homolog (PTEN).  Elimination of the tumor suppressor 
gene PTEN induced robust axon growth of retinal ganglion neurons [134]. Further investigations 
demonstrated that mTOR activity also regulates sprouting of corticospinal tract (CST) neurons 
after injury. Conditional deletion of PTEN attenuated injury-induced loss of mTOR activity in CST 
neurons, and enhanced sprouting and regenerative growth indicating that this signaling 
pathway represents a promising approach to target the intrinsic regenerative capacity of 
neurons after SCI [135-137]. Combining PTEN deletion with the activation of the STAT3 pathway 
showed even more remarkable growth after an optic nerve crush injury [138]. 
 
2.2.2.5. What lessons can we learn from the peripheral nervous system? 
 
The ability of peripheral neurons to mount a regenerative program after PNS injury has been a 
major focus in identifying genes and signaling cascades important for axon regeneration. On one 
side, intrinsic properties of PNS neurons confer them the ability to regenerate on a life-long 
basis. On the other side, there is a striking difference in the structural proteins that make up the 
myelin of the CNS and the PNS. For instance, CNS myelin produced by oligodendrocytes is 
compact and rich in glycolipids, sulfolipid-sulfatides, proteolipid protein (PLP) and myelin-
associated inhibitors such as OMgp. In contrast, myelin protein zero (P0/MPZ) and peripheral 
myelin protein 22 (PMP22) constitute characteristic structural proteins of peripheral myelin 
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[139]. Importantly, the inhibitory myelin components MAG, OMgp, p75 and NgR are not absent 
in the PNS. Rather, after injury they are rapidly cleared by macrophages and Schwann cells. In 
addition, Schwann cells de-differentiate in order to down-regulate inhibitory myelin proteins. 
Unlike Schwann cells, CNS oligodendrocytes do not down-regulate myelin components and do 
not clear myelin debris after injury [140]. 
DRG neurons can be used to study mechanisms of regeneration in both the PNS and CNS, due to 
their unique nature: their cell soma is located in the dorsal root ganglia at each side of the spinal 
cord and they extend two axonal branches, one into the PNS and one into the CNS. The 
peripheral branch retains its ability to regenerate, whereas the central branch fails. Due to this 
fascinating property, they have been extensively used to perform basic research on 
neuroregeneration in vitro and in vivo. 
 
2.2.2.6. The conditioning lesion effect 
 
Sensory neurons of the DRG are pseudobipolar neurons which extend two axonal branches: the 
peripheral one, which innervates sensory organs in the skin, joints, muscles and tendons, and 
the central projection, which crosses the dorsal root entry zone (DREZ) to enter the spinal cord 
and either form connections with spinal cord interneurons residing in the gray matter or 
proceed via the white matter to brainstem nuclei to innervate their CNS targets. In 1969, 
experiments performed with DRG neurons of monkeys revealed a differential response to injury 
of their peripheral versus their central branches [141], a phenomenon, which had already been 
observed by Ramón y Cajal during his extensive examinations of the nervous system [142]. 
Upon damage to axons of the peripheral nerve, genetic and molecular programs are activated, 
which lead to a state of axonal growth [143]. After the growth program is initiated, axonal 
elongation is supported by the growth-permissive PNS environment, by tubes of Schwann cell 
basal lamina, as well as growth-permissive ECM and neurotrophic factor mediated 
chemoattraction [144]. Most intriguing is the ability of a peripheral lesion to elicit regeneration 
of the CNS branch of DRG neurons, which was observed more than 30 years ago. However, in 
this first study a peripheral nerve graft was used as growth substrate [145]. Regeneration of CNS 
branches in the absence of a permissive PNS substrate was demonstrated 15 years later, were a 
conditioning lesion of the sciatic nerve one-two weeks before a dorsal column lesion was shown 
to elicit regeneration of CNS projections beyond the lesion site [146]. Subsequent studies 
attributed the conditioning lesion effect to the elevation of cAMP levels 24 hours after PNS 
injury, which persisted for one week before returning to baseline levels; intra-ganglionic 
injections of db-cAMP could in fact increase neurite outgrowth [111]. cAMP elevation, in turn, is 
able to promote gene expression and regeneration via activation of the transcription factor 
cAMP response element binding protein (CREB) [130]. However, subsequent studies 
demonstrated that conditioning lesions activate a greater and more long-lasting genetic 
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response than cAMP administration [147], suggesting that cAMP is one but not the only key 
player accounting for the conditioning lesion effect. Extensive studies investigating the 
mechanisms behind the conditioning lesion effect might identify promising therapeutical 
approaches based on the regenerative program activated by peripheral nerve injury.    
 
2.3. Cell transplantation to promote neuroregeneration 
 
The therapeutical approaches reviewed above aimed at enhancing regenerative axon outgrowth 
and/or sprouting of injured and spared projections by targeting their extrinsic or intrinsic 
properties. The regenerative capacity of endogenous projections remains, however, still very 
limited and outgrowing axons only extend for modest distances. Considering the long distances 
that regenerating axons need to cover in the human body, robust target reinnervation after 
severe spinal trauma might be utopic. Moreover, boosting endogenous regeneration alone does 
not lead to restoration of neural tissue integrity and function. Neuroregenerative approaches 
might therefore become fully effective only in combination with cell replacement strategies, 
which promote anatomical and functional repair. Cell transplantation should ideally (1) provide 
a permissive physical and molecular substrate for axon growth, perhaps in concomitance with 
secretion of pro-regenerative soluble factors, (2) provide for trophic support and remyelination, 
(3) replace damaged neurons or introduce neurons that can serve as “relays” (a cellular bridge). 
In cell transplantation experiments, these three aspects were addressed separately, some of 
them even in a clinical context. However, we are very far from the application of the “perfect” 
cell transplant covering all these functions. In addition, transplanted cells are heterogeneous in 
terms of age and gender of the donor, organ of source, culturing conditions across laboratories, 
method of delivery and other characteristics. Thus, both pre-clinical and clinical studies might 
report diverging outcomes. 
 
2.3.1. Regeneration versus “relay” formation   
 
Cell replacement strategies can address three main aspects of neural tissue restoration, which 
will be briefly described hereafter.  
Restoration of tissue integrity and regeneration  
Non-neural cells or glial cells can be used to provide physical guidance, as well as trophic and 
metabolic support. They can produce growth-permissive ECM, secrete neurotrophic or 
chemoattractive factors and interact with endogenous glial scar forming or inflammatory cells, 
thereby counteracting the extrinsic factors, which influence the regenerative potential of 
injured neurons. However, they hardly have influence on the intrinsic growth potential, which is 
very limited in CNS neurons. Nevertheless, they are crucial for restoration of tissue integrity and 
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homeostasis, support of elongating axons and modulation of network activity (figure 2.1., A). To 
restore the original neural tissue integrity and function, a CNS-residing cell type would be ideal.  
Remyelination  
Glial cells, specifically Schwann cells, olfactory ensheathing cells (OECs) or oligodendrocytes are 
capable of myelinating axonal projections: either by re-myelinating spared axons or by 
myelinating regenerating axons. Re-/myelination ensures fast transmission of neuronal 
information and balanced neural network activity. If regenerated axonal projections are not 
myelinated, they will only have a limited capacity to contribute to functional recovery. In 
addition, oligodendrocytes provide trophic and metabolic support to axons. Understanding the 
pathways involved in myelination and in axon-glia communication, and how these pathways 
may influence axonal growth responses after injury, is crucial for developing regenerative 
therapies after CNS injury.  
The concept of neuronal “relay” 
Classic intervention / repair strategies for SCI have aimed at boosting the endogenous 
regenerative potential of injured axons, which would extend across the lesion site back into the 
adjacent host spinal cord and beyond to re-innervate their targets. Currently, very few studies 
demonstrate substantial growth of injured axons into and beyond the injury site. In some cases, 
few axons have been identified which re-enter the intact spinal cord but only for a short 
distance. Therefore, in recent years the concept of neuronal „relay“ has gained attention and 
may represent an alternative strategy to reconstruct damaged neuronal networks. Transplanted 
neuronal precursors or immature neurons would differentiate and build a “cellular bridge” 
which receives information from sensory ascending or motor descending projections and 
convey it either by local connectivity with interneurons or by extending towards and re-
innervating original targets (figure 2.1., B). 
This concept has been addressed in recent studies [148, 149], which showed robust axonal 
extension from transplanted dissociated fetal tissue as well as from pluripotent stem cell (PSC)-
derived neural stem cells (NSCs). In addition, these studies reported electrophysiological activity 
of transplanted cells, confirming the functional relevance of this newly formed network, as well 
as partial recovery of hindlimb / motor function. However, additional pre-clinical studies are 
needed to assess the impact and the contribution of the neuronal “relay” to functional 
recovery.  
Generally, regeneration and “relay” formation need to be addressed at the same time. While 
transplantation of a pro-regenerative substrate, f.i. a glial-cell substrate, might not be enough to 
boost robust endogenous regeneration, it might guide axotomized projections towards “relay” 
forming cells. The latter on the other side might take advantage of a glial-cell substrate, as this 
might support their survival and maturation.  
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2.3.2. Transplantation of non-CNS cells  
 
2.3.2.1. Mesenchymal stem cells  
 
Mesenchymal stromal or stem cells (MSCs) have been extensively used for transplantation into 
the CNS. These self-renewing / multipotent stem cells, isolated from the bone marrow, can 
differentiate into osteoblasts, adipocytes and chondroblasts, as well as putative neural cells and 
myoblasts in vitro [150]. MSCs represent a very attractive and promising cell source for tissue 
repair because they can be easily obtained from autologous bone marrow, cryopreserved and 
expanded in a relatively short period of time [151]. In addition, they are well tolerated and 
there are no reports of adverse reactions in both autologous and allogeneic transplantations.  
MSCs have been reported to have anti-inflammatory, neuroprotective and pro-regenerative 
effects by decreasing demyelination and scar formation, promoting regeneration and guiding 
axons [152, 153]. Improvements of locomotor, sensory and autonomic function, as well as 
Figure 2.1 Cell replacement after SCI: regeneration versus neuronal „relay“ formation. 
Transplantation of a cellular substrate after SCI can address three  major aspects: (A) the cellular 
substrate provided the optimal conditions for injured neurons to regenerate axons and connect 
with their original targets to restore function, (B)  the stem cell substrate gives  origin  to 
neurons, which receive the signal  from axotomized  host neurons and extend projections 
towards denervated targets, thereby mediating communication and restoring function, and (C) 
re-myelination of de-myelinated spared projections, which can only be addressed if these are 
present.   
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reduction of neuropathic pain were observed in some studies in different animal models [154, 
155]. However, beneficial effects on functional recovery in well-conducted preclinical studies 
were modest. Nevertheless, a number of ongoing and completed clinical trials have assessed 
safety and potential beneficial effects of MSC transplantation after SCI.  Most of these trials only 
enrolled a small number of patients and are therefore unable to draw conclusions about clinical 
efficacy [156, 157].  
Taken together, although MSCs can be easily harvested and cultured for transplantation, their 
non-neural nature might lead to a disappointing outcome in terms of functional recovery. 
 
2.3.2.2. Stimulated macrophages 
 
Despite the detrimental role of the immune response after CNS injury, inflammation can also be 
beneficial after SCI. Macrophages are crucial for clearing ECM as well as cellular debris and 
secrete growth factors which facilitate remyelination and axon growth. In the late 1990s, 
transplantation of non-activated blood-born macrophages after transection of the spinal cord in 
rodents led to enhanced regeneration and recovery of motor function [158], as well as 
decreased expression of the axon-growth-inhibitory myelin protein MAG, increased 
angiogenesis and Schwann cell infiltration [159]. In a later study, a skin biopsy was used as the 
source to activate autologous macrophages that were administered 8-9 days after a rat spinal 
cord contusion. This resulted in less pronounced syringomyelia and improved motor function 
[160]. In subsequent clinical trials, autologous macrophages activated by incubation with 
autologous skin biopsies were injected into the spinal cord caudal to the lesion [161-163]. In 
both clinical trials, transplantation was performed in American Spinal Injury Association 
Impairment Scale (AIS)-A patients within 14 days after injury. While the macrophage cell 
therapy was well tolerated, no significant difference in primary outcomes (conversion from AIS 
A to B or C) between treated and control group was detected. While these are very crude 
clinical outcome measures, stimulated macrophages might not represent a suitable cell source 
for transplantation after SCI. 
 
2.3.2.3. Schwann cells 
 
Schwann cells are responsible for the myelination of PNS axons, but they are also able to 
myelinate CNS axons. They play a central role in PNS regeneration, express neurotrophic 
factors, provide a favorable ECM and guide axons across a lesion after PNS injury [144]. In 
addition, Schwann cells can be relatively easily obtained from peripheral nerve biopsies and 
expanded in culture. In the context of SCI, they have been used for over 30 years [164], not only 
due to their ability to re-/myelinate, but also because they represent a permissive substrate for 
regenerating axons.  
18 
 
Although several pre-clinical studies demonstrated that Schwann cells promote axon 
regeneration, other studies pointed out that they are not sufficient to induce bridging of the 
lesion site, as regenerating axons were not able to exit the graft and grow into the host tissue 
[165, 166]. In contusion SCI animal models, only few studies reported significant improvement 
of motor function when adult rodent Schwann cells were transplanted alone [167-169]. In one 
positive study, functional recovery was induced in mice after compression of the spinal cord, 
however way more efficiently with genetically engineered Schwann cells which overexpressed 
Polysialylated-neural cell adhesion molecule (PSA-NCAM) [170]. Only few pre-clinical studies 
were performed using human Schwann cells. Modest but significant beneficial effects were 
observed; however Schwann cells were transplanted in a combinatorial treatment [171, 172].  
Based on the preclinical evidence, three clinical studies have been conducted to date in which 
Schwann cells were transplanted in SCI patients. From the first two completed studies, only 
limited conclusions about efficacy can be drawn, but the transplantation procedure appeared to 
be safe [173-175]. Supported by safety and toxicity studies in rodents, mini-pigs and primates, a 
FDA-approved phase I study transplanting autologous Schwann cells in patients with subacute 
neurologically complete thoracic SCI was recently initiated, which is still ongoing [176] 
(clinicaltrials.gov ID: NCT01739023). Future clinical application will have to cope with some 
challenges: (1) autologous isolation of Schwann cells requires sacrificing a peripheral nerve, thus 
an alternative source needs to be found; (2) expansion of nerve-derived Schwann cells or 
induction of Schwann cell differentiation from MSCs might take several weeks [177, 178]; (3) 
when transplanted alone without further intervention, Schwann cells led to limited functional 
recovery; (4) cell survival following transplantation is rather low similar to other transplanted 
cells.  
Nevertheless, Schwann cells remain a reasonable treatment approach for SCI. While current 
clinical studies might not show meaningful clinical benefit, the results could provide the basis 
for future studies combining Schwann cell transplants with other treatments that have shown 
promise in animal models. 
 
2.3.2.4. Olfactory ensheathing cells 
 
OECs were first described in the 19th century by Golgi [179] and Blanes [180] as specialized glial 
cells exclusively located in the olfactory nerve and glomerular layers, one region of the CNS 
where axonal regeneration is possible throughout adulthood. They ensheat and isolate olfactory 
axons from the growth-inhibitory CNS environment, enabling axonal growth from the olfactory 
epithelium (PNS) towards targets in the olfactory bulbs (CNS) [181]. The unique axonal growth 
promoting properties of OECs were confirmed in vitro and in vivo after dorsal root transections 
[182] and complete thoracic transections [183]. In the following years, the pro-regenerative and 
neuroprotective effects of OECs were investigated in various rodent models of SCI [184, 185]. 
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OECs did not only promote axonal regeneration in the injured CNS, but also functional 
reconnection of injured axons, remyelination, formation of blood vessels, and re-organization of 
the glial scar [185, 186]. However, other studies which compared OECs and Schwann cells 
showed only limited beneficial advantages [167, 168, 187]. This might be at least partially 
attributable to the source of the transplanted cells, culturing conditions, number of passages 
and the site of injection [184, 188, 189]. 
The pre-clinical evidence encouraged the initiation of several clinical studies. In Australia OECs 
isolated from nasal biopsies were transplanted in patients with chronic SCI. These studies 
confirmed the feasibility and safety of the approach. While functional improvement was not 
detected, the studies with 3 - 6 patients were too small to draw definitive conclusions [190, 
191]. Two subsequent clinical trials reported functional improvement [192, 193], but again, a 
limited number of patients was included. Larger clinical trials are needed to confirm the safety 
and efficacy of OECs for the treatment of SCI. 
 
2.3.3. Neural stem cells: sources, transplantation and application in clinical 
trials 
 
The cell sources described in paragraph 2.3.2. had some beneficial effects when transplanted in 
pre-clinical and clinical SCI studies. They had neuroprotective and immunomodulatory effects, 
enhanced remyelination and / or promoted regeneration. However, none of these are native to 
the CNS and can therefore only partially restore tissue integrity, but not fulfill all tasks normally 
fulfilled by CNS neurons and glia. Full restoration of damaged CNS tissue may only be achieved 
by transplanting CNS-NSCs which can give origin to appropriate neuronal and glial phenotypes. 
CNS astrocytes and oligodendrocytes can provide physical, trophic and metabolic support, and 
re-/myelinate axonal projections, while neurons might serve as a “relay”, as mentioned in 
paragraph 2.3.1.   
NSCs can be obtained from different sources: adult NSCs can be isolated from the postnatal 
forebrain subependymal zone or from the spinal cord [194-196] and fetal NSCs from the fetal 
brain or spinal cord [197-201]; on the other side, NSCs and their progeny can be obtained via 
differentiation from embryonic or induced pluripotent stem cells (ESCs, iPSCs) [202-213] or from 
somatic cells via direct fate conversion [214-218]. In comparison to non-CNS cell types described 
above, NSCs are more difficult to obtain and their generation and expansion takes several 
weeks to months. Human adult NSCs isolated during surgery or post mortem [196, 219], fetal 
NSCs cannot be used for autologous transplantation and their use is moreover subject to ethical 
considerations. On the other hand, NSCs obtained from PSCs or generated by fate conversion 
can be tumorigenic due to genetic or epigenetic abnormalities [220]. Therefore, although they 
are a highly promising cell source for SCI repair, NSCs derived from either source have to be 
used with caution. 
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Numerous pre-clinical SCI studies have examined the potential of NSCs to mediate functional 
recovery after SCI. In general, a portion of the transplanted NSCs survive, adopt mature neural 
phenotypes and can integrate into the host tissue. Transplanted NSCs can provide a substrate 
for regenerating axons [221-223], serve as a “relay” [148, 149, 224], re-myelinate spared 
projections [200, 201, 210, 225-227] or can be neuroprotective [228]. More recent studies have 
also reported that human iPSC-derived NSC can promote functional recovery [148, 149, 229-
231]. 
The first NSC transplantation studies which were translated into a clinical setting were based on 
the generation of oligodendrocyte precursor cells (OPCs) from human ESCs (hESCs) to re-
myelinate spared axons and to promote functional recovery [211, 212]. A Phase I “first-ever” 
clinical study using human ESCs was initiated in 2009 by the Geron Corporation (Menlo Park, 
California, USA) to evaluate safety and efficacy of human ESC transplantation in acute SCI [232]. 
After five patients, the clinical trial was suddenly discontinued in 2011, apparently due to 
financial concerns [233].  Asterias Biotherapeutics Inc. (Fremont, California, USA) has recently 
initiated a Phase I/IIa trial using ESC-derived OPCs in subacute cervical SCI (clinicaltrials.gov ID: 
NCT02302157), which will be completed in 2018. Prior to this clinical trial, the ESC-derived OPC 
line AST-OPC1 was evaluated for pre-/clinical safety in a rodent animal model [234].    
Two further clinical trials in SCI were conducted with fetal NSCs isolated from the brain and 
from the spinal cord, respectively. Stem Cells Inc. (Newark, California, USA) sponsored one 
phase I/II clinical trial conducted in Canada and Switzerland from 2011 to 2015 (clinicaltrials.gov 
ID: NCT01321333), in which human spinal cord derived cells (HuCNS-SC cells) were delivered via 
intramedullary transplantation in patients with thoracic SCI. Prior to this clinical trial, the 
HuCNS-SC® cell line, which was purified and expanded by the company Stem Cell Inc., was 
evaluated for pre-/clinical safety in rodent animal models [235]. Whereas no safety concerns 
have arisen during the clinical trial, recovery of sensory function was observed in 3 out of 12 
patients [235]. From 2014 to 2016 safety of human spinal cord stem cells was assessed in a 
second phase I clinical trial in patients with complete SCI, which was sponsored by Neuralstem 
Inc. (Germantown, Maryland, USA) (clinicaltrials.gov ID: NCT01772810). This specific cell line 
(HSSC) was also tested in a multi-centric phase I/II clinical trial in ALS patients. Adverse events 
were observed, however they were not related to the transplanted cells [236].    
Recent pre-clinical studies demonstrated that NSCs isolated from embryonic day 14 (E14) or 
differentiated from the ESC lines HUES7 and 566RSC as well as from iPSCs are able to extend 
long-distance axons into the injured spinal cord and form synaptic connections, thereby possibly 
acting a “relay” [148, 149]. However, two subsequent replication studies reported ectopic 
growth of transplanted cells in CNS regions distant from the lesion site [237] and no locomotor 
recovery [238], drawing attention to the necessity to further assess safety and effect of both 
fetal and PSC-derived NSCs. 
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2.4. Tissue engineering: the promise of pluripotent stem cells 
 
The major advantage of transplanting dissociated fetal spinal cord derived NSCs without further 
in vitro manipulation is that these NSCs display characteristics of a naturally defined 
developmental stage and bear a low risk to form tumors – although ectopic colony formation is 
quite alarming [237]. At this stage NSCs are already patterned and committed to differentiation 
lineages, but are still malleable and resistant to stress, therefore they are likely to survive in the 
injured host tissue. However, obtaining the appropriate amount of day 40 human fetal tissue 
(corresponding to the rat E14 developmental stage) from abortions may not be trivial. Isolation 
of primary tissue is subject to batch-to-batch variability, and the isolated fetal tissue may not be 
enough to fill the lesion site (quantity).  
Fetal spinal cord derived cell lines (i.e. HuCNS-SC® and HSSC), which were described in 
paragraph 2.3.3., overcome potential batch-to-batch variability issues and have been expanded 
to obtain the appropriate quantity needed for clinical studies. They have been tested in several 
pre-clinical and clinical studies and are therefore “ready-to-go”. However, due to extensive 
propagation in vitro, these cell lines may have acquired “artificial” properties. 
Both primary fetal spinal cord tissue and fetal spinal cord derived NSC lines are subject to ethical 
implications and their transplantation has to be accompanied by immunosuppressive 
treatments to avoid graft rejection. In addition, both cell sources are committed to specific NSC 
lineages, therefore limiting the degree of freedom to select specific NSC populations, such as 
OPCs.   
In this context, ESCs and ESC-homologue iPSCs represent means to obtain large amounts of any 
cell type of the human body, however only iPSCs allow for autologous transplantation without 
ethical implications. Both cell sources will be briefly reviewed hereafter. 
 
2.4.1. Embryonic stem cells and induced pluripotent stem cells 
 
The term “pluripotent” describes in a broader sense a cell that can generate cell types of each of 
the three germ layers: endoderm, mesoderm and ectoderm. On the other side, a totipotent 
stem cell has the ability to generate any cell within an organism. ESCs are obtained from the 
inner cell mass (ICM) of blastocysts and are therefore not totipotent: they can give origin to any 
cell type of an organism but not to trophoblasts, which constitute the envelope surrounding the 
ICM. 
Human ESCs have been successfully isolated from blastocysts about 20 years ago [239], leading 
to the optimistic idea that they represent an unlimited source of any cell type for future basic 
research, drug screenings and cell transplantation. However isolation of ESCs from human 
blastomeres led to vehement public debate, although a method was published to generate hESC 
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lines without embryo destruction [240]. Ethical concerns about the morality of the use of 
human embryos for research purposes led to the prohibition or tight regulation of their use. 
Nevertheless numerous hESC lines were established and patented world-wide, including several 
clinical grade hESC lines which have been derived following Good Manufacturing Practice (GMP) 
guidelines and throughoutly genomically characterized [241-243]. Unfortunately, these lines did 
not gain the popularity of previously established hESC lines, such as the HUES6, HUES7, HUES9 
(Harvard University Embryonic Stem Cell) lines, and were never used in clinical trials [244]. 
Although derivation of hESCs is standardized and although they express similar markers at the 
undifferentiated state, hESCs do not have an equal developmental potential. The differentiation 
propensity of HUES lines 1-17 was compared following spontaneous as well as specific / 
directed differentiation at early and late passages to assess dependency of differentiation 
propensity on hESC senescence. While senescence did not affect predisposition for specific 
differentiation lineages, significant differences were observed across HUES lines. Some lines 
were committed to the mesodermal lineage (f.i. HUES1, HUES4, HUES8) and to the endodermal 
lineage (HUES4, HUES8), whereas others were inclined towards ectodermal / neural lineages 
(HUES6, HUES9) [245]. Altogether, hESCs represent an extremely powerful tool for regenerative 
medicine and in vitro disease modeling, as they are a virtually unlimited source of any cell type 
of the human body. However, their use is tightly regulated and accurate testing is necessary to 
assess their differentiation potential. On the other side, their genomic integrity has been 
throughoutly characterized and the existence of clinical grade hESCs enables faster and safer 
transfer into a clinical setting.  
A decade ago, Kazutoshi Takahashi and Shinya Yamanaka reported the successful development 
of an unimaginable and incredible technique, which opened up infinite possibilities for 
development and disease modeling as well as for regenerative medicine: by retroviral 
introduction of four factors - today known as Yamanaka factors - Oct3/4, Sox2, c-Myc and Klf4 
into somatic cells, the authors were able to obtain cells which had lost their somatic identity and 
assumed morphology, gene expression and growth properties of ESCs. In addition, 
reprogrammed somatic cells were able to give origin to all three germ layers and to contribute 
to development when introduced into a blastocyst [213, 246-249]. These cells were named 
induced pluripotent stem cells (iPSCs) and represent, similarly to ESCs, an unlimited source of all 
cell types of the human body. The discovery of iPSCs was a breakthrough, had a huge impact on 
the scientific community world-wide and was awarded with a Nobel Prize in Physiology and 
Medicine in 2012, only 6 years after the first publication.  
The impact of iPSCs in the field of regenerative medicine is remarkable: somatic cells can be 
harvested through minimally invasive or non-invasive methods, reprogrammed into a 
pluripotent state and used to obtain any desired cell type for autologous transplantation. 
Therefore iPSCs represent a unique and non-controversial tool for personalized and autologous 
therapeutic intervention.   
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The following paragraphs will be dedicated to the generation and differentiation of iPSCs, as 
well as their application. Lastly, the emerging field of direct fate conversion will be briefly 
reviewed.  
 
2.4.1.1. Generation and safety of induced pluripotent stem cells 
 
Conversion of somatic cells to a pluripotent state was first achieved by retroviral introduction of 
either combination of four transcription factors into fibroblasts: Oct3/4, Sox2, c-Myc and Klf4 
(Yamanaka factors) or Oct3/4, Sox2, Nanog and Lin28 [250]. Within only two years after the first 
publication, several laboratories world-wide published high-impact studies where a variety of 
somatic cell sources and transcription factor combinations were used to obtain iPSCs, including 
fibroblasts, blood cells, cord blood cells, liver cells, stomach cells, pancreatic cells, adult NSCs 
and keratinocytes. These studies proved the reproducibility and reliability of the novel 
technique [251-262].  
Delivery of the Yamanaka factors into somatic cells was originally achieved using moloney 
murine leukemia virus (MMLV)-derived retroviruses containing the pMX vector and the 
transcription factors of interest. Each viral vector contained one transcription factor; therefore 
each transcription factor was delivered separately to somatic cells within a viral cocktail [213, 
246]. Reprogramming efficiencies were very low, about 0.01% for human fibroblasts. Moreover, 
the fact that each reprogramming factor is delivered separately may lead to highly variable 
expression levels of each factor in each target cells, which in turn may lead to an extremely 
heterogeneous resulting iPSC population.  
Within the past decade, several alternative reprogramming methods were developed to 
enhance efficiency of reprogramming and address biosafety issues, which are summarized in 
figure 2.2.  
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In fact, when germline competence of retrovirally-reprogrammed iPSCs was tested, about 20% 
of the chimeric progeny developed tumors, probably due to reactivation of the viral transgenes 
[249]. In addition, integration of the reprogramming factors into the genome may as well result 
in tumor formation. Therefore, two studies tested an adenovirus-mediated delivery system 
[258, 263], as the genetic material of adenoviruses is neither integrated into the host genome 
nor replicated during cell division: after its release into the host cell, the double-stranded DNA is 
transcribed and degraded [258]. This reduces the efficiency of reprogramming, which was not 
Figure 2.2 Generation of induced pluripotent stem cells. 
Numerous techniques for the generation of iPSCs have been developed in the past decade to 
avoid the necessity of viral delivery of the four reprogramming factors and potential 
mutagenesis in de-differentiated somatic cells. Viral delivery was first replaced by DNA-based 
delivery, which however, in the case of integrative DNA fragments, still bares the risk for 
mutagenesis. RNA-based and protein-based introduction of the four reprogramming factors are 
the safest reprogramming methods, although their efficiency is still very low.    
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successful when the four reprogramming factors were delivered separately, even if 
adenoviruses were delivered repeatedly [263]. In one of the studies, reprogramming via plasmid 
transfection was tested; however, reprogramming efficiency was very low and integration of the 
plasmid into the genome was detected [263]. To improve reprogramming efficiencies and 
activate/deactivate the reprogramming factors in a controlled manner, polycistronic lentiviral 
vectors which contain all transcription factors in a single cassette were developed, whereby 
gene expression was either regulated by tetracycline (i.e. doxycycline) presence/absence or 
silenced by Causes Recombination (CRE)-mediated excision of the expression cassette [264-
266]. These lentiviral vectors were named STEMCCA (“STEM Cell Cassette”) and are now 
commercially available (Millipore, #SCR548, #SCR518, #SCR513, #SCR512). A subsequent study 
published by the STEMCCA developers stressed the importance of eliminating residual 
transgene expression from iPSC lines [267]. However, due to integration of the expression 
cassette into the genome and to the possibility that activation/deactivation of the oncogenes 
may not be completely reliable, tumor formation cannot be excluded when using lentiviral 
STEMCCA plasmids for reprogramming. Therefore, non-viral multiprotein expression cassettes 
were developed and delivered to somatic cells within a PiggyBac transposon containing a 
tetracycline trans-activator [268]. A “transposon” is a mobile (=transposable) genetic element: it 
can change its position within the genome via a non-replicative “cut & paste” or a replicative 
“copy & paste” mechanism. Long after their discovery, which was awarded with a Nobel Prize in 
Physiology and Medicine in 1983, transposons were instrumentalized as non-viral gene delivery 
system [269]. In addition, CRE-mediated factor excision can be used to ensure elimination of the 
oncogenes from iPSCs [268]. The system seems to represent a reliable means to generate non-
genetically modified iPSCs without viral delivery.  
Non-integrative reprogramming methods were also developed to bypass the potential and 
permanent genetic modifications resulting from integration of retroviral and lentiviral vectors, 
as well as of transposons. Non-replicative as well as replicative episomal (=extra-chromosomal) 
vectors were used for DNA-based, non-viral and non-integrative reprogramming [270-272]. 
Episomes are commercially available (ThermoFisher Scientific #A14703) plasmids which can be 
introduced into somatic cells without viral-mediated delivery and persist as well as replicate in 
the cytoplasm during the host cell cycle. In absence of a selection drug, plasmid replication does 
not occur and the episomal DNA is not passed on to the progeny during cell division. Transgene-
free progeny can therefore be selected for further use. However, since Episomes in general can 
persist in the cytoplasm as well as get integrated into chromosomal DNA, a screening is 
necessary to identify integration-free cell progeny.  
Last but not least, two reprogramming methods have been developed, which are not based on 
DNA delivery and thereby completely bypass the risk for genetic alterations due to insertional 
mutagenesis: RNA-based and protein-based delivery of reprogramming factors. The first 
method is based on repeated delivery of a synthetic mRNA molecule which was designed to 
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overcome immediate degradation by the cell’s antiviral response and to be efficiently 
translated. In addition, the reprogramming efficiencies were very high - however the 
methodology is relatively complex: RNA engineering, optimization of delivery methods, 
treatment with soluble interferon to counteract immediate degradation and optimization of cell 
culture conditions (culture media, feeder cell types, amount of oxygen) were necessary to 
obtain the desired outcome [273]. In the second study, Oct4, Sox2, Klf4 and c-Myc recombinant 
proteins containing a poly-arginine (11R) protein transduction domain were generated and 
transduced into fibroblasts, where they readily entered the nucleus. Repeated transduction as 
well as the HDAC inhibitor valproic acid (VPA) were used to enhance reprogramming efficiency 
[274]. Generation of iPSCs using protein transduction is very promising as it relies on a safer, 
faster and simpler reprogramming method.    
Altogether, generation of iPSCs has been performed world-wide using diverse reprogramming 
techniques and donor cells from several mammalian species and tissues. Although the end-
result, i.e. characteristics of the reprogrammed progeny, is generally reproducible, the necessity 
to define a standardized reprogramming method to reduce laboratory-to-laboratory batch-
variability needs to be addressed. In addition, most commonly used reprogramming methods 
introduce genetic mutations into the donor cells, and reprogramming, as well as 
characterization of the resulting iPSC line are very time-consuming.  
 
2.4.1.2. Induced pluripotent stem cells for regenerative medicine 
 
Currently, clinical application of PSC-derived progeny comprises five fields: age-related macular 
degeneration (AMD), Parkinson’s disease (PD), SCI, type I Diabetes and myocardial infarction 
[275]. One clinical trial using iPSCs was started in Japan in an individual with AMD. The outcome 
was satisfactory, as the patient’s vision has stopped deteriorating [276]. However, when the 
second patient was about to receive the treatment, the presence of potentially dangerous 
genetic mutations were detected in the iPSC line, leading to the termination of the trial and to 
critical considerations about the use of iPSCs in a clinical setting [275]. A feasibility clinical trial 
for the production of autologous retinal pigment epithelial cells from iPSCs was initiated in 2015 
to assess the safety and efficacy of the differentiation protocol prior to application in AMD 
(clinicaltrials.gov ID: NCT02464956). However, there are no reports about the outcome of the 
study. This example shows that although iPSCs are a highly promising source of any cell type for 
autologous cell therapy, they are still very far from routine clinical use and have to be used with 
caution.   
One reason behind this is the lack of a standardized production and quality control procedure. 
While commercially available ESC are well-characterized and have been used for decades of 
research, iPSCs still remain heterogeneous in terms of reprogramming method adopted, donor 
tissue, genetic and epigenetic profile, and more importantly of quality. Therefore, while the 
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potential of iPSCs in the field of regenerative medicine is enormous, as big is the risk of a 
fragmented development of their application.  
Nowadays it becomes more and more common that iPSCs are generated in a core facility, such 
as the iPSC core facility of the Helmholtz-Center in Munich, Germany (https://www.helmholtz-
muenchen.de/ipsc/index.html). The idea behind is to have a central “bank” of iPSC lines, which 
are generated following highly standardized protocols and throughoutly characterized. In 
particular, the generation of standardized iPSCs for pre-clinical and clinical use should comply 
with GMP guidelines.  
GMP is a world-wide guideline for ensuring that products, such as f.i. food and pharmaceutical 
products, are produced and controlled according to quality standards. The guidelines indicate 
the “minimum requirements” that a manufacturer must meet to make sure that the products 
are of high quality and of no risk to the customer or patient. GMP fundamentals and a full GMP 
manual, as well as numerous books about production, validation, quality management and 
regulations, are published by Maas and Peither GMP Publishing (https://www.gmp-
publishing.com/en/gmp-home.html) and cover a whole range of topics including structure and 
hygienic conditions of manufacturing facilities, environmental conditions, manufacturing 
processes, manufacturing documentation (Good Documentation Practice, GDP), qualification of 
operators, product distribution.  
GMP regulatory guidelines for “iPSCs as a product” include the type and method for the 
procurement of somatic donor cells; the derivation, expansion and cryopreservation of iPSC 
lines; the characterization of their properties, including genetic and epigenetic profile; 
monitoring of absence/presence of pathogens; monitoring of phenotypical stability over 
prolonged passaging or storage. Importantly, similar guidelines should be applied to the 
differentiation procedure.  
An ideal pre-requisite for a transfer of iPSCs into routine clinical use would be the establishment 
of a global “GMP iPSC haplobank” [277]. In fact, while on one side it seems utopic to generate 
iPSC lines and differentiate them to match any type of target tissue for autologous 
transplantation ad hoc in a timely manner, a haplobank would represent a core storage facility, 
in which iPSCs are generated in a standardized manner from selected donors, whose profiles 
matches the widest possible amount of recipients world-wide. For instance, donors would have 
blood group 0 and would be homozygous for common human leukocyte antigens (HLA), thereby 
reducing the risk of rejection by the recipient(s). This would reduce the necessity for local GMP 
compliant iPSC production and reduce global variability of iPSC sources. 
Altogether, it is becoming clear that iPSC production and application should be tightly regulated 
by globally accepted guidelines prior to a transition into the clinic. 
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2.4.1.3. Differentiation of pluripotent stem cells into neural phenotypes 
 
The relevance of PSCs for regenerative medicine has been extensively discussed above; 
however neural tissue engineering would not be possible without deep knowledge of the 
neurodevelopmental mechanisms which underlie the formation of mature neurons and glia and 
the establishment of neural networks, both in health and disease. Corticogenesis and the 
complex mechanisms of CNS development have been investigated and recapitulated in vitro 
using PSCs [278], significantly contributing to our understanding of neurodevelopmental 
processes as well as of neurological disorders. Due to the complexity and inaccessibility of the 
human brain for experimental investigation, animal models have traditionally been utilized to 
study embryonic and postnatal CNS development. The advent of PSCs, and especially of iPSCs, 
opened up the possibility to study human neural development in health and disease [279], 
culminating in the establishment of 3D in vitro cultures, in which differentiating cells self-
organize to form complex structures. The latter have been referred to as “organoids”. Organoids 
contain the neural phenotypes normally present in the CNS, and these are in addition self-
organized to recapitulate both tissue and organ structure [280-282].  
Soon after the discovery of iPSCs, protocols for their differentiation into specific neural lineages 
have been established, based on early or more recent knowledge gained from ESC in vitro 
differentiation [283-290].    
The most common in vitro neural induction procedure for hPSCs [288, 291] starts with exposure 
of free-floating PSC colonies, referred to as embryoid bodies (EBs), to a basic neural medium. 
Cells acquire a neural plate - homologue neuroepithelial identity and, once plated on a 
substrate, they self-organize in multi-layered concentric structures, which mimic the closure and 
stratification of the neural tube and are referred to as neural rosettes (NRs). During neural 
development, patterning or lineage specification of neural tube progenitors is mediated by 
exposure to soluble factors called morphogens. For instance, bone morphogenetic proteins 
(BMPs) and sonic hedgehog (SHH) are released dorsally from the roof plate and ventrally from 
the notochord, respectively. Neural tube progenitors are exposed to gradients of morphogens, 
and this in turn leads to their commitment to a specific cell fate: for example, ventrally 
patterned neural progenitors will give origin to ventral motor neurons. On the other side, 
exposure to retinoic acid (RA) confers them a caudal or spinal cord phenotype [292-294]. 
Similarly, NR progenitors are most sensitive to in vitro patterning, and commitment to a specific 
fate is maintained in later stages [288]. After patterning, NRs are manually picked and cultured 
either at low-adhesion (neurospheres) or on substrate (adherent monolayer) in the presence of 
the growth factors basic fibroblast growth factor (FGF) 2 and epidermal growth factor (EGF). 
During this step, neuroepithelial progenitors become tri-potent NSCs and their differentiation 
will give origin to astrocytes, oligodendrocytes and neurons.  
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Within the past decade, neural differentiation protocols have been optimized for the directed 
differentiation of PSCs into a nearly pure desired cell population, such as OPCs [208, 211, 212, 
285, 295], astrocytes [205, 296, 297] and neurons. In the latter case, protocols for neuronal 
differentiation have been additionally fine-tailored in order not to obtain a randomly mixed 
population [288], but neurons with a defined neurotransmitter-phenotype, including pyramidal 
neurons [298], midbrain dopaminergic neurons [299-302], spinal motor neurons [206, 303, 304] 
and serotonergic neurons [207]. Phenotypical specification offers the possibility to investigate 
or manipulate mechanisms of development or disease progression in a cell population of 
interest. For instance, iPSC-derived dopaminergic neurons can be useful to investigate 
molecular mechanisms underlying neurodegeneration in PD. In addition, the healthy neuronal 
cell population can be engrafted to substitute diseased neurons: healthy dopaminergic neurons 
can be transplanted in individuals affected by PD. Similarly, neuronal precursors which have 
been patterned towards a spinal cord phenotype will be more suitable to substitute damaged 
neurons after SCI than non-spinal cord-residing dopaminergic neurons.   
It has to be said, however, that although protocols for directed differentiation of PSCs are very 
promising, they hardly lead to pure populations without additional selection procedures, such 
as fluorescence-activated cell sorting (FACS)-mediated purification. In addition, they are not 
easily reproducible, partially due to the variability of the PSC line used. Thus, these protocols are 
still not sufficiently robust.  
In summary, PSCs are a useful tool for the investigation and recapitulation of neural 
development, which constitutes the basis for tissue engineering (figure xx). Based on broad 
knowledge of neurodevelopmental mechanisms, protocols for the directed differentiation of 
PSC into specific neural phenotypes have been established, however these methods are not 
easy to reproduce.  
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2.4.2. Direct fate conversion of somatic cells into neuronal phenotypes 
 
While one advantage of hPSCs is the high degree of freedom regarding the progeny that can be 
obtained, a big disadvantage is that most of the differentiation procedures are extremely time-
consuming [205]. Moreover, each step of neural induction may introduce additional laboratory-
to-laboratory or batch-to-batch variability and strongly influence the outcome of differentiation. 
For example, both size and density of EBs, NRs and neurospheres or adherent progenitors may 
affect their sensitivity to a certain soluble factor necessary for directed differentiation. In 
addition, iPSCs still bear the risk of incomplete differentiation in vivo and consequent tumor 
formation. 
In order to shorten the duration of differentiation and to minimize variability, as well as the risk 
of tumor formation, forced expression of lineage-specific factors has been used to directly 
Figure 2.3 Induced pluripotent stem cells for tissue engineering. 
Somatic cells, for instance skin cells, can be obtained from any patient in a minimally invasive 
way.  Using viral or non-viral mediated delivery of the four reprogramming factors, somatic cells 
can be de-differentiated to a ESC-like pluripotent state.  Thereafter, by applying soluble factors, 
they can be guided towards any desired cell fate. For instance, via incubation with basic neural 
medium, their differentiation into NSCs is promoted. These can in turn give origin to neurons 
and glia and promote tissue repair, restoration of neural network function and functional 
recovery after spinal cord injury. 
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switch the phenotype of somatic cells - this process is called trans-differentiation or direct fate 
conversion. In 2010/2011 first evidence was published, that combinatorial (forced) expression 
of neural-lineage-specific transcription factors can efficiently convert fibroblasts into functional 
neurons in vitro, which are referred to as induced neurons (iN) [305, 306]. Mouse iNs not only 
expressed the neuronal markers ß-III-tubulin, NeuN and microtubule-associated protein 2 
(MAP2), but also synapsin, indicative of functional synapses; in addition, electrophysiological 
recordings demonstrated that they are functional [305]. Using the same transcription factors, 
human iNs were generated, however these were not electrophysiologically active. Expression of 
an additional transcription factor and extended culturing time were necessary for neurons to 
assume mature features [306]. In both studies GABAergic and glutamatergic neuronal 
phenotypes were predominant. One later study published by the same group demonstrated 
that one single pro-neural transcription factor, achete-scute family bHLH transcription factor 1 
(ASCL1), was sufficient to convert both mouse and gamma-Aminobutyric acid human fibroblasts 
into functional iNs, which however required a longer maturation process [215]. Subsequently, 
rodent fibroblasts were trans-differentiated into GABAergic interneurons [307], into OPCs which 
were able to mature and ensheat axons both in vitro and in vivo [308], as well as into functional 
astrocytes [309], demonstrating that fate conversion can be used to obtain a desired neural 
phenotype without an intermediate pluripotent state.  
Altogether, direct fate conversion represents a faster and safer method for the generation of a 
desired cell phenotype for disease modeling or tissue engineering. However, it is still not clear if 
the phenotype of trans-differentiated cells is stable for longer time-frames and, similarly to 
iPSC-derived cells, the limited availability of a human cell population which can be used as a 
reference makes it difficult to assess how close the phenotype of trans-differentiated cells 
matches the phenotype of native cells. The progeny obtained by direct fate conversion has low 
or no proliferation potential and can therefore not be expanded, for instance for 
transplantation purposes. In addition, in contrast to differentiation of PSCs, only one cell type at 
the time can be obtained by trans-differentiation. Last but not least, fate conversion is to date 
induced by viral - mainly lentiviral - delivery of lineage specific transcription factors [215, 305, 
308, 309]. As mentioned in 2.4.1.1., viral delivery and genomic integration of the expression 
cassette are potentially mutagenic. Therefore, although trans-differentiation does not 
necessarily include a pluripotent stage, the risk for tumor formation cannot be ruled out. 
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2.4.3. Pluripotent stem cell - derived neural stem cells in pre-clinical 
studies of spinal cord injury 
 
Soon after the advent of iPSCs and the establishment of neural differentiation protocols, the 
therapeutic potential of iPSC-derived NSCs for spinal cord injury repair was investigated in 
rodent models of SCI. The first goals of these studies were to assess safety, survival, 
differentiation and integration of iPSC-derived NSCs. First, safety of iPSC-derived neurospheres 
was evaluated by transplantation into the brain of non-obese diabetic / severe combined 
immunodeficiency (NOD/SCID) mice [229]. Transplantation into the intact CNS is in fact 
necessary to assess the properties and behavior of iPSC-derived NSCs in a physiologically 
healthy environment. iPSC-derived NSCs, which did not lead to tumor formation were 
considered to be safe and were thereafter transplanted into the spinal cord of mice after a 
contusion injury. Transplanted NSCs differentiated into functional oligodendrocytes, astrocytes 
and neurons and promoted functional recovery. Myelin-binding protein (MBP)+ myelin 
produced by oligodendrocytes, BDNF and NT3 likely released by astrocytes, tissue sparing and 
the presence of 5-HT+ fibers in close proximity to the graft were considered to be potential 
mechanisms contributing to functional recovery [229]. Next, the therapeutic potential of human 
iPSC-derived NSCs was examined in NOD/SCID mice after contusive SCI. NSCs differentiated into 
the three neural lineages, promoted angiogenesis, axonal regeneration and myelination, and 
formed synapses with host cells. Functional recovery persisted for several months after 
transplantation [230]. Pro-active contribution of grafted iPSC-derived NSCs, which were 
expanded in monolayer cultures to enhance homogeneity, to functional recovery was confirmed 
in a subsequent study by diphtheria-toxin (DT)-mediated selective ablation. This study also for 
the first time addressed the concept of “neuronal relay” in the context of iPSC-derived NSC 
transplantation. To this end, WGA-expressing adenoviruses were injected into the motor cortex 
of spinal cord injured mice. Wheat germ agglutinin or WGA, a plant lectin, which can be passed 
to second or third-order neurons across synapses, was detected caudally to the injury site. In 
addition, synapses between transplanted and host cells were detected by 
immunohistochemistry. Altogether, this study suggested that transplanted iPSC-derived NSC can 
give rise to functional neurons, which form synaptic connections with descending motor neuron 
projections as well as with caudal targets, therefore serving as “neuronal relay” and possibly 
accounting for the observed functional recovery [231]. These three studies addressed relevant 
questions in clinically relevant contusive SCI models. However, several aspects remained to be 
addressed. In fact, iPSC-derived NSCs were not patterned to assume spinal cord identities / 
phenotypes, therefore their efficacy to serve a functional relay in a spinal cord environment 
might not reach an optimal level. In addition, transplantations were performed acutely or sub-
acutely after SCI, raising the question if their therapeutical potential can be exploited in a 
chronic injury environment. Both these issues were addressed next. Caudalized human iPSC-
derived NSCs were transplanted into an “early chronic” model of SCI, four weeks after contusive 
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injury. In this study, iPSC-derived NSCs were found to differentiate into the three neural 
lineages, but no functional recovery was detected [310]. This suggests that iPSC-derived NSC 
transplantation approaches might need to be adapted to be effective in chronic SCI models, but 
it might also suggest that they might not be effective at all. Lastly, a very impressive study 
showed robust long-distance axonal outgrowth of transplanted human iPSC-derived NSCs three 
months after lateral hemisection of the rat spinal cord. Not only axonal outgrowth was 
remarkable, but extended axons also formed synapses with endogenous neurons. In addition to 
graft axonal-outgrowth, host axonal-ingrowth was detected, whereby host serotonergic axons 
penetrated the graft and formed synapses with grafted cells, suggesting the formation of a 
functional neuronal “relay”. However, no functional recovery was detected in this study. 
Alarmingly, human iPSC-derived axonal terminals were detected in the cortex, olfactory bulb 
and cerebellum of rats which received transplantation, and iPSC-derived NSCs were detected in 
the spinal cord central canal distally from the lesion site. More alarmingly, ectopic colony 
formation was observed in replication studies after transplantation of fetal-derived NSCs into 
the rat spinal cord, up to the brain stem and 4th ventricle (hindbrain). Ectopic colonies moreover 
expressed the proliferation marker Ki67 [237, 311, 312]. These findings indicate that although 
robust survival, differentiation and integration of NSC grafts into the host spinal cord are 
promising for tissue regeneration, they may also lead to undesired and potentially deleterious 
outcome.     
All in all, the presented studies addressed key aspects of iPSC-derived NSC transplantation after 
SCI. Transplanted cells are able to differentiate and integrate into the host spinal cord by 
functionally interacting with host cells, as well as to contribute to functional recovery. However, 
functional recovery was not observed throughout all studies, possibly due to the batch-to-batch 
variability of transplanted cells or of the adopted experimental procedure. In addition, although 
synapse formation was detected, whether these synaptic connections are electrophysiologically 
active was not demonstrated. 
In general, several mechanisms of action of iPSC-derived NSCs have been identified 
(myelination, production of neurotrophic factors, “relay” formation) as potential contributors to 
functional recovery. Still, to date it is not clear which role they play and the extent or necessity 
of their contribution needs to be determined. One reason behind this issue is the mixed 
phenotypical identity of iPSC-derived differentiated NSCs. Batch-to-batch NSC variability may 
lead to differentiated progeny with variable compositions of neurons and glia. The latter, in 
turn, fulfill very specialized tasks in the healthy and injured CNS. For instance, a true spinal cord 
“relay” mechanism can only be mediated by neurons, which receive an excitatory signal and 
convey it to the next neuron, such as glutamatergic neurons. In this case, forebrain GABAergic 
inhibitory or midbrain dopaminergic neurons are most likely of no use. On the other side, 
astrocytes produce ECM molecules and secrete neurotrophic factors such as BDNF, GDNF, NT-3 
and VEGF, which can promote axonal regeneration. Therefore, variable extent of astrocytic 
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differentiation in independent studies might lead to differential endogenous regeneration. In 
order to address mechanisms of tissue repair and promote functional recovery in a more 
controlled way, it is necessary to transplant well-characterized cells with a tailored phenotype.  
 
2.5. Astrocytes for tissue replacement after spinal cord injury 
 
Glial cells constitute about 90% of cell of the human brain [313], and are often being referred to 
as the “brain glue” due to their multiple roles in brain physiology, metabolism, development 
and disease, as well as response to traumatic injury. Astrocytes, which account for 20-40% of 
the total cells in the mammalian brain [314], regulate blood flow, homeostasis of water, ions, 
neurotransmitters, sugars and metabolites, secrete ECM components, regulate synapse 
formation and neurotrophins and modulate neuronal network activity. Therefore, they are 
crucial for brain function in health and disease.   
In a broad sense, astrocytes are glial cells of typically stellate morphology, characterized by 
extension of some big processes and numerous small processes. Astrocyte have been 
subdivided into two main categories based on their morphologies: protoplasmic astrocytes are 
located in the gray matter and have numerous short highly branched processes, whereas 
fibrous astrocytes are located in the white matter and have long sparsely branched processes. 
However, the astrocytic population is extremely heterogeneous: glial progenitors are subject to 
developmental patterning, leading to morphological und functional diversity, which is not well 
characterized and under investigation [315, 316].   
It has been shown that astrocytes are organized in individual spatial domains: spatial overlap 
between two adjoining astrocytes amounts approximately 5% of their volume and only involves 
the outer portion of their processes, whereas the core region is never penetrated by other 
astrocytes [317, 318]. Within each domain, a single astrocyte can regulate the function of 105 
synapses in the rodent cortex and hippocampus and likely more than 106 in the human cortex 
[319]. Moreover, at least one astrocytic end-foot surrounds blood vessels [320]. Accordingly, 
each astrocyte plays a role in the regulation of both neural network and neurovascular function. 
From a neurodevelopmental point of view, specification and maturation of astrocytes has been 
extensively investigated but remains confusing, especially in terms of marker expression [321]. 
Initiation of astrogliogenesis or specification from an A2B5+ glial restricted precursor (GRP) [322] 
has been attributed to the transcription factors Sox9 and nuclear factor I-A (NFIA), which act 
synergistically to regulate genes involved in glial specification [323]. Following the gliogenic 
switch, NFIA induces expression of excitatory amino acid transporter 1 (EAAT1 also known as 
GLAST) in astroglial precursors, one of the two major astrocytic glutamate transporters [324]. 
Thereafter, maturing astrocytes are characterized by expression of the canonical astrocytic 
marker glial fibrillary acidic protein (GFAP), as well as by expression of S100 calcium-binding 
protein ß (S100ß), aldehyde dehydrogenase 1 family member L1 (Aldh1l1), the cell surface 
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marker CD44, the water channel aquaporin 4 (Aqp4), the astrocytic gap junction component 
connexin 43 (Cx43), aldolase C (AldoC) and the glutamate transporter EAAT2 (also known as 
GLT1), the latter four being associated with mature astrocytes [325-331]. However, timing of 
astrocytic marker expression is still not throughoutly clear. For instance, although Aqp4 is 
considered to be a hallmark of mature astrocytes [332], it is also expressed in subventricular 
zone-residing postnatal NSCs [333]. In addition, expression of the cytoskeletal filament marker 
vimentin has been associated with immature as well as with reactive astrocytes [334-336].  
Hereafter, the roles of astrocytes in the healthy as well as damaged CNS will be briefly reviewed. 
 
2.5.1. Role of astrocytes in the healthy central nervous system 
 
2.5.1.1. Cerebrovascular regulation of water, ion and sugar homeostasis 
 
Neural activity is a complex process, which demands a lot of energy. Therefore, the CNS is 
extremely dependent on continuous supply of energy sources, such as lactate, ATP and glucose, 
through the blood flow. It has been shown that the distribution of the cerebral blood flow is 
regulated according to the functional activity of different brain regions in time: when the 
activity of a certain brain region increases, also the blood flow in this region is increased. This 
mechanisms is called hyperaemia and is responsible for adequate delivery of energy sources to 
meet the needs of different tissues under physiological and pathological conditions [337]. 
Adjustments in blood circulation at a micro-environmental level are regulated by neurovascular 
units, which comprise endothelial cells (blood vessels), pericytes, a neuronal process and an 
astrocytic end-foot, as well as microglia and smooth muscle cells. Neurovascular units are not 
only important for modulating cerebral blood flow, but also play a big role in the regulation of 
the BBB [338-340]. Astrocytic end-feet almost completely enwrap blood capillaries; here, 
through the water channel Aqp4, multiple types of K+ channels and purinergic P2Y receptors 
[320], astrocytes regulate water and ion homeostasis and respond to purinergic signals (ATP).  
Importantly, extracellular K+ ion concentrations play crucial role in synaptic transmission: 
maintenance of a constant level of K+ during neuronal activity is a pre-requisite to maintain 
neuronal excitability [341]. 
On the other side, astrocytes release ATP in response to neurotransmitters through connexin 
hemichannels linking adjacent astrocytic processes in order to activate their own purinergic 
receptors. These results in intracellular Ca2+ fluctuations which propagate from one astrocyte to 
adjacent astrocytes, process referred to as Ca2+ wave. In addition, ATP’s catabolic end-product 
adenosine, which is released by astrocytes in the neurovascular unit, leads to vasodilation [342] 
and consequently to a decrease in vascular resistance and an increase in local blood flow. 
Therefore, through their role in the neurovascular unit, astrocytes are potent regulators of 
cerebral blood flow and therefore of energy supply. 
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Glucose is the metabolite which provides most of the energy needed in the brain. One very 
prominent human brain imaging technique, positron emission tomography or PET, is based on 
detection of 2-deoxyglucose in functionally and therefore metabolically active brain regions 
[343]. Interestingly, astrocytes respond to enhanced neuronal activity, particularly to the 
neurotransmitter glutamate, with increased production of glucose and with enhanced aerobic 
glycolysis. As a metabolic result, astrocytes produce and release lactate, which is taken up by 
neurons and used as alternative source of energy [343-345]. Hence, astrocytes serve as 
providers of energy for neurons.  
 
2.5.1.2. Regulation of neurotransmitter homeostasis 
 
In addition to K+, extracellular and intracellular concentrations of Na+ ions are of pivotal 
importance for neuronal and glial physiology. In the CNS, Na+ concentrations are crucial for the 
regulation of neurotransmitter homeostasis: most astrocytic neurotransmitter transporters are 
dependent on trans-membrane Na+ gradients to regulate extracellular neurotransmitter 
concentrations. Specifically, the glutamate (EAAT1 und EAAT2), GABA (GATs) and glycine (GlyT1 
and GlyT2) transporters require co-transport of Na+ ions to the intracellular space for an 
efficient uptake of the corresponding neurotransmitters. Stimulation of neuronal fibers leads to 
elevation of intracellular Na+ concentrations in astrocytes, which is coupled to neurotransmitter 
clearance [346]. The latter is crucial to ensure neuronal network activity: when glutamate is 
released from excitatory synapses, only rapid removal from the extracellular space will allow 
continuous neurotransmission. In addition, glutamate can be excitotoxic by leading to neuronal 
overstimulation, which results in neuronal degeneration. Under pathological conditions, such as 
traumatic injury of the CNS, excessive synaptic release, decreased clearance and leakage of 
glutamate from damaged cells contribute to an increase in extracellular glutamate 
concentrations. This in turn results in a secondary degeneration cascade [347]. The astrocytic 
transporters EAAT1 and EAAT2 maintain low extracellular concentrations of glutamate; in 
particular, EAAT2 accounts for more than 90% of the total glutamate uptake in the brain [347, 
348]. Therefore, defects in astrocytic glutamate transporter function might have a deleterious 
impact in the CNS. For example, expression of a defective splice variant of EAAT2 has been 
associated with Alzheimer’s disease (AD), although it is not clear if this is causal or 
consequential [349-352]. Once taken up by astrocytes, glutamate is metabolized to glutamine 
by the enzyme glutamine synthetase. Thereafter, glutamine is transported back into neurons, 
where it can be used as substrate for the synthesis of glutamate [346]. 
In summary, Na+-dependent glutamate uptake and metabolism by astrocytes is crucial for the 
maintenance of neuronal network activity.    
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2.5.1.3. Modulation of neural network activity 
 
As mentioned above, a single astrocyte can contact potentially more than 106 synapses in the 
human brain. Accordingly, one single astrocyte is able to sense, modulate and integrate 
information from several neighboring neurons at once [353]. Since astrocytes are organized in 
non-overlapping spatial domains [317, 318], the activity of a particular synapse is regulated by 
one astrocyte only. Astrocytes are able to sense neurotransmitters and react with intracellular 
Ca2+ fluctuations, phenomenon which is referred to as non-electrical excitability [353] and which 
allows them to monitor synaptic activity and react accordingly. In fact, astrocytes do not only 
sense but also release neuromodulators, termed “gliotransmitters”. These include ATP, 
adenosine, D-serine and glutamate [353]. For instance, in response to stimulation, Ca2+ is 
released from endoplasmic reticulum stores into the cytoplasm of astrocytes, which in turn may 
trigger release of glutamate into the extracellular space. Glutamate can here bind to pre-/ or 
post-synaptic glutamate receptors (mGluR and NMDARs) and regulate neuronal glutamate 
release and synaptic transmission. Astrocyte-released glutamate has been shown to modulate 
short-term plasticity of excitatory synapses by increasing (facilitation) or decreasing 
(depression) their strength [354, 355]. Interestingly, spatial localization and kinetics of 
glutamate-induced Ca2+ fluctuations are dependent on the concentration and duration of 
extracellular glutamate application: low concentrations of glutamate induce asynchronous Ca2+ 
fluctuations in single astrocytes or even in micro-domains within astrocytic processes without 
propagation to the soma; in contrast high concentrations of glutamate induce a global 
intracellular Ca2+ increase, which can propagate between adjacent astrocytes [355-357]. These 
so called astrocytic “Ca2+ waves” are considered to be one key mechanism of long-range 
modulation of neuronal network activity. The recognition of this bi-directional communication 
between neurons mediated by neurotransmitters led to the concept of “tri-partite synapse”. In 
this model a pre-synaptic terminal, as post-synaptic dendritic spine and an astrocytic process 
converge to form a functional unit [355].  
In summary, astrocytes are able to sense neuronal activity at a micro-domain and at a global 
level and can modulate synaptic transmission via fluctuations of intracellular Ca2+ 
concentrations and release of gliotransmitters.   
 
2.5.1.4. Production of extracellular matrix 
 
Among their functions, astrocytes are able to shape the extracellular environment to provide a 
stable milieu for neuronal activity: both neurons and astrocytes synthetize ECM components to 
support formation, maintenance and function of synapses [358]. Interestingly, ECM components 
are expressed in dynamic patterns during development and in the adult CNS [359], suggesting 
that they tightly regulate developmental processes as well as postnatal CNS function [360]. In 
38 
 
addition, the ECM is altered after traumatic injury of the CNS [28], in brain aging [361], as well 
as in several diseases of the nervous system [362-364].  
The ECM is an ensemble of glycoproteins and proteoglycans which form a highly organized 
environment embedding cells and regulating their interactions with molecular ligands or with 
other cells. ECM glycoproteins include laminin, tenascins and thrombospondins; proteoglycans, 
on the other side, can be subdivided into two major classes based on the type of GAG covalently 
linked to the core protein: heparin sulphate proteoglycans (HSPGs) and CSPGs [358].  
The neuronal soma, their proximal dendrites and the initial segment of the axon are enwrapped 
by a condensed and specialized ECM which is referred to as “perineuronal net” (PNN) and was 
first described by Camillo Golgi in 1882. The main components of the PNN are tenascin-R, 
hyaluronan (HA), CSPGs and link proteins, which stabilize the interaction between the latter 
two. On the other side, the C-terminal domain of CSPGs binds to trimeres of Tenascin-R [365, 
366]. The function of the PNN has not been fully understood yet, however it has been suggested 
to ensheat and thereby support highly active neurons, especially in terms of synapse formation 
and synaptic activity/plasticity. In fact, development of new synapses is coupled to the 
emergence of the PNN. On the other side, the negative charge of GAGs might serve as cation 
buffering agent, controlling the diffusion of K+, Na+ and Ca2+ ions and therefore neuronal activity 
[366]. 
Again, the role of astrocytes is crucial: they are able to secrete relevant ECM components, such 
as collagen, fibronectin, laminin, tenascin-C, thrombospondins, decorin, HSPGs such as glypican 
and syndecan and CSPGs such as versican, brevican, neurocan and phosphacan. Therefore, they 
contribute to the PNN, as well as to healthy CNS ECM and ECM alterations in CNS disease and 
after traumatic injury [28]. 
      
2.5.1.5. Astrocytic secretome 
 
Via exocytosis, diffusion through trans-membrane pores and active trans-membrane 
transport, astrocytes also serve as CNS secretory cells: they secrete diverse substances which 
contribute to CNS development and homeostasis, synaptogenesis and neuronal network 
function [367]. This secretory network has been termed “gliocrine system” [368].  
Components of the astrocytic secretome are neuro-/gliotransmitters, neuromodulators, 
hormones and peptides, metabolic substrates, scavengers of reactive oxygen species (ROS), 
inflammatory factors and, last but not least, growth factors and neurotrophic factors [368]. 
One prominent example is BDNF, a powerful regulator of dendritic and axonal growth during 
development and of their maintenance in the mature CNS [369]. BDNF is produced both by 
neurons and by astrocytes [370] and has two main forms: pro-BDNF, which binds to the 
neurotrophin receptor p75, and mature or mBDNF, which binds to TrkB receptors. 
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Interestingly, neurons usually release pro-BDNF which is taken up and processed by 
astrocytes to its mature form prior to release into the extracellular space [371]. While mature 
BDNF promotes survival, differentiation, synaptic long-term potentiation and neurite 
outgrowth as well as arborization through cytoskeleton remodeling, pro-BDNF is involved in 
the regulation of apoptosis, long-term depression, as well as neurite pruning and retraction, 
[369, 372]. Therefore, a well-balanced ratio of neuronally produced pro-BDNF and 
astrocytically secreted mature BDNF is crucial for an appropriate maintenance of neuronal 
circuit connectivity and activity.  
Both neurons and astrocytes also secrete GDNF, a potent neurotrophic factor which 
predominantly has trophic and neuroprotective effects on dopaminergic neurons [373] as 
well as noradrenergic, serotonergic and peripheral motor and sensory neurons [374]. Due to 
its trophic effect on dopaminergic neurons, GDNF has been under investigation as possible 
target for the treatment of PD and has been already applied in clinical trials [375-378]. In 
addition, a neurodevelopmental role has been attributed to GDNF in the pre-/ and postnatal 
regulation of primary sensory and motor neuron development [379]. 
NGF, also secreted by astrocytes [380], was the first nerve growth promoting factor 
discovered [381, 382] and supports survival and maintenance of several types of neurons in 
the CNS and PNS. Similarly to BDNF, NGF can have two forms: a less active pro-NGF form and 
a mature or ß-NGF form. When secreted, NGF binds to its receptor TrkA prior to uptake into 
neurons, where it exerts functions in survival, differentiation and growth of cholinergic, 
sympathetic and sensory neurons. It has been shown that NGF signaling plays a big role in the 
development of neuropathies, including diabetes and HIV-associated neuropathy, as well as 
in neuroprotection of cholinergic neurons in the basal forebrain complex, which is highly 
affected in AD. Based on this rationale, both pre-clinical and clinical studies have been 
conducted, where NGF was delivered to address neuropathies and neurodegenerative CNS 
diseases [383].   
Altogether, both neurons and astrocytes secrete neurotrophic factors which regulate 
neurodevelopment, neuronal survival, differentiation, growth and arborization, pruning and 
retraction as well as neuronal network activity. 
 
2.5.2. Reactive astrogliosis and glial scar formation  
 
One hallmark of CNS pathologies is reactive astrogliosis, a process in which astrocytes undergo 
morphological and functional changes in reaction to the altered CNS environment. Astrocytes 
respond to several forms of CNS insult, including infection, ischemia, neurodegenerative disease 
and traumatic injury [384], thereby significantly influencing pathobiology. Reactive astrogliosis is 
however a highly complex and still not throughoutly understood phenomenon.  
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Several molecular mediators leaking from the disrupted BBB or released by neurons, 
oligodendrocytes, microglia, endothelial cells, leukocytes or other astrocytes in response to 
insult have been shown to trigger aspects of reactive astrogliosis. These include cytokines and 
growth factors, such as LIF, CNTF, tumor necrosis factor (TNF) α, interferon (INF) γ, interleukin 
(IL) 6 and IL10; neurotransmitters, such as glutamate and noradrenalin; ATP; nitric oxide and 
ROS; Amyloid-ß; hypoxia and glucose deprivation. As a consequence, astrocytes (I) undergo 
hypertrophy or structural changes, particularly concerning the expression of intermediate 
filaments (GFAP, vimentin, nestin), (II) increase proliferation and migration rates, (III) act in a 
pro-inflammatory or anti-inflammatory manner, (IV) regulate extracellular homeostasis and (V) 
contribute to the formation of a glial scar [384].     
After traumatic injury of the CNS, tissue remodeling leads to the formation of a mature lesion, in 
which three major components can be identified: the lesion core, compact astrocytic scars and 
perilesion perimeters. The lesion core is characterized by a fluid-filled cyst of variable size or by 
a permanent fibrotic scar containing non-neural cells and ECM, as well as cellular debris, 
inflammatory and inhibitory molecules. The astrocytic scar is initiated by proliferation and 
migration of astrocytes to the lesion site to form a dense cellular barrier surrounding the lesion 
core [385], with packing densities up to double than in healthy tissue [24]. The perilesion 
perimeter is constituted by neural cell types, including neurons, oligodendrocytes and 
astrocytes which exhibit gradually decreasing reactive phenotypes with increasing distance from 
the lesion core [385].   
As major component of the glial scar, astrocytes exert diverging effects after injury: on one side 
they are neuroprotective by confining the lesion core in order to prevent diffusion of injury-
induced signals and consequent secondary damage; on the other side they represent an 
impediment to axon regeneration by expressing growth inhibitory molecules, including growth 
inhibitory ECM [24, 28, 385]. As mentioned above, CSPGs are upregulated in glial scar forming 
astrocytes and significantly contribute to the non-permissive environment leading to 
regenerative failure [28, 48]. Digestion of CSPGs with chondroitinase ABC has been extensively 
exploited in pre-clinical SCI studies in order to reduce the growth-inhibitory lesion environment 
and pave the way for regenerating axonal projections.  
Although the astrocytic scar has been widely regarded as one major impediment to 
neuroregeneration, its disruption does not have pro-regenerative effects, but the exact 
opposite. One recent study throughoutly addressed this issue in a rodent SCI model by a triple 
approach: (I) loss-of-function strategies to ablate scar-forming astrocytes, (II) genetic 
attenuation of scar-forming astrocytes and (III) ablation of chronic astrocytic scars. Interestingly, 
transgenic ablation or disruption of the glial scar did not lead to a significant reduction in CSPG 
expression in the lesion core or in adjacent regions, indicating that non-astrocytic scar-forming 
cells produce considerable amounts of CSPG. Next, although regeneration of injured axons was 
boosted by conditioning lesions of by neurotrophic factor delivery, regeneration was not 
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augmented but instead completely prevented in mice with defective glial scar. At a mechanistic 
level, the study showed that scar-forming astrocytes are able to up-regulate growth supportive 
CSPGs and laminin [25]. In conclusion, the study challenges the dogma which sees astrocytic 
scar formation as principle cause of CNS regenerative failure by demonstrating that glial scar 
disruption does not rescue but exacerbate it. 
In summary, astrocytes play a major role in the response of the CNS to traumatic injury by 
integrating several environmental signals and undergoing morphological and functional changes 
(figure 2.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Astrocytes have a crucial role in the healthy and diseased CNS. 
Astrocytes are a key component of the CNS: they regulate homeostasis of water, ions, 
metabolites and neurotransmitters; they produce ECM components and neurotrophic factors; 
they regulate the BBB and contribute to the response to traumatic injury; they regulate synapse 
formation and function. These are only selected features of astrocytes: their contribution to 
neural network development and function as well as to the response to injury is indispensable.  
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2.5.3. Transplantation of astrocytes following central nervous system 
trauma 
 
Due to the multiple and crucial roles of astrocytes in the CNS both under physiological and 
under pathological conditions, they represent a very attractive cell source for transplantation 
after SCI. They can contribute to restoration of tissue integrity by filling the lesion site and 
providing physical, trophic and metabolic support to damaged or sprouting axons. Through 
production of a permissive ECM or PNN-specific ECM, as well as through release of neurotrophic 
factors, they can influence neuronal growth and neural network connectivity. Through 
neurovascular units, they can regulate exchange of water and sugar between the vascular 
system and neurons, thereby ensuring adequate supply of energy to meet the neural network’s 
requirements. In addition, through regulation of ions and neurotransmitter homeostasis, they 
regulate neuronal activity. Therefore, reconstitution of damaged neural tissue may not be 
possible without an astrocytic scaffold.  
Several pre-clinical SCI studies have been conducted, in which astrocytes have been 
transplanted into the lesion site as substrate for repair. In transection as well as dorsal column 
injuries of the rat spinal cord, astrocytes differentiated from rat embryonic GRPs were found to 
promote robust axon growth and recovery of locomotor function. After unilateral dorsal column 
lesion, transplanted astrocytes were able to fill the lesion site, counteract endogenous 
astrogliosis and delay the expression of growth-inhibitory ECM components, thereby 
contributing to axon-growth into as well as beyond the lesion site. When performing in a grid 
walk test, rats which received astrocytic transplants performed significantly better than lesioned 
rats [222]. In a subsequent study, the authors compared rat embryonic GRP-derived astrocytes 
which were differentiated in the presence of either CNTF or BMPs. Both factors contribute to 
the commitment of multipotent CNS precursors to an astrocytic fate [386]. Morphological 
differences between the two astrocytic populations were detected, as BMP-treated GRPs gave 
origin to big, flat astrocytes, whereas astrocytes differentiated with CNTF where rather small, 
thin and bipolar. Once transplanted after dorsal column lesion of the rat spinal cord, CNTF-
astrocytes survived well at the lesion site, but produced inhibitory CSPGs and were not able to 
induce axonal regeneration or functional recovery. In contrast, BMP-astrocytes did not express 
inhibitory CSPGs and promoted axon growth and locomotor recovery [387]. This study 
addressed, for the first time, the question whether some astrocytic subtypes may be more 
suitable than others to promote repair after SCI. The authors confirmed this hypothesis with 
astrocytes derived from human 9-week old fetuses in the presence of either CNTF or BMP. 
Supporting their previous findings, they demonstrated that astrocytes treated with BMP were 
more suitable to promote regeneration after SCI [388]. However, other studies showed that 
there was no difference between the two astrocytic populations in the pro-regenerative 
43 
 
capacity after transplantation into the rat injured dorsal column, and functional improvement 
promoted by BMP-treated astrocytes could not be reproduced [389, 390]. 
Further pre-clinical studies addressed more in detail astrocytic mechanisms of action underlying 
their beneficial effects after CNS trauma. In particular, the authors focused on the ability of 
astrocytes to clear extracellular glutamate, which may accumulate at the injury site due to 
primary damage and in turn induce secondary damage. In fact, the astrocytic glutamate 
transporter EAAT2 (also known as GLT-1) is lost at the lesion core after SCI and newly generated 
astrocytes lack EAAT2 expression [391]; as a consequence, defective clearance of glutamate and 
its accumulation in the extracellular space may result in susceptibility of the CNS tissue to 
further damage. To test their hypothesis that astrocytic glutamate clearance is relevant for 
spinal cord neuroprotection and repair, the authors transplanted mouse glial progenitors 
overexpressing EAAT2 into the spinal cord of rats which were subject to hemi-contusion of the 
spinal cord. Indeed, lesion size was reduced in rats which received EAAT2-overexpressing 
astrocytes; in addition, transplanted cells preserved phrenic motor neurons and consequently 
diaphragm function [392]. By AAV-mediated overexpression of EAAT2 in endogenous astrocytes 
of the injured cervical dorsal horn in mice, the authors also demonstrated that defective 
glutamate clearance may underlie the development of neuropathic pain after SCI, which can be 
reversed by restoration of astrocytic EAAT2 function [393].    
Altogether, this first set of pre-clinical evidence demonstrates the relevance of astrocytes for 
spinal cord neuroprotection and repair. However, astrocyte transplantation has not been 
sufficiently investigated to date.   
 
2.5.4. Generation of astrocytes from pluripotent stem cells 
 
In the above mentioned studies, morphologically and functionally distinct astrocytic populations 
were differentiated from fetally-derived murine or human GRPs. However, these do not 
represent a suitable cell source for autologous transplantation and always have to face ethical 
implications relative to the use of fetuses for experimental and clinical research. On the other 
side, although the generation of safe, non-tumorigenic iPSCs is still being addressed world-wide 
for future applications, iPSCs represent a cell source of unlimited potential and protocols for 
their efficient differentiation have been established. While most efforts have been focused on 
the generation of specific neuronal populations, little attention has been dedicated to the 
generation of transplantable astrocytes.    
Commitment of neural precursors to the astrocytic phenotype can be induced in multiple ways. 
Two decades ago it was shown that the cytokine LIF and the neurotrophic factor CNTF, which 
act through the same receptor/signaling system (gp130), are potent inductors of astrocytic fate 
commitment: CNTF was able to induce astrocytic differentiation in more than 98% of precursors 
isolated from the fetal murine brain [386, 394]. At the same time, BMP4 and BMP2 were found 
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to induce commitment of subventricular zone-residing NSCs and bipotent oligodendroglial-
astroglial cortical progenitor cells to the astroglial cell fate, respectively [386, 395, 396]. 
Interestingly, CNTF and BMP4 exerted their astrocyte-inductive effects by distinct pathways 
[386], suggesting that they might drive specification of phenotypically distinct astrocytes. 
Indeed, when directly compared, astrocytes differentiated from GRPs with either CNTF or BMPs 
had distinct properties [387, 389], although their phenotypical properties could be reversed by 
interchanging the treatment. While A2B5+ GRPs treated with fetal bovine serum (FBS) or BMP 
gave origin to flat, stellate A2B5-/GFAP+ astrocytes, CNTF treatment led to intermediate 
A2B5+/GFAP+ with long processes; phenotypical properties were not reflected in a different pro-
regenerative potential in vivo [389]. In addition to CNTF and BMP4, fetal serum was found to be 
a potent inductor of astrocytic maturation in vitro [335], and is currently used in astrocytic 
cultures, despite its not well characterized composition.  
The first published protocols for the efficient generation of astrocytes from PSCs [205, 397] 
were based on prolonged culturing of neurospheres in minimal neural medium at low adhesion 
conditions: the authors postulated that, while early neurospheres are neurogenic, neurospheres 
cultured at least until day in vitro (DIV) 180 under these conditions become gliogenic due to a 
natural commitment-switch of neural precursors to the astrocytic lineage. After the gliogenic 
switch, progenitors were plated on a laminin substrate and their maturation was induced by 
treatment with CNTF. Using this simple approach, the authors were able to obtain nearly pure 
GFAP+ astrocytic populations which were: (I) regionally patterned, following treatment of NRs 
with the caudalizing agent RA, with the anteriorizing agent FGF8 and with the ventralizing agent 
SHH; (II) functionally active, as demonstrated by electrophysiological measurements of 
glutamate uptake and Ca2+ waves. Although the results of this study are convincing, the 
generation of pure astrocytic populations using this extremely simple protocol seems 
unrealistic. In addition, the fact that six months are required for completion is a major drawback 
from a clinical point of view.  
While the above mentioned protocol relies on GFAP expression as a hallmark of astrocytic 
identity, another study addressed the complexity of astrocytic maturation and the phenotypical 
diversity of mature astrocytes. For instance, it has been shown that protoplasmic astrocytes are 
rather mature/quiescent and express low levels of GFAP but high levels of EAAT2, whereas 
fibrous astrocytes are rather reactive and express high levels of GFAP but low levels of EAAT2 
[296]. Using dual-SMAD-inhibition-based induction of iPSC neural differentiation and exposure 
of neural progenitors to 1% FBS, the authors obtained nearly pure populations of maturing 
astrocytes within DIV 90. To induce maturation of astrocytes, instead of using the canonical 
CNTF treatment, the authors treated the cultures with FGF1 after FBS withdrawal. As a 
consequence, expression of GFAP, as well as the early astrocytic markers NFIA and connexin 43 
were down-regulated, while glutamate uptake was increased – hallmark of a mature/quiescent 
astrocytic phenotype. However, this seemed to underlie increased expression of EAAT1, but not 
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EAAT2. In contrast, exposure of progenitors to TNFα led to a reactive astrocytic population, 
characterized by significant increase in chemokine expression. 
As previously mentioned, the importance of astrocyte-mediated glutamate clearance was 
investigated in a rodent model of SCI [392]. The same group examined the efficacy of human 
iPSC-derived astrocytes in this respect. Neural progenitors with a caudal phenotype were 
obtained by dual-SMAD-inhibition and exposure to RA. Subsequently, exposure to neural 
medium supplemented with FBS for 60 DIV was used to induce astrocytic differentiation. Prior 
to transplantation, overexpression of EAAT2 in iPSC-derived astrocytes was induced lentivirally, 
as regular iPSC-derived astrocytes expressed little-to-no EAAT2. Astrocytes were injected 
immediately after C4 unilateral contusion in mice; EAAT2 expressing astrocytes led to reduced 
lesion size, as well as preservation of diaphragm innervation by phrenic motor neurons and of 
diaphragm function [398]. This study demonstrated the potential benefits of iPSC-derived 
astrocyte transplantation after SCI. However, the use of a lentiviral vector for the induction of 
EAAT2 expression may lead to mutagenesis. Ideally, EAAT2 expressing, glutamate sequestering 
astrocytes should be generated without genetic modifications.  
To date, no study has used a comparative approach to identify iPSC-derived astrocytes suitable 
for transplantation after SCI. 
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2.6. Rationale and Hypotheses 
 
Previous studies have demonstrated that transplantation of astrocytes with specific 
characteristics can be beneficial after SCI [222, 387, 388, 392, 393]. In particular, Davies et al. 
directly compared two astrocytic subtypes derived from murine or human glial restricted 
precursors upon terminal differentiation with FBS in combination with either CNTF or BMPs. 
Davies et al. pointed out that different astrocytic subtypes exhibit a more or less pronounced 
ability to serve as pro-regenerative substrate in the injured spinal cord [222, 387, 388]. On the 
other side, Falnikar et al. and Li et al. demonstrated the beneficial effect of astrocytes 
overexpressing the glutamate transporter EAAT2, also known as GLT-1, in an animal model of 
cervical SCI [392, 393]. Thus, selection of astrocytes with a distinct phenotypical and functional 
profile might increase the efficacy of this therapeutical approach. Generation of large amounts 
of astrocytes from human iPSCs for autologous transplantation is not subject to ethical debate 
and was achieved in independent laboratories [205, 296, 397, 399, 400]. These protocols were 
used as a reference to generate astrocytes from two iPSC lines and one well-characterized 
commercially available ESC line, which was used as a control. 
 
Hypothesis 1: 
Astrocytes can be generated from human ESCs and iPSCs by replication of previously published 
protocols. Astrocytes obtained following the same procedure will exhibit a similar profile. 
 
Hypothesis 2: 
Astrocytes terminally differentiated with CNTF, BMP2/4 or FGF1 are phenotypically different. 
The phenotypical profile acquired in vitro is at least partially maintained in vivo and therefore 
extensive in vitro characterization allows the selection of an astrocytic population which is more 
suitable to support neuroregeneration in vivo.  
 
Hypothesis 3:  
Pre-differentiated astrocytes survive after transplantation into the spinal cord, mature into their 
final phenotype and are able to restore tissue integrity as well as to promote regeneration of 
damaged neuronal projections.  
 
The experimental goal of this thesis was the generation and extensive in vitro as well as in vivo 
characterization of astrocytes to define the characteristics of an astrocytic substrate suitable to 
promote regeneration after SCI.  
To test hypothesis 1, I partially replicated and modified previously published protocols [205, 
397], whereby terminal differentiation was performed not only with CNTF, but also with 
BMP2/4 and FGF1. Authenticity of the astrocytic phenotype was assessed by calcium imaging in 
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response to ATP stimulation, as responsiveness to ATP is a peculiar property of mature 
astrocytes [401]. 
To test hypothesis 2, I analyzed the morphological and functional profile of astrocytes 
differentiated for two weeks. This included (1) cell size and basic morphology, (2) expression of 
astrocytic markers, (3) expression of NSC markers and proliferation markers, (4) expression and 
secretion of ECM components and of the neurotrophic factor BDNF and (5) direct influence on 
neurite elongation in co-cultures with primary DRG neurons. To test if their phenotype was 
stable and maintained in vivo, their expression profile was analyzed after transplantation into 
the spinal cord of Fischer 344 rats. 
To test hypothesis 3 pre-differentiated astrocytes were transplanted into the spinal cord of 
Fischer 344 rats after a dorsal column wire knife lesion at level C4. 
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3. Materials and methods 
 
3.1. Materials 
 
3.1.1. Chemicals, reagents and kits 
Chemical Company 
Adenosine triphosphate (ATP)  Sigma Aldrich 
Aprotinin Sigma Aldrich 
ß-Mercaptoethanol Roth 
Bovine serum albumin (BSA) Sigma Aldrich 
CaCl2∙2H2O Roth 
D(+)-Sucrose Roth 
Ethylenediaminetetraacetic acid (EDTA) Roth 
Ethanol 99.8%  (denatured) Roth 
Ethylene glycol Roth 
Donkey serum  Biochrome 
Fluoromount-G SouthernBiotech 
Fura-2-acetoxymethyl ester (Fura-2) Sigma Aldrich 
Glacial acetic acid Roth 
Glucose NeoLab 
Glycine Sigma Aldrich 
HCl VWR 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Roth 
Isopropanol Roth 
KCl NeoLab 
Methanol (MeOH) Roth 
MgCl2∙6H2O NeoLab 
Na2CO3 NeoLab 
NaHCO3 NeoLab  
Na2HPO4  Roth 
Na3PO4 Roth 
NaCl VWR 
NaH2PO4 Roth 
NaOH 10 N solution Roth 
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Chemical Company 
Na-Pyruvate 100 mM solution Thermo Fisher Scientific 
O-phenylenediamine (OPDA) Sigma Aldrich 
Paraformaldehyde Roth 
Phenylmethylsulfonylfluorid (PMSF) Sigma Aldrich 
ROTIPURAN® Glycerol Roth 
Sodium azide  Roth 
Tissue-Tek O.C.T. ™ compound Sakura 
Tris(hydroxymethyl)-aminomethan (TRIS) base NeoLab 
Tris(hydroxymethyl)-aminomethan (TRIS) hydrochloride NeoLab 
Triton X-100 NeoLab 
 
3.1.2. Reagents and kits for RNA isolation, cDNA synthesis and RT-PCR 
 
Reagents and Enzymes Company 
1,4-Dithiothreitol (DTT) Roth 
6x loading dye  Fermentas 
DNA ladder, 2log (1 mg/mL) New England Biolabs 
DNase I (100 Kunitz units/mL) Cellsystems  
Diethylpyrocarbonat (DEPC) Roth 
Deoxynucleoside triphosphate (dNTP)s (10mM) Promega 
Ethidium bromide (EtBr) NeoLab 
MMLV 5x reaction buffer Promega 
MMLV reverse transcriptase (200U/µL) Promega 
Oligo d(T) primers (500 µg/mL) Promega 
RNase A (20 mg/mL) Thermo Fisher Scientific 
RNAsin (40U/µL) Promega 
UltraPure™ Agarose Thermo Fisher Scientific 
  
Kits Company 
RNeasy Mini Kit Qiagen 
RNase-Free DNase Set Qiagen 
5-PRIME RT-PCR reaction mix VWR 
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3.1.3. Solutions and buffers 
 
3.1.3.1. General 
 
TRIS-buffered saline (TBS), pH 7.4 
Reagent For 1.0 Liter solution 
TRIS base   1.94 g 
TRIS hydrochloride   13.22 g 
NaCl 9.0 g 
ddH2O 1.0 L 
 
0.25 M monobasic sodium phosphate solution 
Reagent For 1.0 Liter solution 
NaH2PO4 27.60 g 
ddH2O 1.0 L 
 
0.4 M dibasic sodium phosphate solution 
Reagent For 1.0 Liter solution 
Na2HPO4 28.51 g 
ddH2O 1.0 L 
 
0.2 M phosphate buffer, pH 7.3 
Reagent Final concentration For 1.0 L solution 
NaH2PO4 0.2 M 230 mL 
Na2HPO4 0.2 M 770 mL 
To prepare 0.2 M phosphate buffer (pH 7.3), solutions of monobasic and dibasic sodium 
phosphate are prepared separately. When both salts are completely dissolved in ddH2O, the 
solutions are mixed and the pH verified using a pH meter. 
 
0.1 M phosphate buffered saline (PBS) 
Reagent Final concentration For 1.0 L solution 
NaCl - 9.0 g 
Phosphate buffer, 0.2 M 0.1 M 500 mL 
ddH2O - 500 mL 
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3.1.3.2. Calcium Imaging 
 
Buffered saline (SGG) for Ca2+ imaging 
Reagent Final concentration For 1.0 L solution 
CaCl2∙2H2O 2 mM 0.29 g 
Glucose 35.6 mM 6.305 g 
Glycine 1 mM 0.075 g 
HEPES 10 mM 2.3 g 
KCl 2.5 mM 0.186 g 
MgCl2∙6H2O 1 mM 0.203 g 
NaCl 140 mM 8.18 g 
Na-pyruvate 100 mM solution 0.5 mM 5 mL 
 
 
3.1.3.3. Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Coating buffer, pH 9.6 
Reagent Final concentration For 250 mL solution 
Na2CO3 - 397 mg 
NaHCO3 - 733 mg 
ddH2O - 250 mL 
 
Washing buffer 
Reagent Final concentration For 1.0 L solution 
NaCl - 14.36 g 
Triton-X-100, 100% 0.05% 500 µL 
PBS - 500 mL 
 
Blocking buffer 
Reagent Final concentration For 100 mL solution 
BSA  - 3.0 g 
PBS - 100 mL 
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Homogenization buffer 
Reagent Final concentration For 250 mL solution 
BSA  - 1.25 g 
NaCl - 3.6 g 
EDTA, 0.5 M 5 mM 2.5 mL 
Triton-X-100, 100% 0.1% 250 µL 
PBS - 500 mL 
These two components are added immediately prior to use: 
Reagent Final concentration For 100 mL solution 
Aprotinin - 228 µL 
PMSF, 0.2 M in MeOH - 125 µL 
 
Peroxidase buffer 
Reagent Final concentration For 100 mL solution 
BSA - 0.1 g 
Triton-X-100, 100% 0.25% 250 µL 
PBS - 100 mL 
 
Citric acid solution 
Reagent Final concentration For 100 mL solution 
Citric acid - 1.91 g 
ddH2O - 100 mL 
 
OPDA buffer, pH 5.0-5.4 
Reagent Final concentration For 100 mL solution 
Citric acid, 0.1 M 15mM 16.5 mL 
Dibasic sodium phosphate solution, 0.4 M 30 mM 8.3 mL 
ddH2O - 66.0 mL 
OPDA - 50 mg 
 
10% sulfuric acid solution 
Reagent Final concentration For 100 mL solution 
H2SO4, 2N  - 12 mL 
ddH2O - 88 mL 
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3.1.3.4. Gel electrophoresis 
 
50x TRIS-acetate-EDTA (TAE) buffer for gel electrophoresis 
Reagent Final concentration For 1.0 Liter solution 
Trizma Base - 242.0 g 
Glacial Acetic Acid - 57.10 mL 
EDTA, 0.5 M 50 mM 100 mL 
ddH2O - fill up to 1.0 L 
 
3.1.3.5. Immunocyto- and histochemistry  
 
Immunofluorescence blocking buffer for immunocytochemistry  
Reagent Final concentration For 100 mL solution 
Donkey serum 1% 1.0 mL 
Triton-X-100, 10% 0.1% 1.0 mL 
TBS - fill up to 100 mL 
 
4% Paraformaldehyde (PFA) / 0.1 M phosphate buffer 
Reagent Final concentration For 100 mL solution 
Paraformaldehyde - 40.0 g 
Phosphate buffer, 0.2 M 0.1 M 500 mL 
NaOH 10 N - 4 drops 
ddH2O - 500 mL 
ddH2O is heated to 65°C under constant stirring. Paraformaldehyde is carefully added, then 
NaOH is added drop-wise. The solution is cooled down to 40°C under constant stirring. After the 
paraformaldehyde has completely dissolved, the solution is filtered through a Whatman filter-
paper into  0.2 M phosphate buffer (1:1). Until used, the paraformaldehyde is stored at 4°C. 
 
30% Sucrose solution 
Reagent Final concentration For 1.0 L solution 
D(+)-Sucrose - 300.00 g 
Phosphate buffer, 0.2 M 0.1 M 350.00 mL 
ddH2O - 350.00 mL 
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Tissue collecting solution (TCS) 
Reagent Final concentration For 1.05 Liter solution 
Glycerol - 250 mL 
Ethylene glycol - 300 mL 
Phosphate buffer, 0.2 M 0.1 M 250 mL 
ddH2O - 250 mL 
 
Immunofluorescence blocking buffer for immunohistochemistry 
Reagent Concentration For 100 mL solution 
Donkey serum 5% 5 mL 
Triton-X-100 0.25% 250 µL 
TBS - fill up to 100 mL 
 
3.1.4. Antibodies  
 
3.1.4.1. Primary antibodies (ICC, IHC)  
 
Epitope Species Isotype Type Dilution Company 
Β-III-tubulin ms IgG monoclonal 1:1000 Promega 
CS-56 ms IgM monoclonal 1:300 Sigma Aldrich 
DCX gt igG polyclonal 1:500 Santa Cruz 
GFAP rb IgG polyclonal 1:1000 Dako 
hGFAP ms IgG1 monoclonal 1:1000 Stem Cells Inc. 
HoxB4 rt IgG2a monoclonal 1:10 DSHB 
Human Ki67 rb IgG monoclonal 1:500 Cell signaling 
Laminin rb IgG polyclonal 1:800 Sigma Aldrich 
Nestin ms IgG1 monoclonal 1:1000 Merck Millipore 
Neurofilament-H 
(NFH) 
rb IgG Polyclonal  1:500 Merck Millipore 
Human NUC (hNUC) ms IgG1 monoclonal 1:1000 Merck Millipore 
Sox2 gt IgG polyclonal 1:200 Santa Cruz  
Vimentin ms IgG1 monoclonal 1:1000 Merck Millipore 
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3.1.4.2. Secondary antibodies  
 
Epitope Species Isotype Dilution Company 
Alexa Fluor 488 α-ms dk IgG (H+L) 1:1000 Thermo Fisher Scientific 
Alexa Fluor 488 α-rb dk IgG (H+L) 1:1000 Thermo Fisher Scientific 
Alexa Fluor 488 α-gt dk IgG (H+L) 1:1000 Thermo Fisher Scientific 
Alexa Fluor 488 α-rt dk IgG (H+L) 1:1000 Thermo Fisher Scientific 
Alexa Fluor 594 α-ms dk IgG (H+L) 1:300 Thermo Fisher Scientific 
Alexa Fluor 594 α-rb dk IgG (H+L) 1:300 Thermo Fisher Scientific 
Alexa Fluor 594 α-gt dk IgG (H+L) 1:300 Thermo Fisher Scientific 
Cy5 α-ms dk IgG (H+L) 1:500 Dianova 
Cy5 α-rb dk IgG (H+L) 1:500 Dianova 
FITC α-ms  dk IgM (H+L) 1:500 Thermo Fisher Scientific 
4’,6-Diamidine-2’-phenylindole dihydrochloride (DAPI) 1:1000 Sigma Aldrich 
 
3.1.4.3. Primary antibodies (ELISA)  
 
Epitope Species Isotype Type Dilution Company 
BDNF rb IgG polyclonal 1:2000 Acris 
BDNF ch IgY polyclonal 1:2500 Promega 
 
3.1.4.4. Secondary antibodies (ELISA) 
 
Epitope Species Isotype Dilution Company 
Peroxidase-conjugated  α-ch rb IgY (H+L) 1:1000 Promega 
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3.1.5. Primers for RT-PCR 
 
Primer 5’-3’ sequence  Annealing °C Company 
Aqp4 fwd GGAATTTCTGGCCATGCTTA 53-54 Eurofins MWG Operon 
Aqp4 rev AGACTTGGCGATGCTGATCT  Eurofins MWG Operon 
Chl1 fwd ATGGAGCCGCTTTTACTTGGA 54-55 Eurofins MWG Operon 
Chl1 rev GGCAACTTGGACTTTTGACTGT  Eurofins MWG Operon 
EAAT1 fwd ATCCTTGGATTTACCCTCCGA 54-55 Eurofins MWG Operon 
EAAT1 rev CGCCATTCCTGTGACAAGAC  Eurofins MWG Operon 
FoxG1 fwd AGGAGGGCGAGAAGAAGAAC 55-56 Eurofins MWG Operon 
FoxG1 rev TCACGAAGCACTTGTTGAGG  Eurofins MWG Operon 
GAPDH fwd CCTTCATTGACCTCAACTAC 55 Eurofins MWG Operon 
GAPDH rev GGAAGGCCATGCCAGTGAGC  Eurofins MWG Operon 
HoxA5 fwd CCGGAGAATGAAGTGGAAAA 53-54 Eurofins MWG Operon 
HoxA5 rev ACGAGAACAGGGCTTCTTCA  Eurofins MWG Operon 
HoxB4 fwd ACACCCGCTAACAAATGAGG 55 Eurofins MWG Operon 
HoxB4 rev GCAGCAAAGATGAGGGAGAG  Eurofins MWG Operon 
Isl1 fwd AAACAGGAGCTCCAGCAAAA 53 Eurofins MWG Operon 
Isl1 rev AGCTACAGGACAGGCCAAGA  Eurofins MWG Operon 
NFIA fwd ACAGGTGGGGTTCCTCAATC 54-55 Eurofins MWG Operon 
NFIA rev GTGGGACGCTGCAACTTTT  Eurofins MWG Operon 
NFIX fwd ATGTACTCCCCGTACTGCCTC 55-56 Eurofins MWG Operon 
NFIX rev ACATCCGCTTTTCATGCTTCTT  Eurofins MWG Operon 
NG2 fwd GTCTTTTGAGGCTGCCTGTC 54-55 Eurofins MWG Operon 
NG2 rev CTGTGTGACCTGGAAGAGCA  Eurofins MWG Operon 
Nkx2.1 fwd CGCATCCAATCTCAAGGAAT 53 Eurofins MWG Operon 
Nkx2.1 rev TGTGCCCAGAGTGAAGTTTG  Eurofins MWG Operon 
Nkx2.2 fwd TGCCTCTCCTTCTGAACCTTGG 55-56 Eurofins MWG Operon 
Nkx2.2 rev GCGAAATCTGCCACCAGTTG  Eurofins MWG Operon 
Nkx6.1 fwd ACACGAGACCCACTTTTTCCG 56-58 Eurofins MWG Operon 
Nkx6.1 rev TGCTGGACTTGTGCTTCTTCAAC  Eurofins MWG Operon 
Olig1 fwd TTGCATCCAGTGTTCCCGATTTAC 56-58 Eurofins MWG Operon 
Olig1 rev  TGCCAGTTAAATTCGGCTACTACC  Eurofins MWG Operon 
Olig2 fwd CAGAAGCGCTGATGGTCATA 53 Eurofins MWG Operon 
Olig2 rev TCGGCAGTTTTGGGTTATTC  Eurofins MWG Operon 
Pax3 fwd GAACACGTTCGACAAAAGCA 52-53 Eurofins MWG Operon 
Pax3 rev GCACACAAGCAAATGGAATG  Eurofins MWG Operon 
PDGF-R fwd CTATCCACACTGTCAAACAGGTTG 56-58 Eurofins MWG Operon 
PDGF-R rev TCTGCTGGACTGAGAAGTTTCATC  Eurofins MWG Operon 
S100ß fwd AAAGAGCAGGAGGTTGTGGA 53 Eurofins MWG Operon 
S100ß rev AGGAAAGGTTTGGCTGCTTT  Eurofins MWG Operon 
57 
 
3.1.6. Cell culture 
 
3.1.6.1. Cell lines and primary cell cultures 
 
Name Type Source  Background 
Skin fibroblasts Primary Strain: Fischer344 rats 
Age: 9 - 13 weeks old 
Gender: female 
Weight: 140 - 180 g 
Direct source: Charles River Laboratories, Harlan 
Laboratories (Envigo) or in-house breeding 
Wild type 
DRG neurons Primary Strain: Fischer344 rats 
Age: 9 - 13 weeks old 
Gender: male 
Weight: 140 - 180 g 
Direct source: Charles River Laboratories, Harlan 
Laboratories (Envigo) or in-house breeding 
Wild type  
HUES6 PSCs Cell line Human embryonic inner cell mass 
Cell line established at Harvard University  
Passage number: 39 
Direct source: Laboratory of Prof. Dr. Beate Winner, 
Friedrich-Alexander Universität Erlangen-Nürnberg 
Wild type 
iPSC #1 Cell line Human Skin Biopsy 
iPSC clone name: 21E6 
Passage number: 46 
Direct source: Laboratory of Prof. Dr. Beate Winner, 
Friedrich-Alexander Universität Erlangen-Nürnberg 
Wild type 
iPSC #2 Cell line Human Skin Biopsy 
iPSC clone name: 19-23 
Passage number: 34 
Direct source: Laboratory of Prof. Dr. Beate Winner, 
Friedrich-Alexander Universität Erlangen-Nürnberg 
Wild type 
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3.1.6.2. Basic media, enzymes and supplements 
 
Chemical/Reagent Company 
2.5% Trypsin/EDTA  Life Technologies 
B27-Supplement (50x) Thermo Fisher Scientific 
Calpain Inhibitor Calbiochem 
Collagenase XI (10 mg/mL) Sigma Aldrich 
Dispase I (10 mg/mL) Worthington 
Destilled water Thermo Fisher Scientific 
DMEM/F12  Thermo Fisher Scientific 
Dimethyl sulfoxide (DMSO) NeoLab 
DPBS (1x) Thermo Fisher Scientific 
Fibrinogen (100 mg/mL) Sigma Aldrich 
Gentamicin (10 mg/mL) Thermo Fisher Scientific 
Hanks' Salt Solution Biochrome 
Heparin Sigma Aldrich 
Hibernate®-A Thermo Fisher Scientific 
L-Glutamine (100x) Thermo Fisher Scientific 
Laminin (1 mg/mL) Sigma Aldrich 
Non-essential amino acids (NEAA) (100x) Thermo Fisher Scientific 
N2-Supplement (100x) Thermo Fisher Scientific 
PAA Gold fetal bovine serum (FBS) Biochrome 
Penicillin / Streptomycin (10,000 Units/mL) Thermo Fisher Scientific 
Poly-L-ornithine (PLO) (10 mg/mL) Sigma Aldrich 
Retinoic Acid (RA) Sigma Aldrich 
Thrombin (100 U/mL in 10 mM CaCl2) Sigma Aldrich 
TrypLETM Express (1x) Thermo Fisher Scientific 
 
3.1.6.3. Growth factors and cytokines 
 
Factor (Cell culture) Factor (Additional for surgery) Company 
Recombinant hEGF Recombinant hGDNF PeproTech 
Recombinant hFGF1 Recombinant hHGF PeproTech 
Recombinant hFGF2 Recombinant hIGF PeproTech 
Recombinant hBDNF (ELISA)  Recombinant hNT-3 PeproTech 
Recombinant hBMP2 Recombinant hPDGF PeproTech 
Recombinant hBMP4  PeproTech 
Recombinant hCNTF  PeproTech 
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3.1.6.4. Cell culture media composition 
 
Basic neural medium (bNM) 
Reagent Concentration of stock Final concentration 
DMEM/F12  - - 
NEAA  100x 1x 
N2-Supplement 100x 1x 
B27-Supplement 50x 1x 
Heparin 2 mg/mL 2 µg/mL 
Penicillin/Streptomycin 10,000 U/mL 100 U/mL 
Gentamicin 10 mg/mL 1 µg/mL 
 
Proliferation medium for HUES6/iPSC-derived neurospheres 
Reagent Concentration of stock Final concentration 
bNM  - - 
Recombinant hEGF 100 µg/mL 20 ng/mL 
Recombinant hFGF2 100 µg/mL 20 ng/mL 
 
Proliferation medium for HUES6/iPSC-derived adherent NSCs 
Reagent Concentration of stock Final concentration 
bNM  - - 
FBS 100% 1% 
Recombinant hEGF 100 µg/mL 20 ng/mL 
Recombinant hFGF2 100 µg/mL 20 ng/mL 
 
Differentiation medium for HUES6/iPSC-derived adherent NSCs:  
Treatment Reagent Concentration of stock Final concentration 
 bNM  - - 
 FBS 100% 1% 
No factors - - - 
BMP Recombinant hBMP2 + hBMP4 200 µg/mL 10 ng/mL each 
CNTF Recombinant hCNTF 200 µg/mL 20 ng/mL 
FGF1 Recombinant hFGF1 200 µg/mL 20 ng/mL 
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Maintenance medium for primary DRG neurons 
Reagent Concentration of stock Final concentration 
DMEM/F12 - - 
Penicillin/Streptomycin 10,000 U/mL 100 U/mL 
L-glutamine 100x 1x 
B27 supplement 100x 1x 
 
3.1.7. Animals 
 
All primary culture preparation as well as animal experiments were carried out with 9-13 week 
old male or female Fischer344 rats weighing 140 to 180 g. Direct source: Charles River 
Laboratories, Harlan Laboratories (Envigo) or in-house breed. Animal experiments were carried 
out in compliance with national guidelines for animal care and use in accordance with the 
European Union Directive (2010/63/EU). All animal protocols were reviewed and approved by 
the local authorities and animal ethics committee. Animals had free access to food and water.  
 
3.1.7.1. Anesthesia mixture 
 
Drug Name Active substance Dosage Company 
Ketamine 10% Ketamine 62.5 mg/kg 
HFW Bremer 
Pharma GmbH 
Vetranquil® 1% Acepromacine 0.625 mg/kg Ceva 
Xylariem® Xylacine 3.175 mg/kg Ecuphar 
NaCl 0.9% - - Braun 
 
3.1.7.2. Post-surgical animal care 
  
Drug Name Active substance Dosage Company 
Ampicillin-ratiopharm®  Ampicillin 25 - 50 mg/kg Ratiopharm 
Bepanthen® Dexpanthenol - Bayer 
Fresubin - - Fresenius Kabi 
NaCl 0.9% - - Braun 
Rimadyl® Carprofen 4 - 5 mg/kg Pfizer 
Ringer solution - - Braun 
Temgesic® Burprenophine 0.03 - 0.05 mg/kg Reckitt Benckiser 
Sandimmun® Cyclosporine A 10 mg/kg Novartis 
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3.1.8. Laboratory equipment and disposables 
Item Company 
Glas bottles NeoLab  
0.5 mL Eppendorf tubes Greiner Bio-one 
1.5 mL Eppendorf tubes Greiner Bio-one 
10 mL disposable pipette tip Greiner Bio-one 
12-well cell culture plates Greiner Bio-one 
15 mL Falcons Greiner Bio-one 
24-well cell culture plates Greiner Bio-one 
24 x 60mm cover glasses Roth 
25 mL disposable pipette tip Corning, Inc. 
2 mL Eppendorf tubes Greiner Bio-one 
4- and 8-well chamber slides Nunc 
50 mL Falcons Greiner Bio-one 
5 mL disposable pipette tip Greiner Bio-one 
6-well cell culture plates Greiner Bio-one 
96-well plate (ELISA) Greiner Bio-one 
AQUAline AL25 water bath Lauda 
1 mL Cryotubes  Greiner Bio-one 
Disposable pipette tips: 10 µL, 20 µL, 200 µL, 1000µL VWR 
Disposable pipette tips w/ filter: 10 µL, 20 µL, 200 µL, 1000µL Greiner Bio-one 
DOS-20S shaker NeoLab 
Eppendorf research plus 8-channel pipet Eppendorf 
Feather® disposable scalpels: no. 11, no. 15 Feather 
Friedman-Pearson rongeur Fine Science Tools 
Gel electrophoresis chamber NeoLab 
Gel electrophoresis power source Peqlab, VWR 
Glas cover slips, round, 13 mm VWR 
Hamilton microliter syringe: 2µL, 5 µL, 10 µL Hamilton 
HERAcell 240i CO2 incubator Thermo Fisher Scientific 
HM 550 cryostate Zeiss 
Superfrost PlusTM microscope slides Thermo Fisher Scientific 
MSC-Advantage sterile hood Thermo Fisher Scientific 
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Item Company 
NanoDrop VWR 
Neubauers' cell counting chamber Supe-Rior Marienfeld 
Olympus CKX41 fluorescence microscope Olympus 
Parafilm NeoLab 
Pasteur capillary pipettes WU Mainz  
Peristaltic pump (perfusion) Ismatec 
PB-11 pH-meter Sartorius 
PCR reaction tubes Roth 
Picospritzer® II microinjector  Science Products 
PIPETBOY acu2 INTEGRA Bioscience 
Pipettes VWR 
Power source 250V VWR 
Precision balance Kern 
Thermometer NeoLab 
Whatman® filter paper Sigma Aldrich 
Surgical retractor Roboz 
RH basic 2 heating/stirring plates IKA 
Rotina 380R cell culture centrifuge Hettich Zentrifugen 
Silkam® silk suture with micro-lancet needle Braun 
Small animal stereotaxic instrument Kopf 
Sterilizer tray World precision instruments 
Straight and curved surgical forceps Fine Science Tools 
Suture clips Fine Science Tools 
Suture Tying forceps Fine Science Tools 
T175 cell culture flasks Greiner Bio-one 
T25 cell culture flasks Greiner Bio-one 
T75 cell culture flasks Greiner Bio-one 
Thermocycler (PCR) BioRad 
Ultra-Low Adhesion T75 Flasks Sigmal Aldrich 
Vortex mixer NeoLab 
Wire knife and retractable wire knife carrier Mc Hugh Milieux 
Wound clip remover Fine Science Tools 
63 
 
3.1.9. Imaging Equipment 
 
Imaging equipment Company 
Tecan sunrise 96-well microplate reader (ELISA) Tecan 
BX53 fluorescence microscope Olympus 
BX61 confocal laser-scanning microscope Olympus 
CKX41 bright field microscope (cell culture) Olympus 
IX81 motorized inverted fluorescence microscope Olympus 
UV gel capture chamber Peqlab 
BX51W1 upright fluorescence microscope Olympus 
 
3.1.10. Software 
 
Software Company Application 
Adobe Illustrator CS6 Adobe Image creation and processing 
Adobe Photoshop CS6 Adobe Image processing 
BioCaptTM Bio-Budget Gel imaging (UV) 
Cell-F  Olympus Fluorescence imaging 
Cell-P Olympus Fluorescence imaging 
Cell-R Olympus Fluorescence imaging (Calcium Imaging) 
Endnote X7 Thomson Reuters Reference management 
Fluoview 2.1.c Olympus Confocal laser scanning imaging 
ImageJ RSB Image processing and evaluation 
Magellan6TM Tecan ELISA: detection 
Microsoft Office Microsoft Data analysis 
Prims 6 Graphpad Graphpad Data anaylsis, statistics,  representation 
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3.2. Methods 
 
3.2.1. Maintenance of human pluripotent stem cells 
 
HUES6 (Harvard University embryonic stem cell line 6) and human iPSC lines were obtained 
from the laboratory of Prof. Dr. Beate Winner, Friedrich-Alexander Universität Erlangen-
Nürnberg. Human iPSCs were generated via retroviral delivery of the OSKM factors and 
thoroughly characterized. After clonal expansion until passage 10 - 11, good/stable iPSC clones 
per donor were selected and further expanded until passage 30 - 40. Hereby, PSCs were 
cultured on MatrigelTM-coated (BD Biosciences) 6-well plates (Nunc®) in mTeSR medium 
(StemcellTM Technologies) and differentiating cells, which may appear at the edges of growing 
PSC colonies, were mechanically removed every day or every other day. Our collaborators 
prepared PSC cultures, so that neural induction could be performed upon arrival.    
 
3.2.2. Neural induction of human pluripotent stem cells 
 
3.2.2.1. Day in vitro 0: generation of embryoid bodies  
Laboratory of Prof. Dr. Beate Winner, Friedrich-Alexander Universität Erlangen-Nürnberg 
 
PSC cultures were mechanically cleaned to eliminate differentiating contaminating cells. PSC 
colonies were then gently lifted with a cell scraper (Corning®). Homogeneous medium-sized 
colony fragments were transferred to ultra-low adhesion 6-well plates (StemcellTM 
Technologies) and cultured overnight in mTeSR medium. Resulting free-floating colonies are 
called EBs due to their capacity to give origin to progeny of all three germ layers. 
 
3.2.2.2. Day in vitro 1: neural induction 
Laboratory of Prof. Dr. Beate Winner, Friedrich-Alexander Universität Erlangen-Nürnberg 
 
Without further dissociation, EBs were centrifuged at 800 - 1000 rpm for 5 minutes and the 
mTeSR medium was replaced with bNM. Free-floating cultures were transferred to T25 or T75 
flasks to be transported to the Spinal Cord Injury Center, Ruprecht-Karls Universität Heidelberg.  
 
3.2.2.3. Day in vitro 3 to 7: maintenance of embryoid bodies 
 
On DIV 3, 5 and 7 EBs were centrifuged at 800 - 1000 rpm for 5 minutes and 50-75% of the bNM 
was replaced. If adherent colonies were observed, EBs were transferred to a new T25 or T75 
flask to prevent adherent colonies from undergoing spontaneous differentiation and releasing 
differentiation signals.  
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Single EBs tend to fuse and form clumps. To maintain a homogeneous culture and to ensure 
that all EBs are exposed to the same gradient of nutrients from the culturing medium, EB-
clumps or unusually big EBs were allowed to settle down by gravity in 50 mL falcon tube and 
mechanically fragmented. 
 
3.2.2.4. Day in vitro 8 (to 12): generation of neural rosettes  
 
Depending on the size of EBs, they might be kept for longer as free-floating suspension (up to 
DIV 12), especially if caudalization with RA is planned. RA has some toxicity for EB colonies, 
therefore very small colonies will die back entirely.   
Prior to plating, 6-well plates were coated with PLO (20 µg/mL in ice-cold water for 1 hour at 
37°C), rinsed and coated with laminin (10 µg/mL in ice-cold water for 2 hours at 37°C). If present, 
EB-clumps or big EBs were mechanically fragmented. EBs were allowed to settle down in a 50 mL 
falcon tube by gravity or by centrifugation at 600 rpm for 5 minutes. Small EBs still present in the 
supernatant were discarded, as they do not survive during the RA treatment. 40 to 50 medium-
sized EBs were plated per well of a PLO/laminin coated 6-well plate and cultured in bNM. The 
next day, the medium was replaced to eliminate debris and dead cells. 
 
3.2.2.5. Day in vitro 11: caudalization with retinoic acid 
 
At DIV 11, neural rosettes (NRs) are visible within attached aggregates as multilayered circular 
structure resembling the closed neural tube. Several NRs were present within one NR 
aggregate. 
At this point, the medium was replaced with fresh bNM medium containing 0.1 - 0.5 µm RA to 
induce caudalization. If no morphogen was added at this stage, the default phenotype of the 
progeny would be rostral (forebrain). RA and RA-containing medium were used in the dark, as 
RA is light sensitive and unstable. The medium was replaced on DIV 12 and 14 to provide fresh 
RA. 
 
3.2.2.6. Days in vitro 15 - 22: picking of early NRs to initiate free-floating 
cultures 
 
According to published protocols [205, 397] and to induce a glial phenotype, NRs and the 
resulting neurospheres need to be cultured as free-floating spheres, as attachment might 
trigger a neurogenic phenotype. 
NRs were selected based on their overall morphology, mechanically picked with a 200 µL pipet 
and transferred to a T25 or T75 flask without being fragmented to initiate the formation of 
neurospheres (early NSCs). Here it was particularly important to collect as many NRs as possible 
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in one T25 flask: the density of the initial culture will influence the proliferation potential of the 
derived NSCs; if  initial densities were too low, resulting NSCs were not well expandable. 
75% of the medium was replaced every 2nd day to provide fresh RA until DIV 22. Importantly, 
NRs were not fragmented or dissociated.  
 
3.2.2.7. Day in vitro 23: dissociation of free-floating late NRs and expansion 
 
At DIV 23, RA treatment was completed. Late NRs were mechanically gently dissociated to 
smaller fragments (not single cells) and, from this day on, cultured in proliferation medium for 
neurospheres. 
 
3.2.2.8. Days in vitro 23 - 180: expansion and freezing of neurospheres 
 
From DIV 23 on, 75% of the proliferation medium was replaced twice per week. In order not to 
expose early neurospheres to stressful conditions, they were allowed to settle down by gravity 
and only 75% of the supernatants was centrifuged at 1000 rpm for 5 minutes. Until day 60, 
neurospheres grew very slowly. Although medium was changed twice a week, passaging was 
performed only every 2 weeks. During the first 60 - 80 days of expansion, neurospheres were 
transferred to a new T25 flask if adherent colonies were observed, as neurosphere adhesion 
augments their neurogenic potential. When neurospheres reached a sufficiently high density, 
they were transferred to low-adhesion T75 flasks for further expansion until DIV 180.  
Density permitting, but generally once a week, neurospheres were frozen. Neurospheres were 
centrifuged at 1000 rpm for 5 minutes, gently resuspended in 900 µL of bNM without 
dissociation and transferred to 1 mL cryotubes. 100 µL DMSO was added immediately prior 
freezing, cryotubes were inverted a few times and then stored at -80°C for maximum 1 week 
before being transferred to the liquid nitrogen storage unit.   
 
3.2.2.9. Days in vitro ~ 40, 50, 65, 80, 90, 100, 180: immunocytochemical 
analysis of neurospheres 
  
Early and late neurospheres were plated on PLO/laminin coated chamber slides or 24-well 
plates and fixed for at least 10 minutes with a 4% PFA solution 2 hours later. After 3 washing 
steps with TBS for 5 minutes and incubation with blocking buffer for 30 minutes at RT, 
neurospheres were incubated overnight at 4°C with antibodies to Sox2, nestin (NSC markers), 
vimentin (NSC and early astrocyte marker) and HoxB4 (a transcription factor expressed in the 
developing spinal cord), respectively diluted in blocking buffer. The next day, after 3 washing 
steps with TBS for 5 minutes, neurospheres were incubated for 2 hours at RT with fluorescent 
secondary antibodies and DAPI diluted in blocking buffer. After 3 additional washing steps, 
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neurospheres were stored at 4°C / in the dark. The % of immunopositive cells was calculated by 
microscopy and cell counting.    
 
3.2.2.10. Days in vitro 80 - 180: maturation of astrocyte precursors without 
FBS 
 
According to the original publication [205, 397], from day 80 up to day 180 precursor cells 
increasingly commit to the astrocytic lineage. At this point, neurospheres can be dissociated, 
plated at low density (5*103 to 2*104 cells per well of a 24 well plate) on PLO/laminin and 
differentiation can be started 1 - 3 days later. Differentiation was induced by withdrawal of 
proliferation factors and stimulation with the pro-astrocytic factor CNTF for 1 week [205, 397].  
Importantly, CNTF-containing bNM was entirely replaced every other day, as CNTF is chemically 
unstable. After 1 and 2 weeks of differentiation, differentiating precursors were fixed and 
immunolabeled as described above. Differentiation was assessed by quantifying expression of 
vimentin, GFAP (early and later astrocytic markers) and ß-III-tubulin (neuronal marker), and 
stemness and proliferation by quantifying expression of Sox2 (NSC marker) and Ki67 
(proliferation marker). The % of immunopositive cells was calculated by microscopy and cell 
counting.    
Both early (DIV ~100) and late (DIV ~180) neurospheres were not differentiating to form 
homogeneous astrocytic cultures. Therefore, the differentiation protocol was adjusted as 
follows. 
 
3.2.2.11. Days in vitro 80 - 180: maturation of “astrocyte precursors” with FBS 
 
From DIV 80 - 90, dissociated neurospheres were plated on PLO/laminin at a (low) density of 
1.5*105 per T75 flask. After a short acclimatization phase, 1% FBS was added to the proliferation 
medium and administered until the end of differentiation. NSCs were cultured as low-density 
monolayers for at least 2 weeks prior to differentiation. Following advantages were observed: 
dead cells were removed from the culture before differentiation; small aggregates were 
dissociated into single differentiating cells; single cells acquired a flat, astrocyte-like 
morphology. Whenever necessary, astrocytic precursors were passaged by adding 2.5 mL 
TripLETM Express to each T75 flask after removing the bNM. After a 3-minute incubation at 37°C, 
cells were resuspended in bNM, centrifuged at 1000 rpm for 5 minutes, counted using a 
haemocytometer and replated in a new PLO/laminin coated T75 flask (1.5*105). After an initial 
phase at low density for 1-2 passages, cells were allowed to reach confluence at each passage.     
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3.2.2.12. Days in vitro ~100 - 160: maturation of astrocyte precursors with 
CNTF, BMP2/4 and FGF1 
 
After at least 2 weeks of FBS treatment at low density, monolayer NSCs were plated at a density 
of 5*103 to 104 cells per well of a 24-well plate. The next day or at latest 3 DIV later 
differentiation was initiated by incubation with differentiation medium containing FBS and no 
additional factor or either CNTF, BMP2/4 or FGF1 (concentration: 20 ng, 10 ng each, 20 ng). 
Importantly, differentiation medium was entirely replaced every other day, as CNTF is 
chemically unstable. In addition, BMP2/4 treatment led to some NSC death, therefore an initial 
cell density of 104 per well of a 24-well plate was required.  
After 2 weeks of differentiation, differentiating precursors were fixed and immunolabeled as 
described above. Differentiation was assessed by quantifying expression of vimentin, GFAP 
(early and later astrocytic markers) and ß-III-tubulin (neuronal marker), whereas residual 
proliferation by quantifying expression of Sox2 (NSC marker) and Ki67 (proliferation marker). 
The % of immunopositive cells was calculated by microscopy and cell counting.   In addition, 
production of ECM was assessed by immunolabeling for CS-56 and laminin. ECM production was 
analyzed by microscopy, conversion of the fluorescence signal to a binary (B/W) signal and 
calculation of the area fraction per cell covered by each ECM component. Whenever possible, 
for each immunocytochemical analysis 3 - 6 fields of 3 wells of 1 - 3 independent 
differentiations were analyzed. Each well represents an individual microenvironment and is 
considered as n = 1. 
 
3.2.3. RNA extraction 
 
For RNA extraction, neurospheres were centrifuged at 1000 rpm for 5 minutes, resuspended 
directly in 250 µL lysis buffer (1% ß-mercaptoethanol in RLT buffer, RNeasy Mini Kit) and 
vortexed before immediate use or storage at -80°C. Total RNA was extracted using the RNeasy 
Mini Kit (Qiagen) and following the manufacturer’s instructions. 
 
3.2.4. cDNA synthesis 
 
RNA was reverse-transcribed to the first-strand cDNA using oligo (dT) primers and M-MLV 
Reverse Transcriptase and according the following scheme: 
 
Reagents solution I Amount BioRad thermocycler protocol 
RNA probe 
Oligo (dT) primers 
4.0 µL 
1.0 µL 
80°C for 3 min 
4°C for ∞ 
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Reagents solution II Amount BioRad thermocycler protocol 
5x MMLV reaction buffer 
MMLV reverse transcriptase, 200 U/µL 
dNTPs, 10 mM 
RNAsin, 40 U/µL  
DTT, 100 mM in H2O 
DEPC-treated H2O 
3.0 µL 
1.0 µL 
0.75 µL 
0.35 µL 
1.5 µL 
3.4 µL 
42°C for 1 hour 
80°C for 10 minutes 
4°C for ∞ 
 
3.2.5. PCR and gel electrophoresis 
 
The expression profile of neurospheres was assessed by PCR amplification of genes of interest 
either associated with positional identity or associated with glial specification, as following: 
 
Reagents  Amount BioRad thermocycler protocol 
2.5x 5-PRIME RT-PCR reaction mix  
10 µM fwd primer 
10 µM rev primer 
ddH2O 
cDNA (30 ng) 
4.0 µL 
0.25 µL 
0.25 µL 
4.5 µL 
1 µL 
95°C for 2 minutes once 
35 cycles of: 
95°C for 30 seconds  
55°C for 1 minute * 
72°C for 1 minute 
72°C for 8 minutes once 
4°C for ∞ 
* Annealing temperatures were calculated and adjusted for each primer. 
 
3.2.5.1. Gel electrophoresis 
 
1.5 g of UltraPure™ agarose were dissolved in 150 mL of 1x TAE buffer at boiling temperature. 
The agarose solution was allowed to cool down under constant stirring, and 1.5 µL EtBr were 
was added. Afterwards, the solution was poured into a gel chamber and let solidify at RT. 2 µL 
6x loading dye were added to the PCR reaction probe, and loaded for gel electrophoresis. 2-log 
DNA ladder was used to estimate amplicon lenghts, but not amplicon amounts. Electrophoresis 
was performed at 100 V for at least one hour.  
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3.2.6. Calcium imaging of maturing astrocytes 
 
3.2.6.1. Imaging procedure 
Laboratory of Prof. Dr. Hilmar Bading, Ruprecht-Karls-Universität Heidelberg 
 
To perform Ca2+ imaging, 2-week differentiated astrocyte cultures were differentiated for 2 
weeks on round 13 mm cover slips in 24-well plates. These were pre-treated with HCl at 65°C 
overnight and stored in isopropanol, then dried and coated with PLO/laminin (100 µg/mL und 
10 µg/mL) immediately prior to use. Due to a less efficient attachment on glass than on plastic 
surfaces, NSCs were plated at higher densities prior to differentiation (8*104 cells per cover slip).     
Two-three days prior to Ca2+ imaging, plates were transported to the laboratory of Prof. Hilmar 
Bading, Ruprecht-Karls-Universität Heidelberg, where the set-up was located, and allowed to 
acclimatize.  
On the day of imaging, few cover slips at one time were transferred to an empty 24-well plate, 
washed with SGG buffer and incubated with Fura-2 (1:1000 in SGG buffer) for 30-45 minutes at 
RT. After an additional washing step with SGG buffer, differentiating cells were incubated with 
SGG buffer for at least 30 minutes at RT. At this point, cover slips were placed into the imaging 
set-up’s chamber under a 40x objective and covered with 1 mL SGG buffer. Up to 13 ROIs 
corresponding to a single cell each were set. Using the Cell-R imaging software, one-frame-per-
second recordings were started at 340 nm and 380 nm in parallel, since Fura-2 is a ratiometric 
fluorophore.  
Resting Ca2+ levels were recorded for 60 seconds, then 1 mL of 200 µM ATP in SGG buffer was 
very carefully pipetted into the chamber in order to expose astrocytes to 100 µM ATP. One-
frame-per-second recordings were performed for up to 5 minutes after ATP application. 
 
3.2.6.2. Analysis  
 
The area and integrated density (ID) of 3 empty ROIs (background / noise signal) and up to 13 
ROIs per cover slip were calculated as numerical / arbitrary values per frame using ImageJ (ROI 
manager), both for 340 nm and 380 nm recordings. The total ID per frame of the 3 empty ROIs 
was subtracted from each ROIs’ ID per frame, both for 340 nm and 380 nm recordings. 
Thereafter, a 340 nm/380 nm ID ratio per frame was calculated for each ROI. The resulting 
values were plotted as curves using Prims 6 Graphpad and represent Ca2+ fluctuations over 
time. 
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3.2.7. BDNF Enzyme-Linked Immunosorbent Assay   
 
All ELISA experiments were performed together with Shengwen Liu, a medical doctor working in 
our research laboratory.  
Differentiation of PSC-derived NSCs into astrocytes was performed in PLO/laminin coated 24-
well plates with the differentiation factor of interest. FBS-containing differentiation medium 
was replaced 48 hours prior to ELISA measurements with differentiation medium without FBS 
(500 µL/well). 
On day 2 of the ELISA protocol supernatants were collected and immediately used. Cells were 
counted to determine the amount of BDNF produced by a defined number of cells.    
 
3.2.7.1. Day 1: coating of 96-well plates 
 
Rabbit anti-BDNF primary antibody was diluted in coating buffer (1:2000) and distributed into 
the 96-well plate (50 µL / well). Control wells were incubated with rabbit serum (1:4000 in 
coating buffer). Plates were incubated overnight at 4 °C in a humid chamber and on a horizontal 
shaker. 
 
3.2.7.2. Day 2: washing, blocking and incubation with cell supernatants 
 
Unbound antibody was removed by washing the wells twice with ELISA washing buffer for 10 - 
30 minutes at RT, thereafter wells were incubated with ELISA blocking buffer for one hour at RT 
and washed again twice. During this time, a purified human BDNF stock solution is diluted in 
ELISA homogenization buffer to obtain 12 solutions with a range of concentrations [pg/well: 100 
/ 66.6 / 44.4 / 29.6 / 19.8 / 13.17 / 8.78 / 5.85 / 3.9 / 2.6 / 1.73 / 0] as standard/reference curve 
to calculate BDNF concentrations of cell supernatants. Cell supernatants were diluted 1:2 in 
homogenization buffer.  
Purified BDNF solutions and diluted supernatants were added to the wells of the 96-well plate 
and incubated overnight at 4°C  in a humid chamber on a horizontal shaker.  
 
3.2.7.3. Day 3: Incubation with anti-BDNF  
 
Samples were removed and wells were washed with ELISA washing buffer at least 4 times for 15 
minutes at RT. Chicken anti-BDNF antibody (1:2500 in ELISA homogenization buffer) was then 
added to each well. The 96-well plate and incubated O/N at 4°C  in a humid chamber on a 
horizontal shaker.  
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3.2.7.4. Day 4: incubation with peroxidase-conjugated secondary antibody 
 
Chicken anti-BDNF antibody was removed and wells were washed with ELISA washing buffer at 
least 4 times for 15 minutes at RT. Peroxidase-conjugated anti-chicken IgY antibody (1:1000 in 
ELISA peroxidase buffer) was added to each well. The 96-well plate and incubated overnight at 
4°C  in a humid chamber on a horizontal shaker.  
 
3.2.7.5. Day 5: measurement of optic densities  
 
Peroxidase-conjugated anti-chicken IgY antibody was removed and wells were washed twice 
with ELISA washing buffer and twice with PBS for 15 minutes at RT. To 16 mL ELISA OPDA per 
96-well plate 8 mg OPDA and 11 µL 30% H2O2 were added immediately prior to use. 150 µL of 
this solution were added to each well. After an incubation of 5 - 30 minutes until the solution 
turned bright yellow, 50 µL of a 10% H2SO4 solution were added to stop the reaction.   
Optic densities were measured with a Tecan sunrise 96-well microplate reader at 490 nm. 
 
3.2.8.  Isolation of dorsal root ganglion neurons and co-culture with 
maturing astrocytes 
 
Differentiation of PSC-derived NSCs into astrocytes was performed in PLO/laminin coated 6-well 
plates or 12-well plates with the differentiation factor of interest. Differentiation medium was 
replaced 2 hours prior to co-culturing with differentiation medium without FBS or any 
differentiation factor, as these might have an effect on neurite growth. Only confluent and 
homogeneous cultures of astrocytes were used for co-culturing experiments.   
 
3.2.8.1. DRG isolation 
 
10 - 13-week old Fischer344 rats were deeply anesthetized. The spinal column was dissected 
and the spinal cord wash flushed out through injection of Hank’s salt solution into the spinal 
canal. Two spine halves were obtained by gently cutting dorsally and ventrally. By gently pulling 
the intra-spinal nerve endings with forceps and gently removing the dura mater surrounding 
them, DRGs were isolated from each segment of the spine along the rostro-caudal axis, 
collected into 1.5 mL Eppendorf tubes and kept on ice in Hibernate A medium.  
 
3.2.8.2. DRG digestion and plating of isolated neurons 
 
When all DRGs were collected, Hibernate A medium was removed and DRGs were washed with 
ice cold Hank’s salt solution. 500 µL of a 1:1 collagenase XI:DispaseI solutions were added and 
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incubated for 30 minutes at 37°C. To ensure that all DRGs are equally exposed to the enzymatic 
solution, Eppendorf tubes were gently turned every 10 minutes. Enzymatic digestion was 
stopped by incubation with warm DMEM/F12 medium containing 10% FBS for a few seconds. 
The FBS-containing medium was then removed and DRGs were washed with warm serum-free 
DMEM/F12 medium. Finally, DRGs are resuspended in DRG maintenance medium and 
mechanically dissociated by pipetting up-and-down through a fire-polished glass pipet. The total 
number of DRG cells, including neurons and glia, was counted and cells were plated onto 
PLO/laminin coated 6-well plates. Importantly, only 0.5 µg/mL laminin were used, since high 
concentrations of laminin lead to extensive neurite growth of dissociated DRG neurons, which 
was not needed here. Plated DRG neurons were kept in DRG maintenance medium at 37°C 
overnight and re-plated after 24 hours: thereby cellular debris and inhibitory ECM components 
such as myelin were washed away prior to plating onto differentiating astrocytes. To this end, 
DRG neurons were gently washed with warm DPBS, incubated with trypsin (0.125% in warm 
DPBS) for 2-3 minutes at 37°C, resuspended in DRG maintenance medium containing 10% FBS, 
counted and centrifuged at 1000 rpm for 5 minutes. After determining the cell number using a 
haemocytometer, up to 1.25*104 and 2.5*104 cells per well of a 12-well or 6-well plate 
respectively were plated onto differentiating astrocytes. 
 
3.2.9. Transplantation of neural stem cells and astrocytes into the rat spinal 
cord 
 
3.2.9.1. Preparation of NSCs and differentiating astrocytes 
 
Either NSCs or differentiating astrocytes were transplanted into the intact or injured spinal cord 
of fischer344 rats. 
NSCs were cultured as free floating neurospheres in proliferation medium and mechanically 
fragmented by pipetting up-and-down prior to transplantation. Importantly, they were not 
dissociated into single cells, since previous studies [228] reported higher survival of transplanted 
cells when neurospheres were transplanted as small fragments. 
Differentiation of PSC-derived NSCs into astrocytes was performed in PLO/laminin coated 6-well 
plates or 12-well plates with the differentiation factor of interest. Differentiation medium was 
replaced 2 hours prior to co-culturing with differentiation medium without FBS or any 
differentiation factor, as these might have an effect on neurite growth.  
On the day of transplantation, cells were resuspended, counted and centrifuged at 1000 rpm for 
5 minutes. The pellet was rinsed once with DPBS, and then the DPBS solution was removed 
completely until the pellet was nearly dry. The volume of the pellet was estimated and the 
remaining volume of a PBS/1% glucose solution was added to reach a concentration of 2.5*105 
to 5*105 cells/µL. Concentration of the cell solution strongly depended on cell size, since NSCs, 
especially if cultured as neurospheres, were generally very small, whereas differentiating 
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astrocytes were bigger: when resuspending astrocytes it was physically not possible to obtain a 
concentration of 5*105 cells/µL. Immediately prior to transplantation, the cell solution was 
diluted 1:2 either in  PBS/1% glucose or in a cocktail of Calpain inhibitor (Stock 100 µM, final 25 
µM) and either 9 growth/neurotrophic factors (BDNF and NT-3: stock for surgery 100 µg/mL, 
final 25 µg/mL; EGF, FGF1, FGF2, GDNF, HGF, IGF, PDGF: stock for surgery 20 µg/mL, final 5 
µg/mL) or only the differentiation factor used to induce astrocytic maturation (CNTF, BMP2/4, 
FGF1: stock for surgery 20 µg/mL, final 5 µg/mL). The stock growth factor cocktail itself was 
diluted 1:2 either in PBS/1% glucose or with fibrinogen (stock for surgery 100 mg/mL, final 25 
mg/mL) or thrombin (stock for surgery 100U/mL, final 25 U/mL), as well immediately prior to 
cell injection. 
 
3.2.9.2. Anesthesia and exposure of the C4 segment of the rat the spinal 
cord  
 
Female 12 to 14-week old Fischer344 rats weighing 140 - 180g were immunosuppressed 24 
hours before surgery by a subcutaneous injection of Sandimmun® (10 mg/kg body weight). 
Sandimmun® was administered daily until the end of the experiment. After surgery, rats 
received subcutaneous injections of Temgesic®, ampicillin and Ringer solution twice a day for 
two days. On the day of surgery, rats were deeply anesthetized, shaved at the dorso-cervical 
level and the skin was rinsed with Braunol. Animals were fixed on a stereotaxic setup. A midline 
skin cut from C2 to C5 was done with a scalpel to expose the musculature, then the paraspinous 
musculature was gently pushed aside with forceps to expose the C4 spinal cord segment and 
the opening was fixed by insertion of a retractor. The C4 segment of the spinal cord was 
thereafter exposed by laminectomy and the dura mater was disrupted either by a small cut 
(scalpel) or a small hole (syringe tip).  
 
3.2.9.3. Hemisection of the spinal cord 
 
After laminectomy and disruption of the dura mater by a small longitudinal cut, the right half of 
the spinal cord was completely sectioned using surgical microscissors. The exposed spinal cord 
segment was covered with a cut-to-fit thin 1% agarose film, thereafter the muscles were 
sutured with a sterile silk thread and the skin was clipped with suture clips.   
 
3.2.9.4. Wire knife injury of the spinal cord 
 
A retractable wire knife carrier was fixed on the stereotactic arm, then the stereotactic arm was 
fixed on the stereotactic setup. Prior to lesioning, the wire knife was carefully extruded from its 
holder in order to position it in the middle of the C4 segment (both on the rostro-caudal and on 
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a medio-lateral axis), whereby the wire knife had to be as accurately as possible perpendicular 
to the rostro-caudal axis. After insertion into the spinal cord through the hole previously 
punched into the dura mater, the depth of the wire knife carrier along the dorso-ventral axis 
was adjusted and the wire knife was slowly extruded. The extruded wire knife was slowly pulled 
towards the dorsal edge of the spinal cord, while the spinal cord was at the same time gently 
pressed towards the knife with a blunt stab in order to transect the dorsal column projections. 
This procedure was repeated until the full-length wire knife was visible underneath the dura 
mater, indicative of successful transection of the dorsal column. The wire knife was slowly 
retracted and pulled out. A representative picture of the lesion was taken to better identify it 
one week later, when cells were transplanted into the injury site. The exposed spinal cord 
segment was covered with a cut-to-fit thin 1% agarose film, thereafter the muscles were 
sutured with a sterile silk thread and the skin was clipped with suture clips.   
 
3.2.9.5. Re-exposure of the spinal cord and cell injection 
 
One week after transection of the dorsal column, the C4 segment was re-exposed as described 
above. Using the picture of the lesion, the site for injection was identified.  
The previously prepared cell solution was pipetted into a pulled glass micropipette (100 µm 
diameter), which was fixed on the stereotactic arm and connected to a Picospritzer. After 
punching a hole into the dura mater, the glass needle was carefully inserted into the spinal cord 
at the lesion site, as well as rostrally and caudally to it. Respectively ~1 µL and ~0.35 µL of the 
cell solution were injected into each site twice:  ~1.25*105 cells/µL diluted in a cocktail of 
Calpain inhibitor (final concentration: 25 µM), a specific growth/neurotrophic factor 
combination (final concentrations ranging from 5 µg/mL to 25 µg/mL) and either fibrinogen 
(final concentration: 25 mg/mL) or thrombin (final concentration 25 U/mL) respectively, for a 
total of 2 µL injection volume into the lesion epicenter and 0.7 µL injection volume rostrally and 
caudally. If PSC-derived NSCs or astrocytes were co-grafted with fibroblasts, they were cultured 
and resuspended separately at a concentration of ~2.0*105 cells/µL and 6*104 cells/µL in a 
growth factor cocktail or PBS/1% glucose respectively, then mixed 1:1 immediately prior to 
transplantation. No fibrinogen or thrombin were applied in fibroblast co-transplantation 
experiments. 
By application of 20 PSI for 5 ms, cells were injected into the lesion site at a depth of 0.8 mm, 
while the glass needle was slowly pulled upwards. When the defined volume of cell solution was 
injected, the glass needle was pulled out after a short break to avoid reflux of injected cells. The 
muscles were sutured with a sterile silk thread and the skin was stapled with suture clips.   
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3.2.9.6. Transplantation of differentiating astrocytes into the intact spinal 
cord 
 
After exposure of the C4 spinal segment as described above, ~1 µL of a ~1.25*105 cells/µL 
solution pre-diluted in a cocktail of Calpain inhibitor and a specific growth/neurotrophic factor 
combination (CNTF, BMP2/4, FGF1 or EGF/FGF2: stock for surgery 20 µg/mL, final 5 µg/mL) was 
injected directly into the intact spinal cord at a depth of 1 mm. When the defined volume of cell 
solution was injected, the glass needle was pulled out after a short break to avoid reflux of 
injected cells. The muscles were sutured with a sterile silk thread and the skin was clipped with 
suture clips.   
 
3.2.10. Perfusion and tissue analysis 
 
3.2.10.1. Perfusion 
 
Either 2 or 4 weeks after cell transplantation, rats were sacrificed and perfused. 
Prior to perfusion, rats were deeply anesthetized and fixed on a grid placed on a plastic vessel. 
Their belly was sprayed with 70% EtOH and a 1 cm transversal cut at the level of the sternum 
was done. A further, deeper small cut was done under the sternum. After cutting the diaphragm 
and opening a hole into the rib cage, the pericardium was opened up to expose the heart. A 
butterfly needle was then inserted into the left heart ventricle (1 - 2 mm depth), with particular 
care in order not to damage the septum. The right atrium was truncated by a scissor to allow 
the blood to flow out. Using a peristaltic pump, ice-cold PBS was pumped into the heart and 
consequently into the blood circulation for approximately 10 minutes. Thereby the blood was 
completely washed out and ice-cold 4% PFA was pumped into the blood circulation in order to 
fix the tissue for approximately 15 minutes. During the whole procedure particular attention 
was paid to avoid flow of air bubbles in the perfusion pipes, as their introduction into the blood 
circulation hampers the efficiency of perfusion. The brain and spinal cord were isolated and 
stored in 4% PFA at 4°C overnight. The next day the PFA was substituted with 30% sucrose, to 
avoid ice-crystal mediated damage the tissue, when the latter is frozen for cryosectioning. The 
brains and spinal cords were stored at 4°C for them to sink, ranging from 2 to 4 days at least. 
 
3.2.10.2. Cryosectioning and immunohistochemistry 
 
Once the brains and spinal cords were sunk, they were cryosectioned. 
The C2-C5 portion of the spinal cord was embedded in Tissue-TekTM, the spinal cord fragment 
was frozen by exposure to -50/-53°C. Sagittal, 35 µm thick tissue sections were obtained using a 
cryostat and stored at in TCS-filled 24-well plates (free-floating) at 4°C until further use. 
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The staining procedure began with 3 washing steps with TBS for 10 minutes and incubation with 
blocking buffer for 1 hour at RT. Tissue sections were then incubated overnight at 4°C and on a 
horizontal shaker with the following antibodies: hGFAP or hNUC (Human-specific markers) in 
combination with Ki67, Sox2, vimentin, GFAP, DCX, Neurofilament-H (NFH), CS-56 and laminin, 
respectively diluted in blocking buffer. The next day, after 3 washing steps with TBS for 10 
minutes, tissue sections were incubated for 2.5 hours at RT with fluorescent secondary 
antibodies and DAPI diluted in blocking buffer. After 3 additional washing steps, tissue sections 
were mounted on glass slides and covered with Fluoromount-G mounting solution and a glas 
coverslip, and thereafter stored at RT / in the dark. The % of immunopositive cells was 
calculated by microscopy and cell counting. To this end, whenever cell survival was high enough 
3 - 6 fields from 3 spinal cord slices from 3 animals were analyzed, for a total number of 
individual cells of x > 1000, and this was considered n = 3. However, this was not possible for all 
experiments. 
 
3.2.11. Statistics 
 
Statistical analysis was performed with Prims 6 Graphpad. No statistical analysis was performed 
if n < 3. When n ≥ 3, either a one-way or a two-way ANOVA statistical tests were performed, 
followed by post hoc testing either without correction or with a correction for multiple 
comparisons. In particular, when 3 treatment groups were compared to the ‘no factors’ control 
group within a single cell line (closed system, 3 direct comparisons), a one-way ANOVA followed 
by Fisher’s LSD post hoc test was performed. When 4 treatment groups were compared across 
cell lines (multiple comparisons), two-way ANOVA followed by Tukey’s post hoc test was used. 
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4. Results 
 
4.1. Generation of astrocytes from human pluripotent stem cells 
 
4.1.1. Neural induction and differentiation protocol 
 
To generate astrocytes from human PSCs, recently published protocols were compared [205, 
296, 397, 399, 400] and neural induction and differentiation were first performed according to 
the protocol published by Krencik et al. (Figure 4.1, left timeline) [397].  
The first attempt to replicate the protocol did not succeed. Neurospheres were expanded in the 
presence of EGF and FGF2 in bNM without B27. Under these conditions, neurospheres did not 
proliferate and each medium change or passaging attempt led to progressive loss of 
neurospheres until the culture was depleted (data not shown). The second attempt to replicate 
the protocol was performed in the presence of B27 in the bNM culture medium and led to 
expandable neurosphere cultures. Neurospheres were generated from four PSC lines: one 
human ESC line, the well-characterized HUES6 line, and three human iPSC lines, either without 
or with caudalizing RA treatment (data not shown). Of all available PSC-derived NSC lines, three 
caudalized NSC lines, referred to as HUES6, iPSC #1 and iPSC #2 were used for further 
experiments. 
 
4.1.2. Characterization and differentiation of pluripotent stem cell derived 
neurospheres 
 
At DIV 60 - 90, neurospheres were characterized by immunocytochemistry and RT-PCR (Figure 
4.2.1 A, B). Neurospheres were homogeneously immunolabeled for the NSC markers Sox2 and 
nestin, the NSC / early astrocytic marker vimentin, as well as the transcription factor HoxB4, 
which is expressed in the developing spinal cord, indicating successful caudalization of 
neuroepithelial cells (Figure 4.2.1 A) [205, 288]. Along this line, RT-PCR showed low or no 
expression of the forebrain transcription factor FoxG1, but appreciable expression of the 
caudal/spinal transcription factors HoxB4, HoxA5 and Isl1 (Figure 4.2.1 B) [288]. Since neural 
rosettes (NRs) were not treated with dorsalizing or ventralizing agents, NSCs expressed both 
dorsal (Pax3) and ventral (Nkx2.1, Nkx2.2, Nkx6.1) transcription factors [288]. Importantly, NSCs 
expressed a broad range of markers associated with the glial lineage, including the 
oligodendrocyte markers Nkx2.2, NG2, Olig1, Olig2 and PDGFR and the astrocyte-specification 
markers NFIA, NFIX, S100ß, Aqp4, Chl1 and EAAT1, also known as GLAST (Figure 4.2.1, B).  
At an early (DIV 65 - 95, passage 3 - 4) and a late (DIV 170 - 180) time-point, neurospheres were 
gently dissociated, plated on PLO/laminin and exposed to CNTF in the absence of EGF and FGF2. 
Based on the original protocol [205, 397], cells were exposed to CNTF for one week, but this 
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time was insufficient to induce astrocytic maturation. After one week, none of the 
differentiated NSC lines gave rise to a considerable amount of GFAP+ positive astrocytes (data 
not shown). Therefore differentiation was extended to two weeks throughout all remaining 
experiments. After two weeks of differentiation, neither early neurospheres (Figure 4.2.2 A) nor 
late neurospheres (Figure 4.2.2 B) gave rise to homogeneous astrocytic cultures as expected 
[205, 397], although they homogeneously expressed the early astrocytic marker vimentin. The 
GFAP+ population amounted to about 10% in HUES6- and iPSC #2-derived differentiated NSCs 
and did not exceed 30% of total differentiating cells in iPSC #1-derived NSCs (Figure 4.2.3 A). In 
contrast to previously published data [205, 397], both early and late NSCs from all lines 
generated up to 15% ß-III-tubulin+ neurons (Figure 4.2.3 B) and the overall differentiation 
potential of late neurospheres was significantly decreased (Figure 4.2.2, A, B) in both iPSC-
derived NSC lines. Surprisingly, iPSC #1-derived late neurospheres did not differentiate into 
GFAP+ astrocytes or into ß-III-tubulin+ neurons at all.  
Expression of the NSC marker Sox2 was significantly increased in DIV 170 - 180 HUES6- and iPSC 
#2-derived NSCs differentiated with CNTF (Figure 4.2.3 C), suggesting that extensively passaged 
neurospheres have a lower capacity of terminally differentiating. Expression of the proliferation 
marker Ki67 did not exceed 40% in any line and at both time points (Figure 4.2.3 D). iPSC #1-
derived late neurospheres exhibited decreased expression of Sox2 and Ki67 (Figure 4.2.3 C, D), 
but maintained homogeneous vimentin expression. Importantly, differentiating neurospheres 
did not consistently give rise to homogeneous monolayer cultures, but also included patches of 
tightly-packed Sox2+ colonies (Figure 4.2.2 A, B).  
Taken together, these results show that the original differentiation protocol by Krencik et al. 
does not lead pure astrocytic cultures under similar experimental conditions with any of the 
three different PSC lines.   
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Figure 4.1: Differentiation of PSCs into astrocytes.  
Schematic representation of the protocols to differentiate PSCs into astrocytes. First, the 
protocol by Krencik et al. was replicated (left). Due to insufficient purity of the resulting cultures, 
the protocol was modified (right): on DIV ~80 free-floating neurospheres were plated at low 
density on PLO/laminin and exposed to 1% FBS for at least two weeks prior to differentiation. 
Maturation of NSCs into astrocytes was induced by treatment with CNTF, BMP2/4 or FGF1 in 
addition to FBS. 
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Figure 4.2.1: PSC-derived neurospheres express markers associated with a glial lineage.  
(A) Representative photomicrographs of early neurospheres (DIV 60 - 80) expressing the NSC 
markers Sox2 and nestin, the NSC / early astrocytic marker vimentin and the transcription factor 
HoxB4, which is expressed by caudal/spinal precursors during neurodevelopment. (B) Total RNA 
was isolated from neurospheres to analyze expression of genes associated with positional 
identity (FoxG1, HoxB4, HoxA5, Isl1, Pax3, Nkx2.1, Nkx6.1) and glial specification 
(oligodendrocytic: Nkx2.2, NG2, Olig1, Olig2, PDGFR; astrocytic: NFIA, NFIX, S100ß, Aqp4, Chl1, 
GLAST) by RT-PCR. HUES6- and iPSC #2-derived neurospheres are shown as representative 
examples of successful neural induction and caudalization.  
Scale bar: 20 µm. A: anterior; P: posterior; D: dorsal; V: ventral.  
A B 
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Figure 4.2.2: Differentiation of PSC-derived neurospheres with CNTF for two weeks results in 
mixed cultures of astrocytes and neurons.  
Representative photomicrographs of PSC-derived (A) DIV 75 - 95 early neurospheres and (B) 
DIV 170 - 180 late neurospheres after differentiation with CNTF for two weeks. Differentiated 
cells expressed the early astrocytic marker vimentin, the astrocytic marker GFAP, the neuronal 
marker ß-III-tubulin, the NSC marker Sox2 and the proliferation marker Ki67. Surprisingly, iPSC 
#1-derived late precursors did not differentiate into astrocytes or neurons, and showed little 
Sox2 and Ki67 expression.  
Scale bar: 20 µm. 
A 
B 
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Figure 4.2.3: Quantitative analysis of differentiation and proliferation in PSC-derived 
neurospheres differentiated with CNTF for two weeks.  
Quantitative analysis of marker expression in DIV 75 - 95 early neurospheres (solid bars) and 
DIV 170 - 180 late neurospheres (striped bars) after two weeks of differentiation with CNTF. 
Cells expressed (A) the astrocytic marker GFAP, (B) the neuronal marker ß-III-tubulin, (C) the 
NSC marker Sox2 and (D) the proliferation marker Ki67. Marker expression in differentiating 
HUES6-derived (black), iPSC #1-derived (red) and iPSC #2-derived (blue) cells was quantified as 
% of DAPI
+
 nuclei. n = 3 - 6 wells / condition; asterisks indicate significant differences between 
early and late neurospheres, hashtags indicate significant differences between cell lines.  One-
way ANOVA, Fisher’s LSD post hoc; * and #: p < 0.05, ** and ##: p < 0.01, *** and ###: p < 
0.001. 
A B 
C D 
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4.1.3. Transplantation of pluripotent stem cell derived neurospheres into 
the injured spinal cord  
 
Although differentiation of neurospheres according to the protocol by Krencik et al. [205, 397] 
(Figure 4.1, left timeline) did not result in pure astrocytic cultures in vitro (Figure 4.2.2 and 
4.2.3), transplanted cells are exposed to signaling cues from the host environment and survival 
and differentiation can be drastically influenced. Therefore, to assess survival and 
differentiation in the lesioned spinal cord, HUES6-derived DIV ~130 neurospheres were 
transplanted one week after C4 lateral hemisection or wire knife lesion of the C4 dorsal column 
(Figure 4.3; Appendix table 4.2 A, B). In addition, to evaluate potential effects of growth factor 
co-delivery on cell survival and differentiation, HUES6-derived neurospheres were resuspended 
in a mix of calpain inhibitor and nine growth factors or in PBS/1% glucose at a concentration of 
2*105 – 2.5*105 cells/µl. ~5 µl were injected into the hemisectioned spinal cord, whereas ~2 µl 
were injected into the wire knife lesioned spinal cord (Appendix, Table 4.2 A) [148, 149].  
Animals received subcutaneous injections of cyclosporine A and were allowed to survive for 
four weeks as indicated. Accordingly, cell integration into the host tissue and phenotype was 
analyzed four weeks after grafting.  
HUES6-derived neurospheres exhibited moderate survival when transplanted without growth 
factors and appreciable survival when transplanted with the growth-factor cocktail. As shown in 
Appendix Table 4.2 A, HUES6-derived cells were detected in all animals that received 
neurospheres in combination with growth factors, whereas neurospheres administered in 
PBS/1% glucose survived in 5 out of 6 transplanted animals (+GF = 100% survival, (-)GF = 83% 
survival). In addition, qualitatively more cells survived when transplanted with the growth factor 
cocktail (Figure 4.4.1). However, across all animals grafted cells were located mostly at the 
lesion edge rather than the lesion epicenter. The latter was filled by infiltrating cells, potentially 
reactive fibroblasts and immune cells such as macrophages. 
To determine the phenotype of transplanted PSC-derived cells into glial and neuronal lineages, 
expression of the astrocytic marker GFAP and of the early neuronal marker DCX was quantified. 
Across all animals, over 90% of the transplanted cells differentiated into GFAP+ astrocytes, 
whereas 5-10% expressed the early neuronal marker DCX (Figure 4.4.2). This indicates that, 
although neurospheres do not fully differentiate into astrocytes in vitro (reflected by GFAP 
expression, Figure 4.2.2 and 4.2.3 A), they are robustly driven to a GFAP+ astrocytic phenotype 
by the host CNS environment. However, reflecting in vitro findings (Figure 4.2.2 and 4.2.3 B), 
neurospheres retained some neurogenic potential in vivo. No significant differences in the 
differentiation potential of transplanted neurospheres were observed between the PBS/1% 
glucose control group and the full growth factor cocktail group. Interestingly, GFAP+ astrocytes 
which were located at the lesion epicenter or at the lesion edge co-expressed vimentin, 
whereas individual cells which migrated into the surrounding host spinal cord further from the 
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lesion site only expressed GFAP and exhibited a complex cytoarchitecture (Figure 4.2 A). Since 
vimentin is expressed in early/immature astrocytes but also in reactive astrocytes, these 
observations suggest that the microenvironment at and immediately surrounding the lesion 
epicenter either prevents maturation of HUES6-derived vimentin+ early astrocytes or it 
stimulates them to acquire a reactive phenotype.  
To evaluate whether HUES6-derived astrocytes contribute to the growth-inhibitory fibroglial 
scar, tissue sections were immunolabeled with human specific GFAP and NFH antibodies. 
hGFAP+ astrocytes and NFH+ projections were closely associated, suggesting that HUES6-derived 
astrocytes were not completely growth-inhibitory. However, without appropriate control or 
comparison group, it is not possible to assess whether transplanted astrocytes were growth-
promoting or less growth-inhibitory than endogenous reactive astrocytes.  
Since a C4 hemisection of the spinal cord is a rather severe SCI model, HUES6-derived 
neurospheres were transplanted after wire knife lesion of the C4 dorsal column, a model in 
which the dura mater is only slightly damaged during the surgical procedure. Similar to the 
above described results, HUES6-derived neurospheres transplanted without additional growth 
factors exhibited only moderate survival, robust differentiation into astrocytes, but also some 
differentiation into neurons (Figure 4.5). 
Taken together, the neurogenic potential of HUES6-derived neurospheres is maintained in vivo 
independent of the lesion model, but their differentiation into vimentin+ and/or GFAP+ 
astrocytes is influenced by the injured host spinal cord. Survival is moderate and mostly 
restricted to the lesion edges. 
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Figure 4.3: Schematic representation of the surgical procedure. 
Level C4 of the rat spinal cord was injured either by lateral hemisection using a surgical micro-
scissor or by transection of the dorsal column using a wire knife. One week post-injury PSC-
derived NSCs were injected into the injury site and four weeks after transplantation animals 
were sacrificed for tissue analysis. 
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B 
Figure 4.4.1: HUES6-derived neurospheres moderately survive in the injured spinal cord. 
Representative photomicrographs of hNUC
+
 HUES6-derived progeny four weeks after C4 
hemisection and cell transplantation. HUES6-derived neurospheres were transplanted either (A) 
without additional growth factors or (B) were re-suspended  in a solution containing calpain 
inhibitor and nine growth/neurotrophic factors. 
Scale bar: 500 µm. GF: growth factor; A: anterior; P: posterior; L: lateral; M: medial.  
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A B 
C 
D 
Figure 4.4.2: HUES6-derived neurospheres mainly differentiate into astrocytes in the injured 
spinal cord. 
Representative photomicrographs of HUES6-derived progeny four weeks after C4 hemisection 
and cell transplantation. HUES6 neurospheres-derived cells expressed (A, D) the astrocytic 
markers vimentin and GFAP and (C, D) some cells expressed the early neuronal marker DCX. 
GFAP+ astrocytes (B) co-localized with NFH
+
 host neuronal projections.   
Scale bars: (A) 200 µm und 50 µm, (B) 300 µm and (C) 100 µm. (D) n = 3 - 4 animals per group. 
A: anterior; P: posterior; L: lateral; M: medial.  
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Figure 4.5: HUES6-derived neurospheres moderately survive and mainly differentiate into 
astrocytes in the injured spinal cord. 
(A) Representative photomicrographs of hNUC
+
 HUES6-derived progeny four weeks after wire 
knife lesion of the C4 dorsal column and transplantation without additional growth factors. 
Transplanted cells (B, C) mainly expressed the astrocytic marker GFAP and some cells expressed 
the early neuronal marker DCX. 
Scale bar: (A) 500 µm and (B) 100 µm. (C) n = 3 animals. 
GF: growth factor; A: anterior; P: posterior; D: dorsal; V: ventral.  
B C 
A 
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4.2. In vitro characterization of pluripotent stem cell derived 
astrocytes 
 
4.2.1. Modified differentiation protocol for the generation of neuron-free 
astrocytic cultures 
 
In vitro differentiation of NSCs into astrocytes is strongly promoted by exposure to FBS. 
As astrospheres differentiated according to the procedure described above did not result in 
pure astrocytic cultures, early (DIV 80 - 90) neurospheres were dissociated, plated on 
PLO/laminin and exposed to 1% FBS for at least two weeks prior to differentiation. In addition, 
to boost astrocytic maturation, NSCs were exposed either to FBS alone or to FBS in combination 
with CNTF, BMP2/4 or FGF1 in absence of EGF and FGF2 (Figure 4.1, right timeline), as these 
three factors are considered to be potent modulators of astrocytic maturation (paragraph 
2.5.4.). In addition, we aimed to determine whether exposure to these factors influences 
astrocytic maturation and thereby generating homogeneous astrocytic cultures more suitable 
for transplantation. 
 
4.2.2. Immunocytochemical analysis and Ca2+ imaging of pluripotent stem 
cell derived astrocytes 
 
NSCs plated at DIV ~80 at low density, pre-treated for at least two weeks with FBS in the 
presence of EGF/FGF2 and eventually differentiated for two weeks with FBS and CNTF, BMP2/4 
or FGF1 (Figure 4.1, right timeline) gave rise to neuron-free (Figure 4.6 B) cultures of maturing 
astrocytes at any time point after FBS pre-treatment (DIV ≥ 95 + two weeks of differentiation). 
About 20 - 30% of differentiating cells were GFAP+ (Figure 4.6 A, C). In HUES6-derived cultures, 
BMP2/4 treatment reduced the number of GFAP+ astrocytes. However, across all lines and 
indicated treatments, the percentage of GFAP+ astrocytes was not higher than in neurosphere 
cultures differentiated without FBS (Figure 4.2.2 and 4.2.3). 
To further confirm the astrocytic identity of differentiating cells, cellular responses to external 
stimuli were tested in DIV ≥ 95 cells differentiated with CNTF for two weeks. As previously 
described [401], in vitro stimulation of astrocytes by exposure to ATP leads to increases in 
nuclear/cytoplasmic Ca2+ concentration. Local application of ATP using a Picospritzer leads to 
single-cell Ca2+ fluctuations, which can be transmitted to neighboring astrocytes via gap 
junctions, generating so called Ca2+ waves. After loading with the Ca2+ indicator Fura-2 and 
stimulation with 100 µM ATP (by bath application), increases in nuclear and cytoplasmic Ca2+ 
concentrations were detected as increases in fluorescence intensity (Figure 4.7 A). Fluorescence 
intensity was measured every second over five minutes and plotted as a continuous intensity-
over-time curve (Figure 4.7 B). Differences between cell lines and response patterns were 
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thereby identified: differentiating astrocytes responded either with an early (< 60 seconds) or 
late (> 60 seconds) single-peak increase in intracellular Ca2+ concentration followed by a 
decrease towards threshold levels or with early or late oscillatory fluctuations, consisting of 
more than two consecutive peaks of similar or smaller amplitude. While about 50% of HUES6-
derived astrocytes responded to ATP stimulation, up to 80% of iPSC #2-derived astrocytes were 
responsive. In contrast, iPSC #1-derived astrocytes were generally unresponsive. HUES6-derived 
astrocytes primarily responded with a single-peak increase in nuclear and cytoplasmic Ca2+ 
concentration whereas iPSC #2-derived astrocytes primarily responded with oscillatory 
fluctuations (Figure 4.7 C).  
The fact that most iPSC #1-derived cells were unresponsive, while about 80% of all iPSC #2-
derived stimulated cells responded, yet both lines contain about 20 - 30% were GFAP+ cells 
(Figure 4.6) suggests that GFAP expression alone is insufficient to identify mature and functional 
astrocytes. 
In summary, iPSC #1-derived astrocytes only rarely responded to ATP stimulation, whereas 
HUES6- and iPSC #2-derived astrocytes exhibited a characteristic response pattern, indicating 
that, while morphologically similar, astrocytic lines and individual cells have a distinct functional 
profile.  
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A  B  
C  
Figure 4.6: Treatment of PSC-derived NSCs with 1% FBS and differentiation with CNTF, BMP2/4 
or FGF1 for two weeks leads to neuron-free cultures.  
(A-B) Representative photomicrographs of (A) GFAP and (B) ß-III-tubulin expression after two 
weeks of NSC-differentiation either with 1% FBS alone or with FBS in combination with the factor 
indicated. (B) NSCs did not differentiate into neurons and (C) GFAP expression was detected in 
~20 - 30% of the cells.  
Scale bar: 20 µm. n = 3 - 6 wells / condition; asterisks indicate significant differences between 
treatment and the ‚no factors‘ control. One-way ANOVA, Fisher’s LSD post hoc, *: p < 0.05. 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: PSC-derived astrocytes respond to ATP with Ca
2+ 
fluctuations.  
(A) Representative photomicrographs and (B) graphic representation of Ca
2+ 
fluctuations after 
ATP-mediated stimulation of astrocytes differentiated for two weeks with CNTF. By means of the 
Ca
2+ 
indicator Fura-2, increases in nuclear and cytoplasmic Ca
2+ 
concentrations were turned into 
changes in fluorescence intensity. (C) The distribution of „peak“ and „oscillatory“, as well as 
„early“ and „late“ responses is shown as % of the total number of analyzed cells . 
n = 3 independent experiments, n = 48 - 71 individual cells per cell line; hashtags indicate 
significant differences. One-way ANOVA, Fisher‘s LSD post hoc was performed separately for 
each response pattern; #: p < 0.05, ##: p < 0.01, ###: p < 0.001. 
A 
B 
C 
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4.2.3. Astrocytes differentiated in the presence of CNTF, BMP2/4 and FGF1 
are morphologically distinct 
 
During differentiation of PSC-derived NSCs with CNTF, BMP2/4 and FGF1, distinct morphological 
changes in all astrocytic lines were observed. To quantify these qualitative observations, 
astrocytes were labeled with the early astrocytic marker vimentin, which was expressed in 
virtually all cells (Table 4.1 and Figure 4.8 A). The perimeters of the cells were traced and the 
area was measured using ImageJ (Figure 4.8 B). This quantification revealed significant 
differences in cell size of differentiating astrocytes across treatments: HUES6-derived and iPSC 
#2-derived astrocytes treated with BMP2/4 were significantly larger, whereas FGF1-treated 
astrocytes exhibited a trend towards a decrease in cell size. In iPSC #1-derived astrocytes, only a 
small BMP2/4 treatment-dependent effect was observed suggesting that this line is not only 
unresponsive to ATP stimulation, but also less sensitive to factors inducing astrocytic 
maturation. In addition, iPSC #1-derived astrocytes had a rather round and less complex 
morphology compared to the other two cell lines.  
These results indicate that although CNTF, BMP2/4 and FGF1 lead to astrocytic cultures with a 
similar degree of GFAP expression, they can have a strong effect on cell morphology and may 
specify distinct astrocytic subtypes, in concert with previously published results [222, 387, 388]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative analysis of vimentin expression in PSC-derived astrocytes differentiated for two 
weeks. Virtually all cells express vimentin independently of the cell line or culturing conditions. 
Table 4.1: PSC-derived NSCs differentiated for two weeks homogeneously express vimentin.  
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Figure 4.8: BMP2/4 treatment leads to an increase in cell size of PSC-derived astrocytes.  
(A) Representative photomicrographs of vimentin expression and (B) quantification of the cell 
size of astrocytes after two weeks of differentiation either with FBS alone or with FBS in 
combination with the factor indicated. Scale bar: 20 µm. n = 3 - 6 wells / condition; asterisks 
indicate significant differences between each treatment applied and the ‚no factors‘ control 
group, one-way ANOVA, Fisher‘s LSD post hoc. Hashtags indicate significant differences between 
cell lines, two-way ANOVA, Tukey‘s post hoc; * and #: p < 0.05, ** and ##: p < 0.01, *** and ###: 
p < 0.001. 
A 
B 
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4.2.4. Pluripotent stem cell derived astrocytes retain Sox2 and Ki67 
expression after two weeks of differentiation 
 
As mentioned above, after two weeks of differentiation only about 20 - 30% of all cells were 
GFAP+ astrocytes.  
In order to assess to which degree differentiating cultures were im-/mature, expression of the 
NSC marker Sox2 was quantified. Across all lines between 20% and 40% of cells were Sox2+ after 
two weeks; the highest amount - up to about 80% - of Sox2+ cells was observed in FGF1-treated 
cultures across all lines (Figure 4.9). This suggests that FGF1 does not promote maturation of 
PSC-derived NSCs into astrocytes. On the other hand, a significant decrease in Sox2+ precursors 
in HUES6-derived and iPSC #2-derived astrocytes treated with BMP2/4 suggests that these cells 
are more mature, which is not reflected in increased GFAP+ expression (Figure 4.6). 
Maturing HUES6-derived and iPSC #2-derived astrocytic cultures retained a generally low 
proliferation potential: between 5% and 20% of the cells were immunolabeled for Ki67 (Figure 
4.10). HUES6-derived astrocytes were the least proliferative, with a significant increase to about 
20% in the FGF1-treated group. Strikingly, in iPSC #1-differentiating cultures about 50% of the 
cells expressed Ki67, whereby about 90% Ki67+ cells were detected in the FGF1-treated group. 
These findings suggest that FGF1 is not a potent inductor of astrocytic maturation for PSC-
derived NSCs. In addition, iPSC #1-derived cultures were highly proliferative, indicating that they 
might be robust, stress-resistant and capable of filling a lesion site after SCI or that they might 
result in uncontrolled proliferation after transplantation. 
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A 
B 
Figure 4.9: FGF1 treatment leads to an increase in Sox2 expression in PSC-derived NSCs.  
(A) Representative photomicrographs and (B) quantification of Sox2 expression in maturing PSC-
derived astrocytes after two weeks of differentiation either with FBS alone or with FBS in 
combination with the factor indicated. 
Scale bar: 20 µm. n = 3 - 6 wells / condition; asterisks indicate significant differences between 
each treatment applied and the ‚no factors‘ control group, one-way ANOVA, Fisher‘s LSD post 
hoc. Hashtags indicate significant differences between cell lines, two-way ANOVA, Tukey‘s post 
hoc; * and #: p < 0.05, ** and ##: p < 0.01, *** and ###: p < 0.001. 
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Figure 4.10: iPSC #1-derived astrocytes are highly proliferative.  
(A) Representative photomicrographs and (B) quantification of Ki67 expression in maturing PSC-
derived astrocytes after two weeks of differentiation with FBS alone or with FBS in combination 
with the factor indicated. 
Scale bar: 20 µm. n = 3 - 6 wells / condition; asterisks indicate significant differences between 
each treatment applied and the ‚no factors‘ control group, one-way ANOVA, Fisher‘s LSD post 
hoc. Hashtags indicate significant differences between cell lines, two-way ANOVA, Tukey‘s post 
hoc; * and #: p < 0.05, *** and ###: p < 0.001. 
A 
B 
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4.2.5. Pluripotent stem cell derived astrocytes produce extracellular matrix  
 
One function of astrocytes which is highly relevant in the healthy and injured CNS is the 
production of ECM components. The latter can be growth-promoting or growth-repulsive. As 
previously mentioned (paragraph 2.5.2.), reactive astrocytes up-regulate CSPGs after injury; of 
these, some can be growth-repulsive (e.g. CSPG1-3 and 7 also known as Aggrecan, Versican, 
Neurocan, Brevican, as well as Phosphacan) and some can be growth-promoting (e.g. CSPG4-5 
also known as NG2 and Neuroglycan C) [25].  
Total CSPG expression in astrocytic cultures was analyzed by immunolabeling of the CSPG core 
protein CS-56 (Figure 4.11 A, C). To quantify the amount of CSPG, the fluorescence signal was 
first converted into a binary (black and white) image and the area-fraction covered by CSPG was 
quantified and divided by the total number of cells per field, to express CSPG levels as % 
covered area per cell.  
Expression of CSPG was significantly higher in astrocytes differentiated for two weeks with 
BMP2/4 (Figure 4.11 C, D) and decreased in FGF1-treated cultures across all lines. iPSC #1-
derived astrocytes produced the lowest amount of CSPG across all treatments, however, due to 
the fact that they had to be passaged at least once during differentiation, the low amount of 
CSPG detected might underlie enzymatic digestion of the ECM. Therefore, CSPG production was 
also analyzed after one week of differentiation, before passaging was necessary (Figure 4.11 A, 
B). The same expression pattern was observed across treatments and cell lines, and iPSC #1-
derived precursors hardly produced any CSPG.  
In summary, HUES6-derived and iPSC #2-derived BMP2/4-treated astrocytes produced the 
highest amount of CSPG both after one week and after two weeks of differentiation. In addition, 
the highly proliferative and ATP unresponsive iPSC #1-derived cultures were not capable of 
producing appreciable amounts of CSPG further indicating their limited differentiation potential.  
As a second ECM component, laminin expression was examined. Laminin has been associated 
with axonal growth in the developing CNS and PNS, such as in areas of the adult CNS where 
regeneration is observed [402, 403], and is used in vitro to promote attachment and growth of 
NSCs as well as their progeny, including neurons.  
Laminin expression in maturing astrocyte cultures was mostly restricted to the HUES6-derived 
line and particularly to FBS only- or CNTF-treated astrocytes (Figure 4.12). iPSC #2-derived 
astrocytes produced low levels of laminin and in iPSC #1-derived cultures hardly any laminin 
immunolabeling could be detected. 
 
 
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: BMP2/4 treatment leads to an increase in CSPG production by PSC-derived 
astrocytes.  
(A, C) Representative photomicrographs and (B, D) quantitative analysis of CSPG expression in 
PSC-derived astrocytes after (A, B) one week and (C, D) two weeks of differentiation with FBS 
alone or with FBS in combination with the factor indicated.  
Scale bar: 20 µm. n = 3 - 6 wells / condition; asterisks indicate significant differences between 
each treatment applied and the ‚no factors‘ control group, one-way  ANOVA, Fisher‘s LSD post 
hoc. Hashtags indicate significant differences between cell lines, two-way ANOVA, Tukey‘s post 
hoc; * and #: p < 0.05, ** and ##: p < 0.01, *** and ###: p < 0.001. 
A C 
B D 
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Figure 4.12: Laminin expression is low in PSC-derived astrocytes.  
(A) Representative photomicrographs and (B) quantitative analysis of laminin expression in PSC-
derived astrocytes after two weeks of differentiation either with FBS alone or with FBS in 
combination with the factor indicated.  
Scale bar: 20 µm. n = 3 wells / condition; asterisks indicate significant differences between each 
treatment applied and the ‚no factors‘ control group, one-way ANOVA, Fisher‘s LSD post hoc. 
Hashtags indicate significant differences between cell lines, two-way ANOVA Tukey‘s post hoc;  
* and #: p < 0.05, ** and ##: p < 0.01, *** and ###: p < 0.001. 
A 
B 
102 
 
4.2.6. Pluripotent stem cell derived astrocytes produce a low amount of 
BDNF 
 
Astrocytes can exert their neurotrophic and growth-promoting effect by releasing neurotrophic 
factors including BDNF into the extracellular space (paragraph 2.5.1.5.).  
Therefore we analyzed BDNF levels in astrocytic supernatants by ELISA after differentiation for 
two weeks. The measured absolute amount was divided by the total number of cells per well to 
calculate the amount of BDNF produced by 106 cells under the same conditions (Figure 4.13). 
Across all lines, up to 300 pg BDNF/106 cells/24h was measured, with a significant increase in 
the BMP2/4 group across all cell lines. iPSC #2-derived BMP2/4-treated astrocytes produced up 
to 3 ng of BDNF, at least ten-fold more than in all other treatments across all lines.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: BMP2/4 treatment leads to an increase in BDNF production in PSC-derived 
astrocytes.  
BDNF ELISA of supernatants from PSC-derived astrocytes differentiated for two weeks with FBS 
alone or with FBS in combination with the factor indicated.  
n = 3 - 6 wells / condition; asterisks indicate significant differences between each treatment 
applied and the ‚no factors‘ control group, one-way ANOVA, Fisher‘s LSD post hoc. Hashtags 
indicate significant differences between cell lines, two-way ANOVA Tukey‘s post hoc; * and #: p < 
0.05, ** and ##: p < 0.01, *** and ###: p < 0.001. 
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4.2.7. Co-culture of two-week differentiated pluripotent stem cell derived 
astrocytes with rat primary dorsal root ganglion neurons   
 
In order to assess the direct interaction between PSC-derived astrocytes and neurons, PSC-
derived NSCs were differentiated for two weeks and then co-cultured with rat primary DRG 
neurons for 24 hours. To this end, rat primary DRGs were isolated, plated on PLO/laminin-
coated 6-well plates and re-plated 24 hours later; immediately prior to re-plating, dead cells and 
potentially inhibitory debris, such as DRG-derived myelin, were washed out. DRG neurons 
survived on astrocytic monolayers and extended numerous branched and unbranched neurites 
within 24 hours (Figure 4.14 A). To quantify the maximal in vitro pro-regenerative effect of 
astrocytic cultures, the longest neurite of each DRG neuron was measured using the NeuronJ 
plugin of ImageJ. The average length of the longest DRG neurites was significantly higher in 
HUES6-derived astrocytic co-cultures, especially in the FBS-only and CNTF groups, where 
neurites with a length of > 2000 µm were measured - a quite impressive length considering the 
short co-culturing time. FBS-only and CNTF-treated HUES6-derived astrocytes also promoted 
the highest amount of neurite outgrowth above 500 µm (Figure 4.14 C). 
iPSC #1- and iPSC #2-derived astrocytes promoted an average neurite outgrowth of 600 µm, 
whereby iPSC #1-derived astrocytes were less pro-regenerative (figure 4.14 B).  
Although it is not possible to establish a causal relationship between these two findings, a 
correlation between the laminin expression pattern (figure 4.12) and the extent of neurite 
outgrowth was observed.    
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Figure 4.14: Influence of PSC-derived astrocytes on neurite growth of DRG neurons.  
(A) Representative photomicrographs of ß-III-tubulin immunolabeled DRG neurons after 24 
hours of co-culturing on PSC-derived astrocytes differentiated for two weeks with FBS and CNTF.  
(B) Quantification of the average length of the longest neurite across cell lines and differentiation 
conditions as indicated. (C) Quantification of the incidence of neurite length-ranges across cell 
lines and differentiation conditions as indicated.   
Scale bar: 250 µm. n = 3 wells; Hashtags indicate significant differences between cell lines, two-
way ANOVA, Tukey‘s post hoc; * and #: p < 0.05, ** and ##: p < 0.01, *** and ###: p < 0.001. 
A 
B 
C 
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4.3. Transplantation of differentiated astrocytes into the intact and 
lesioned spinal cord 
 
PSC-derived neurospheres differentiated without FBS treatment and transplanted into the 
injured spinal cord (Figures 4.4.1, 4.4.2 and 4.5) modestly survived and differentiated into 
astrocytes in vivo, but the neurogenic potential observed in vitro persisted in vivo. 
We next aimed at transplanting proliferative NSCs or neuron-free pre-differentiated astrocytes 
into the injured as well as intact spinal cord to evaluate their survival and whether the set of 
phenotypical and functional properties acquired in vitro are maintained in vivo in the host 
microenvironment, allowing us to choose a pro-regenerative astrocytic subtype. 
To minimize the number of animals, only one PSC-line was chosen for the first pilot animal 
experiment and thereafter only CNTF-treated astrocytes were compared across three lines. Due 
to their high proliferation rate, we hypothesized that iPSC #1-derived NSCs might be robust 
enough to fill the lesion site after a dorsal column wire knife lesion.  
An overview of experimental groups and survival rates of this pilot experiment can be found in 
Appendix table 4.2 B. Animals received subcutaneous injections of cyclosporine A and were 
allowed to survive for two or four weeks as indicated. 
 
4.3.1. iPSC #1-derived neural stem cells hardly survive after 
transplantation into the injured spinal cord        
 
First, to evaluate the robustness of proliferating iPSC#1-derived NSCs cultured with 1% FBS and 
EGF/FGF2, we transplanted DIV ~130 - 160 proliferating precursors one week after a wire knife 
lesion of the spinal cord. To assess which paradigm is more suitable to maximize survival rates, 
prior to transplantation, PSC-derived NSCs were resuspended in a solution containing calpain 
inhibitor and either EGF/FGF2 or nine growth factors, or they were co-grafted with adult rat 
fibroblasts to assess if they can sustain PSC-derived NSCs in the lesion site; either EGF/FGF2 or 
the full growth factor cocktail were used to resuspend the cell mixture.  
In contrast to our hypothesis that proliferating NSCs may be more robust than pre-
differentiated cells, proliferating iPSC #1-derived NSCs exhibited poor survival two weeks after 
transplantation into the injured spinal cord (Figure 4.15 A-D and Appendix Table 4.2 B). 
Although hNUC+ cells were detected in almost all animals, neither the presence of a growth 
factor cocktail (Figure 4.15 B, D) nor co-transplantation with rat fibroblasts (Figure 4.15 C, D) 
resulted in appreciable differences in survival rates. 
Although the lesion site was filled in both fibroblast co-transplantation groups, the vast majority 
of the cells was hNUC- (Figure 4.15 C, D). In addition, in contrast to HUES6-transplanted 
neurospheres (Figure 4.5), only few hNUC+ cells expressed GFAP (Figure 4.15 A-D, and 
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magnifications of boxed areas). In addition, colony-like tightly-packed hNUC+ aggregates were 
detected in some animals (Figure 4.15 A, left-pointing arrow).  
Altogether, these results show that iPSC #1-derived proliferating NSCs did not show superior 
survival after transplantation into the lesioned spinal cord. Poor differentiation into astrocytes 
might be due to the short time-frame (two weeks). Therefore, pre-differentiation of astrocytes 
with CNTF, BMP2/4 or FGF1 might result in a robust astrocytic phenotype in vivo.  
 
4.3.2. iPSC #1-derived differentiated neural stem cells survive after 
transplantation into the injured spinal cord, but do not express GFAP        
 
To evaluate their survival and the stability of their phenotype, astrocytes differentiated for two 
weeks with FBS and the indicated differentiation factor were transplanted one week after wire 
knife lesion of the spinal cord. 
CNTF, BMP2/4 and FGF1 differentiation groups were included: (1) to assess the effect of the 
host microenvironment on their phenotype, (2) to evaluate whether differences observed in 
previous studies between astrocytes treated with CNTF versus BMP2/4 [222, 387, 388] were 
valid for our cultures and (3) to identify a potentially more growth-promoting astrocytic 
phenotype.  
To support growth factor specific differentiation of astrocytic subtypes and to at least initially 
counteract the influence of the host microenvironment on the phenotype of grafted cells, 
differentiated astrocytes were re-suspended in a solution containing calpain inhibitor and the 
differentiation factor (CNTF, BMP2/4 or FGF1) used in vitro prior to transplantation.  
iPSC #1-derived FGF1-treated NSCs exhibited a similarly low survival rate as proliferating 
precursors and did not result in decreased cavity formation (Figure 4.16 C and Appendix Table 
4.2 B). CNTF- and BMP2/4-treated iPSC #1-derived NSCs on the other side were able to survive 
both at the edge of the lesion and at the lesion epicenter. Some small cavities were observed, 
however the lesion site was filled with hNUC+ cells. In addition, hNUC+ cells were found within 
the host tissue rostral and caudal to the lesion site (Figure 4.16 A, B and Appendix Table 4.2 B).  
This result could be positively interpreted, since survival of transplanted cells is one of the major 
issues in stem cell-based SCI studies. However, hNUC+ cells did not express the astrocytic 
marker GFAP (Figure 4.16 A-C and magnifications of boxed areas). Considering that they had 
been pre-differentiated for two weeks, this finding was unexpected.  
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4.3.3. iPSC #1-derived differentiated neural stem cells are likely 
tumorigenic, whereas HUES6- and iPSC #2-derived differentiated 
astrocytes express GFAP and laminin in vivo 
 
As mentioned above, proliferative or differentiated iPSC #1-derived NSCs did not differentiate 
into GFAP+ astrocytes within two weeks after injection into the wire knife lesioned spinal cord. 
To test whether the duration of the experiment (two weeks) or the host microenvironment 
underlie this outcome, we transplanted iPSC #1-derived NSCs after two weeks of differentiation 
into the intact spinal cord and allowed them to differentiate in vivo for four weeks (Appendix 
table 4.2 C).  
iPSC #1-derived NSCs gave origin of tumor-like colonies of hNUC+ cells, which expanded in all 
directions in the intact spinal cord. Colonies were densely packed and confined, with only few 
hNUC+ cells migrating and integrating into the host tissue (Figure 4.17). This phenomenon was 
not observed in all animals: as shown in Appendix table 4.2, hNUC+ cells were detected only in 
33 - 50% of the animals, suggesting host rejection of transplanted iPSC #1-derived NSCs and 
clonal expansion of tumor-forming cells. To address this issue we transplanted HUES6- and iPSC 
#2-derived NSCs differentiated for two weeks with CNTF into the intact spinal cord and, after 
four weeks, we compared the three lines phenotypically (Figures 4.18.1 and 4.18.2, and 
Appendix table 4.2 C).  
Reflecting the in vitro differences between iPSC #1 versus HUES6-/iPSC #2-derived differentiated 
NSCs (Figures 4.7, 4.8, 4.10, 4.11, 4.12 and 4.14), the latter two cell lines did not give origin to 
tumor-like colonies, and the survival rate was considerably lower (Figure 4.18.1 A, C). 
Independent on the differentiation factor applied, iPSC #1-derived NSCs pre-differentiated for 
two weeks were hardly GFAP+ in vivo (Figure 4.18.1 B, magnification and figure 4.18.2 A, light 
blue bars), but ~15 - 25% of the cells were proliferative (Figure 4.18.2 B). Alarmingly, iPSC #1 
hNUC+ cells were surrounded by a thick layer of GFAP-expressing host astrocytes, suggesting 
that they might have induced an astrogliotic reaction. In contrast, HUES6- and iPSC #2-derived 
NSCs pre-differentiated for two weeks with CNTF in vitro homogeneously expressed GFAP 
(Figure 4.18.1 A, B, magnifications and Figure 4.18.2 A, grey bars). To determine if these 
astrocytes are functional, we analyzed expression of laminin, which is indicative of their ability 
to produce ECM. Laminin expression was observed in areas where hNUC+ cells were present, but 
co-localized both with hNUC+ and hNUC- host cells (figure 4.18.1 A, C, magnifications). Reflecting 
the in vitro findings (Figure 4.12), HUES6-derived astrocytes produced higher amounts of 
laminin and/or induced laminin production in host cells (Figure 4.18.2 C).  
Altogether, in vivo findings reflect in vitro observations: phenotypical differences observed 
between the three lines in vitro correlated with phenotypical differences in vivo. However, due 
to the low number of animals and the low survival rate (Appendix table 4.2), these last animal 
experiments are not sufficient to draw definitive conclusions.    
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Figure 4.15: iPSC #1-derived NSCs hardly survive in the injured spinal cord and do not 
differentiate into GFAP+ astrocytes.   
Representative photomicrographs of hNUC
+
 iPSC #1-derived progeny two weeks after 
transplantation into a C4 wire knife lesion (A) with EGF/FGF2, (B) with the full growth factor 
cocktail, (C) co-grafted with fibroblast and EGF/FGF2 or (D) co-grafted with fibroblast and the full 
growth factor cocktail. Higher magnification of boxed areas shows that transplanted cells hardly 
expressed the astrocytic marker GFAP. Scale bar: 500 µm (left panels) and 100 µm (right panels). 
GF: growth factor; A: anterior; P: posterior; D: dorsal; V: ventral.  
B 
A 
C 
D 
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Figure 4.16: iPSC #1-derived NSCs differentiated for two weeks survive in the injured spinal 
cord but do not express GFAP.  
Representative photomicrographs of hNUC
+
 iPSC #1-derived progeny differentiated in vitro for 
two weeks with the factor indicated followed by injection into a C4 wire knife lesion (A) with 
CNTF, (B) BMP2/4 or (C) FGF1. Higher magnification of boxed areas shows that very few 
transplanted cells expressed the astrocytic marker GFAP under all conditions. 
Scale bar: 500 µm (left panels) and 100 µm (right panels).  
A: anterior; P: posterior; D: dorsal; V: ventral.  
B 
A 
C 
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Figure 4.17: iPSC #1-derived NSCs differentiated for two weeks survive in the intact spinal cord 
but exhibit tumor-like growth.  
Representative photomicrographs of hNUC
+
 iPSC #1-derived progeny after two weeks of 
differentiation with the factor indicated followed by injection into the C4 level of the intact spinal 
cord (A) with CNTF, (B) BMP2/4 or (C) FGF1.   
Scale bar: 500 µm. SC: spinal cord; A: anterior; P: posterior; D: dorsal; V: ventral.  
 
B 
A 
C 
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Figure 4.18.1: HUES6- and iPSC #2-derived NSCs differentiated for two weeks with CNTF 
moderately survive in the intact spinal cord and express GFAP and laminin.  
Representative photomicrographs of hNUC
+
 (A) HUES6-, (B) iPSC #1- and (C) iPSC #2-derived 
progeny after two weeks of differentiation with CNTF followed by injection into the C4 level of 
the intact spinal cord. Magnifications show that HUES6- and iPSC#2-derived cells which express 
the astrocytic marker GFAP show immunolabeling for laminin, whereas iPSC #1-derived cells did 
not differentiate into GFAP
+
 astrocytes, but retained Ki67 expression.  
Scale bars: 500 µm and 20 µm. SC: spinal cord; A: anterior; P: posterior; D: dorsal; V: ventral.  
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Figure 4.18.2: Quantification of marker expression of PSC-derived NSCs pre-differentiated in 
vitro for two weeks after transplantation into the intact spinal cord.  
Quantification of marker expression of hNUC
+
 cells in (A, C light grey) HUES6-, (A, B light blue) 
iPSC #1 and (A, C dark grey) iPSC #2-derived progeny pre-differentiated in vitro for two weeks 
with the factor indicated and for four weeks in vivo after injection into the intact spinal cord. 
HUES6- and iPSC#2-derived cells expressed the astrocytic marker GFAP and showed laminin 
immunolabeling, whereas iPSC #1-derived cells did not differentiate into GFAP
+
 astrocytes, but 
retained a higher percentage of Ki67-expressing cells. Symbols represent individual values, bar 
represent the mean value; n = 1 - 2 as indicated.  
B A C 
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HUES6- and iPSC #1-derived NSCs cultured with EGF and FGF2 were transplanted into the (A-B) 
injured and (C) intact spinal cord in the presence or absence of a growth factor (GF) cocktail and 
with or without fibroblast co-grafting.  
iPSC #1-derived cells treated for two weeks with FBS and CNTF, BMP2/4 or FGF1 were 
transplanted into the (B) injured and (C) intact spinal cord.  
(C) HUES6- and iPSC #2-derived astrocytes treated for two weeks with CNTF were transplanted 
into the intact spinal cord. 
Appendix table 4.2: Overview of PSC-derived NSC and astrocyte transplantations into the 
intact or injured rat spinal cord. 
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5. Discussion 
 
This study aimed to define and specify a cellular substrate from PSCs which is able to restore 
tissue integrity after SCI. In particular, the generated cell graft should (1) fill the lesion site, 
thereby decreasing lesion size and cavitation, (2) take on tasks typical of adjuvant CNS cells such 
as providing physical, trophic and metabolic support to healthy, injured and spared neurons.  
Due to their multiple crucial roles in the developing, healthy and diseased CNS (paragraph 2.5 
and figure 2.4), this study focused on the specification of astrocytes.  
Human ESCs and iPSCs were chosen as primary cell sources based on their potential in the field 
of tissue engineering and regenerative medicine. In fact, since the first isolation of mouse ESCs 
more than three decades ago [404, 405] and the isolation of human ESCs almost two decades 
ago [239], developmental processes have been not only elucidated at a molecular level, but also 
recapitulated in vitro, culminating in the generation of complex tri-dimensional organoids [279-
282]. Our understanding of developmental processes has considerably advanced within the past 
few decades, allowing us to obtain basically any known/characterized somatic cell from PSCs in 
vitro.  
Based on knowledge gained from neurodevelopmental in vitro studies, I first aimed at 
generating astrocytes from human PSCs, which were thereafter transplanted into the intact and 
injured spinal cord of Fischer344 rats.  
 
5.1. Generation of astrocytes from human pluripotent stem cells 
 
5.1.1. Embryonic neural stem cells: the gliogenic switch  
 
To date, only few studies have focused on the generation of astrocytes from human PSCs [205, 
296, 397, 399, 400], since the generation of neuronal subtypes is highly relevant for modeling 
neurodegenerative diseases and developing therapeutical approaches to counteract the 
symptoms. For instance, the generation of dopaminergic neurons from PSCs is considered to be 
a promising means for the treatment of PD [406-408]. Although transplantation of neurons into 
the injured spinal cord might allow for re-connection of injured neurons and their targets 
(Paragraph 2.3.1. and Figure 2.1), they cannot survive and efficiently exert their function in the 
lesion environment without the support of an astrocytic substrate.   
The studies published by Krencik et al. in 2011 [205, 397] represented a time consuming but 
seemingly uncomplicated method to obtain large amounts of pure astrocytic populations from 
PSCs and was based on the principle of a “gliogenic switch” of developing NSCs. 
In the embryo, NSCs arise from neuroepithelial cells after the closure of the neural tube, first 
produce neuronal progenitors and then start to differentiate into glia: both in vivo and during in 
vitro expansion, embryonic NSCs have been shown to switch from an early neurogenic to a late 
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gliogenic state, which in the mouse embryo culminate at E12 and start at E18 respectively. 
Unlike astrocytes, which can differentiate from NSCs in several regions of the CNS, 
oligodendrocytes only arise from specific CNS areas, such as the ventral neural tube [208, 409].  
It was suggested that neurons produced by NSCs in vivo instruct the latter to switch to a 
gliogenic phenotype via a negative feedback mechanism [410], which is however not provided 
during in vitro expansion of NSCs. Nevertheless, an increase in gliogenic potential has been 
observed in NSCs in vitro with increasing passaging, leading to the hypothesis of an “inner clock” 
regulating this cell fate switch [409].  
Based on this knowledge and based on observations by Sun et al. about the higher neurogenic 
potential of NSCs cultured as monolayers compared to NSCs cultured as free-floating spheres 
[409], Krencik et al. proposed a method in which human PSC-derived NSCs are expanded as 
neurospheres at low-adhesion serum-free conditions for ~160 days [205, 397] and then 
differentiated into astrocytes by exposure to CNTF for one week. According to the authors, at 
this late time point the in vitro gliogenic switch had already occurred (paragraph 4.1. and figure 
4.1, left timeline). 
However, Sun et al. also pointed out that NSCs cultured as neurospheres, especially big-sized 
ones, can be more heterogeneous than NSCs cultured as monolayers, due to their three-
dimensional structure and complex cell-cell interactions. In addition, Sun et al. mentioned that 
human fetal NSCs can retain their neurogenic potential for over 200 days in vitro [409].  
Last but not least, we experienced in the laboratory of our collaborator Prof. Dr. Beate Winner, 
Friedrich-Alexander Universität Erlangen-Nürnberg, that in vitro maturation of human PSC-
derived NSCs into neurons requires up to eight weeks; therefore, only one week of exposure to 
CNTF seemed to be a very short time for the in vitro maturation of astrocytes.      
As a result, in our hands differentiation of human PSCs based on the protocol published by 
Krencik et al. led to mixed populations of neurons, astrocytes and undifferentiated cells (Figures 
4.2.2 and 4.2.3), both in DIV ~80 and in DIV ~180 neurospheres. In addition, DIV ~180 
neurospheres differentiated for two weeks had a reduced differentiation potential and 
expressed a higher % of the NSC marker Sox2 compared to DIV ~80 differentiated neurospheres 
(figure 4.2.3), suggesting that extensive passaging reduced their ability to differentiate. 
However, when DIV ~130 HUES6-derived neurospheres were transplanted into the injured rat 
spinal cord, about 90-95% of the cells differentiated into GFAP+ astrocytes, indicating that 
neurospheres can give origin to almost pure astrocytic populations when exposed to the 
complex CNS microenvironment (Figures 4.4.1, 4.4.2 and 4.5).  
Thus, in vitro differentiation may not provide sufficient cues to induce the maturation of human 
PSC-derived NSCs.  
Reflecting in vitro findings (Figures 4.2.2 and 4.2.3), HUES6-derived neurospheres gave origin to 
5-10% DCX+ young neurons in vivo (Figure 4.4.2 and 4.5). 
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In summary, these results do not demonstrate or recapitulate a “gliogenic switch” in PSC-
derived NSCs in vitro, but highlight the strong influence of the spinal cord lesion environment on 
the differentiation into astrocytes. 
 
5.1.2. Astrocytic specification by exposure to FBS and selected soluble 
factors 
 
As mentioned above, neurospheres are composed of a mixed cell population [409]. On the 
other side, although there is no specific study claiming its absolute necessity, fetal bovine serum 
has been used to culture astrocytes for almost four decades [335, 411, 412], including fetally 
derived astrocytes [222, 387, 388] and astrocytes derived from human PSCs [296, 400].  
For this reason, and to minimize cell-cell contact and heterogeneity, I dissociated DIV ~80 
human PSC-derived neurospheres, plated them at low density on PLO/laminin and exposed 
them to 1% FBS (paragraph 4.2. and figure 4.1, right timeline) for at least two weeks. Under 
these conditions, all NSCs had an equal amount of space and were equally exposed to FBS and 
to the growth factors EGF and FGF2. As a result, their cell size increased and they assumed a flat 
and more complex morphology (data not shown), possibly indicative of a preliminary astrocytic 
stage.  
When EGF and FGF2 were withdrawn and substituted by the inductors of astrocytic maturation 
CNTF, BMP2/4 and FGF1 for two weeks, human PSC-derived NSCs gave rise to cultures, which 
were neuron-free (Paragraph 4.2. and figure 4.6). Although the % of GFAP+ astrocytes was 
within the same range as in cultures differentiated from neurospheres (Figures 4.2.2 and 4.2.3 
versus 4.6), astrocytic morphology was more complex in cells exposed to 1% FBS and BMP2/4 
than in cells differentiated from neurospheres, which were generally small and bipolar (figure 
4.6).  
Up to 80-90% of iPSC #2-derived cells differentiated for two weeks with CNTF were 
electrophysiologically active in response to ATP stimulation (Figure 4.7), a feature typical of 
mature astrocytes [401, 413, 414], which is relevant for neural network activity [415]. In both 
HUES6- and iPSC #2-derived “CNTF astrocytes”, responses to ATP were either a peak in 
intracellular Ca2+ concentrations or complex oscillatory responses (Figure 4.7). This indicates 
that these astrocytes not only expressed functional P2Y ATP-sensitive receptors, but were also 
able to elicit complex responses, which were independent of their GFAP expression. According 
to these observations, GFAP expression is not sufficient to determine the amount of mature or 
functional astrocytes in PSC-derived differentiating astrocytes. On the other side, although 
~10% iPSC #1-derived cells expressed GFAP, they were mostly non-responsive, indicative of an 
immature phenotype.  
Interestingly, HUES6- and iPSC #2-derived astrocytes exhibited differences in the distribution of 
the “preferred” response pattern (figure 4.7), indicating that different astrocytic populations 
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can have specific characteristics even if they are morphologically similar, which make them 
unique.  
In summary, DIV ~80 PSC-derived NSCs plated at low density, exposed to 1% FBS for at least two 
weeks (DIV ~95) and differentiated for two weeks with CNTF, BMP2/4 and FGF1 show 
morphological and functional features of mature astrocytes, whereas neurons were depleted 
from these cultures.  
 
5.2. Characterization of human pluripotent stem cell derived 
astrocytes  
 
5.2.1. Diversity of astrocytic subtypes 
 
Although astrocytes are generally depicted as more or less homogeneous cell population 
characterized by a stellate morphology, it is now clear that astrocytes are actually highly 
diverse.  
Astrocytes are generally subdivided into protoplasmic and fibrous astrocytes, which have been 
attributed to the grey matter and white matter, respectively; however, it becomes more and 
more clear that astrocytes are morphologically and functionally at least as diverse as neurons 
[319]. It seems logical that astrocytic precursors are as sensitive as neurons to morphogens 
during development and that in response to patterning morphogens they will adopt a 
phenotype which enables them to fulfill functions specific to the microenvironment they reside 
in [319]. Accordingly, they will for instance have an appropriate size and express appropriate 
neurotransmitter receptors, cell-adhesion molecules and ECM. 
In order to generate astrocytes with a caudal / spinal identity [293], neuroepithelial cells (NRs) 
were exposed to RA for 10 days (Figure 4.1) [205, 397]. Expression of the caudal transcription 
factors HoxA5, HoxB4 and Isl1 was detected in PSC-derived neurospheres, along with the dorsal 
transcription factor Pax3 and the ventral transcription factors Nkx2.1 and Nkx6.1 (Figure 4.2.1). 
In addition, since according to literature LIF/CNTF and BMP2/4 exert their inductive effects on 
astrocytes via distinct signaling pathways [386] and FGF1 was found to promote differentiation 
of human PSCs into quiescent astrocytes [296], these three factors are possibly promoting 
specification of distinct astrocytic subtypes.  
Supporting this hypothesis, CNTF-, BMP2/4- and FGF1- treated human PSC-derived cells 
differentiated for two weeks were morphologically tremendously different (figure 4.8): BMP2/-4 
treated astrocytes were 3- to 4-fold larger than CNTF-treated astrocytes, while FGF1-treated 
astrocytes were smaller and rather bipolar. iPSC #1-derived NSCs seemed to be less responsive 
to BMP2/4 treatment, as the size of their progeny was not increased after two weeks of 
differentiation. However, FGF1-treatment led to significantly decreased cell size. 
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In addition, although cell size differences were consistent across cell lines, differences in the 
“basic” morphology of astrocytes (“no factors” group) were also observed (Figure 4.8).  
Differences in basic morphology as well as in the pattern of response elicited by ATP stimulation 
(Figure 4.7) are both indicative of the unique character of astrocytic populations. Based on 
these observations it can be concluded that even when exactly the same differentiation 
protocol is applied, it is possible to obtain comparable but not even nearly identical progeny 
from human PSCs. This can be due to a number of factors, including intrinsic factors such as 
genetic and epigenetic background and extrinsic factors such as slight technical variability, for 
instance variability in size and density of neurosphere cultures. Considering the amount of 
external signals that stem cells are exposed to within their microenvironment to acquire the 
required phenotype, it seems logical that these cells are very sensitive to slight 
microenvironmental changes in vitro.   
Astrocytes differentiated from all three human PSC lines by exposure to 1% FBS and CNTF, 
BMP2/4 and FGF1 were extensively characterized in order to identify an astrocytic subtype 
which may be more beneficial / regeneration-promoting after transplantation into the injured 
spinal cord. Based on literature, a difference in pro-regenerative potential has been suggested 
between CNTF and BMP2/4-treated astrocytes [222, 387, 388]. 
 
5.2.2. Astrocytes are proliferative 
 
Unlike other post-mitotic cells including neurons, astrocytes retain the ability to proliferate, a 
feature which was first observed more than four decades ago [416]. In particular, astrocytes 
were found to be proliferative in the intact [416, 417] as well as in the injured brain [418]. 
Proliferation in astrocytes was found to be induced by soluble factors such as EGF, but 
interestingly also by signals coming directly from adjacent neurons: neuronal removal was 
shown to induce changes in astrocytic morphology and an increase in their proliferation in vitro 
[419]. In addition, proliferation was found to be one key feature of reactive astrogliosis [420].  
On the other side, unlike neurons, astrocytes express the transcription factor Sox2, which is 
mainly associated with neural progenitors [421]. Astrocytes which express Sox2 might be less 
mature and to some extent phenotypically flexible. 
These two features confer to astrocytes a certain resistance to stressful conditions and a certain 
ability to adapt to micro-environmental changes, which neurons lack. Herewith, astrocytes are 
for instance able to readjust in response to injury, a mechanism which is crucial for the 
prevention of secondary damage.   
Thus, I analyzed expression of the NSC marker Sox2 and of the proliferation marker Ki67. 
Presence of Sox2 might partially explain why only ~20-40% of PSC-derived astrocytes expressed 
the astrocytic marker GFAP. After two weeks of differentiation, expression of Sox2 amounted to 
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~20-40% across all lines, with a significant decrease in HUES6-derived and iPSC #2-derived 
BMP2/4-treated astrocytes and a significant increase to ~80% in FGF1-treated cells across all 
PSC lines (Figure 4.9).  
These results suggest that expression of Sox2 is a shared feature of different astrocytic lines. 
Correlating with their increased cell size and complex morphology, PSC-derived BMP2/4-treated 
astrocytes might be more mature and at the same time less resistant to stressful conditions. In 
fact, as mentioned in paragraph 3.2.2.12, PSC-derived NSCs differentiated with BMP2/4 had to 
be seeded at two-fold density prior to differentiation due to their lower survival rate. In 
contrast, correlating with their decreased cell size and less complex morphology, PSC-derived 
FGF1-treated astrocytes are likely less mature but possibly more resistant to stressful 
conditions. This specific finding is in contrast with findings published by Roybon et al., who 
stated that human PSC-derived FGF1-treated astrocytes have features of mature quiescent 
astrocytes [296]. 
Expression of the proliferation marker Ki67 was generally low in HUES6- and iPSC #1-derived 
astrocytes, reaching about ~20%. Again, Ki67 immunolabeling showed a trend towards and a 
significant decrease in BMP2/4-treated HUES6- and iPSC #1-derived astrocytes, supporting the 
hypothesis that these astrocytes are more mature. FGF1 treatment induced a significant 
increase in Ki67 expression in HUES6- and iPSC #1-derived astrocytes, again in contrast with the 
hypothesis that FGF1 induces a mature quiescent astrocytic phenotype (Figure 4.10) [296]. 
Surprisingly and quite astonishingly, proliferation in iPSC #1-derived differentiating cells 
amounted to ~50-90%, correlating with their lower sensitivity to BMP2/4 (Figure 4.8) treatment 
and lack of electrophysiological activity in response to ATP (Figure 4.7). This finding may reflect 
the robustness of this cell line, which may be of advantage after transplantation into the injured 
spinal cord. However, as it is known that iPSC-derived progeny may rise to tumors, high Ki67 
expression might also be indicative of uncontrolled proliferation and propensity to form tumors 
in vivo. Indeed, residual proliferation was detected in iPSC #1-derived NSCs differentiated for 
two weeks in vitro and for four weeks in vivo in the intact spinal cord (Figure 4.18.1 and 4.18.2), 
which likely underlies the resulting formation of tumor-like colonies (figure 4.17).    
 
5.2.3. Astrocytic extracellular matrix in health and injury 
 
The ECM is an ensemble of extracellular molecules which provide not only a physical substrate 
for attachment and cohesion of cells, but also signaling cues, which can regulate cell survival, 
proliferation, growth, progression along their lineage and migration. In the CNS, ECM molecules 
can be produced by endothelial cells, microglia, macrophages, pericytes, oligodendrocytes, 
neurons and astrocytes. Astrocytes, in particular, are able to secrete a wide range of ECM 
molecules including agrin, brevican, collagen IV and VIII, decorin, fibronectin, glypican, laminin, 
neurocan, phosphacan, syndecan, tenascin-C, thrombospondins and versican [28]. Changes in 
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ECM composition are crucial in the CNS response to traumatic injury: (1) the barrier produced 
by glial scarring cell is able to confine the lesion environment and to protect the surrounding 
tissue from secondary damage; (2) signaling ECM cues may serve as attractors for astrocytes, 
fibroblasts and immune cells; (3) signaling ECM cues promote proliferation, de-differentiation 
and re-differentiation in cells residing around the injured area.  
As members of the CSPG family, aggrecan, versican, neurocan, brevican, known as CSPG1-3 and 
7, as well as phosphacan, are upregulated after SCI and represent a growth inhibitory barrier for 
axon growth. In fact, enzymatic digestion of CSPGs with ChABC has been extensively used in 
animal models of SCI to promote regeneration [35, 39, 42, 44, 48]. However, complete ablation 
of the glial scar has been shown to have deleterious effects on the regenerative potential after 
SCI, pinpointing its importance for recovery after injury. Moreover, not all CSPG family members 
are growth inhibitory: NG2 and Neuroglycan C, known as CSPG 4 and 5, can be growth 
promoting [25]. The growth-inhibitory CSPGs neurocan and phosphacan, the growth-promoting 
CSPG NG2 as well as the above mentioned HSPGs glypican and syndecan have been detected in 
the ventricular zone of the embryonic brain and have been associated with regulatory functions 
within the NSC niche and with the formation of neural networks [422]. As an example, a 
phosphacan short isoform has been associated with neuronal differentiation, myelination and 
neurite outgrowth of cortical neurons [423].    
Laminin, on the other side, is an ECM molecule, which has been associated with axonal growth 
in the developing CNS and PNS. Developing neurons have been shown to elongate along 
laminin-expressing cells until the completion of axonal outgrowth, when laminin declines in the 
extracellular space. In the adult CNS, axonal sprouts were found in close association with 
laminin expressing astrocytes after SCI, suggesting that laminin does not only play a role in 
embryogenesis but also in the pro-regenerative response to injury [402]. One decade later it 
was shown that growth-modulating ECM molecules, such as collagen IV, fibronectin and laminin 
co-localize with infiltrating Schwann cells, but not with astrocytes in the injured human spinal 
cord [424]; however laminin co-localizes with GFAP+ glial processes and with regenerating axons 
in other model systems, such as fish [425]. In addition, laminin is a key player in the 
regenerative response after PNS injury [426].  
Historically, in the astrocytic scar formed after SCI, laminin has been suggested to mediate axon 
growth, whereas CSPGs have been associated with inhibition of growth [427]. To assess if 
human PSC-derived astrocytes differentiated for two weeks with 1% FBS and the factors 
indicated are (1) functional in terms of their ability to produce ECM and (2) potentially growth-
promoting or growth-inhibitory, expression of laminin and of the CSPG core protein CS-56 were 
analyzed.  
While the electrophysiologically inactive, highly proliferating iPSC #1 derived differentiating 
NSCs were generally not able to produce considerable amounts of ECM, HUES6- and iPSC #2-
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derived astrocytes produced CSPGs, especially if treated with BMP2/4 (Figure 4.11). These 
observations (1) indicate that PSC-derived astrocytes exhibit functional properties of mature 
astrocytes, (2) support the hypothesis that BMP2/4-treated astrocytes are more mature 
(Paragraph 5.1.2. and Figures 4.9 and 4.10) and (3) suggest that BMP2/4-treated astrocytes are 
potentially growth-inhibitory.  
Laminin expression was detected mainly in HUES6-derived astrocytes, especially in the “no 
factors” and CNTF groups, and to some extent in iPSC #2-derived astrocytes (Figure 4.12). These 
observations (1) confirm the ability of PSC-derived astrocytes to produce ECM components 
relevant for the modulation of axon growth, (2) suggests that HUES6-derived CNTF-treated 
astrocytes might be growth-supportive and (3) again shows that PSC-derived astrocytic cell lines 
are functionally comparable but not identical.   
Interestingly, the intrinsic capacity of PSC-derived CNTF-treated astrocytes to produce laminin 
was maintained in vivo after transplantation to the intact spinal cord (Figure 4.18.1 and 4.18.2), 
whereby differences in laminin expression between HUES6-derived versus iPSC #2 derived 
astrocytes in vivo reflected the in vitro expression pattern. This finding suggests in vitro features 
of PSC-derived astrocytes are intrinsic and can be maintained in a complex microenvironment. 
Close observation of the laminin expression pattern in vivo (Figure 4.18.1) revealed that (1) 
laminin expression was confined to the region where hNUC+/GFAP+ cells were present, but (2) 
laminin was also expressed in hNUC- host cells within this specific area. This interesting finding 
suggests potential graft-host cross interactions, whereby transplanted PSC-derived astrocytes 
are able to induce phenotypical changes in host astrocytes. 
Since HUES6- and iPSC #2-derived astrocytes were not transplanted into the injured spinal cord 
within this thesis and since the exact composition of the CSPG ECM component was not 
characterized in detail in vitro (incidence of growth-inhibitory versus growth-promoting CSPGs), 
it cannot be determined at this point if PSC-derived astrocytes, for instance CSPG-expressing 
BMP2/4-treated astrocytes versus laminin-expressing CNTF-treated astrocytes, differ in their 
growth-promoting potential. 
 
5.2.4. BDNF-mediated stimulation of axonal extension 
 
As previously described (paragraph 2.5.1.5), astrocytes are able to process the immature form 
of BDNF, pro-BDNF, to mature BDNF, which promotes axonal outgrowth and dendritic 
branching [372]. Due to this property, BDNF has been administered in numerous pre-clinical 
studies of SCI to promote regeneration and sprouting, either by viral delivery or by genetic 
modification of cells, which served as biological mini-pumps after transplantation into the lesion 
site [428]. In order to assess if human PSC-derived astrocytes are naturally able to serve as 
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BDNF-producing mini-pumps without further genetic manipulation, BDNF production was 
analyzed by ELISA in supernatants of PSC-derived NSCs differentiated for two weeks.  
The amount of BDNF produced by PSC-derived astrocytes was relatively low. While across all 
conditions and cell lines the amount of BDNF was hardly detectable, it reached up to 3 ng 
produced by one million cells within 24 hours in BMP2/4-treated cells across all lines (figure 
4.13).  
Again, this might be indicative of a more mature phenotype in PSC-derived cells differentiated 
with BMP2/4. However, whether such small amounts of BDNF can have effects on axonal 
outgrowth in vivo remains to be determined, especially considering the low survival rate of PSC-
derived NSCs and astrocytes after transplantation (Figures 4.4.1, 4.4.2, 4.5, 4.15, 4.18.1 and 
Appendix Table 2). 
 
5.2.5. Direct interaction between astrocytes and DRG neurons in vitro                
 
All findings mentioned so far are indicative of phenotypical differences among astrocytic 
subtypes, both dependent on treatment with a specific factor and on the PSC-line of origin; 
however their predictive value in terms of pro-regenerative potential is only valid if their effect 
on axonal growth is directly assessed.  
To address this issue, their effect on axonal growth was tested in an in vitro-ex vivo system: 
primary DRG neurons, which extend an axonal branch into the PNS and a sensory ascending 
branch into the CNS, were co-cultured on homogeneous layers of PSC-derived astrocytes. 
Mirroring the laminin expression pattern, neurite extension was highest in DRG neurons co-
cultured on HUES6-derived astrocytes differentiated with 1% FBS alone or in combination with 
CNTF (figure 4.14). However, whether this correlation is causal has not been demonstrated in 
this study. 
On the other side, CSPG expression did not seem to have a big impact on neurite outgrowth. 
Lower neurite extension was observed in DRG neurons co-cultured on HUES6-derived BMP2/4 
treated astrocytes compared to “no factors”- or CNTF-treated astrocytes, however this was not 
the case in iPSC #2-derived astrocytes, where neurites reached an average length of 600 µm in 
all groups.  
Although this technique (co-culturing) is the only experiment of this study that directly 
addresses the interaction between astrocytes and axotomized neurons, it has several 
limitations. First of all the absence of a “control” condition: a “PLO/laminin control” could not 
be used due to the fact that our astrocytic cultures are plated on a substrate whose initial 
laminin concentration is twenty-fold higher than the concentration normally used to culture 
DRG neurons. Plating DRG neurons on 10 µg/mL laminin does not represent an appropriate 
control: during the two weeks of differentiation the initial concentration of laminin has likely 
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decreased due to detachment from the plastic surface and to astrocyte-mediated digestion or it 
has increased due to astrocyte-mediated deposition. For this reason, only neurites which were 
on top of astrocytes or astrocytic processes were included in the analysis.  
Another possibility would have been to co-culture DRG neurons on another cellular substrate, 
such as human BMSCs or fibroblast, or rat primary astrocytes. The first two cell types are not of 
interest, since the aim of this study is not to transplant BMSCs or fibroblasts, but to create a 
cellular substrate of neural identity. Rat primary astrocytes are, on the other side, obtained 
from the brain of new born rats and have therefore neither the appropriate age nor the 
appropriate caudal phenotype.  
Therefore, this experiments aims at comparing PSC-derived astrocytic populations in a closed 
system: it is not possible to say if PSC-derived astrocytes are generally more or less growth-
promoting compared to spinal cord-residing astrocytes, but it is possible to select the astrocytic 
population with the highest pro-regenerative potential among the cell lines and treatments 
analyzed.  
An additional limitation of this experiment is due to the unique character of DRG neurons. It is 
known that their peripheral branch is able to regenerate after PNS insult, but their central 
branch has a limited ability to re-grow in response to CNS injury. In this co-culture experiment it 
is not possible to say if the longest neurite of a DRG neuron is a dendrite or an axonal projection 
and more importantly it not possible to say if the axonal projection is a central or a peripheral 
branch. Again, the use of alternative primary neurons would not necessarily have been of 
advantage; hippocampal neurons, which are relatively easy to isolate, are not spinal neurons or 
motor neurons and therefore do not represent a target population.  
In summary, DRG co-cultures represent a closed system to roughly evaluate the effect of 
different classes of astrocytic populations on axonal outgrowth of from a more general point of 
view.     
 
5.3. Transplantation of pluripotent stem cell derived neural stem cells 
and astrocytes into the spinal cord  
 
5.3.1. Animal models of spinal cord injury 
 
SCI leads to an extremely complex series of molecular and cellular events and his extremely 
diverse in terms of type and severity of injury as well as of region affected. First animal models 
of SCI date back to over a century ago [429] and have since then considerably contributed to our 
understanding of SCI, from molecular mechanisms to neurological outcome.  
Obviously, non-human primates constitute the animal model closest to humans; however size 
and longevity of “old-world” primates is a big limiting factor for pre-clinical studies, as these 
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only allow small studies, in which few experimental conditions can be tested. On the other 
extreme, rodents are easy to house and allow large pre-clinical studies. Hereby, mice are a 
powerful tool for genetic studies due to the availability of thousands of transgenic lines, but rats 
represent the preferred animal model of SCI due to the functional, electrophysiological and 
morphological similarities with human SCI [430].  
The next question is, which segment of the spinal cord should be injured. Complete transection 
of the spinal cord at thoracic levels will lead to complete and permanent loss of hindlimb 
function, as well as of bowel and bladder control. The advantage of this model is that axon 
growth and functional improvement can only be attributed to true regeneration and not to 
sprouting or compensatory mechanisms. However, cervical models of SCI, including the models 
presented in this study, are becoming more and more relevant due to epidemiological data 
which indicate that more than 50% of SCI patients have injuries in the cervical spine, whereby 
the most common segments affected are C5, C4 and C6 [431, 432]. Accordingly, throughout this 
study the injury was applied at cervical segment 4 (Figure 4.3). Lateral hemisection of the spinal 
cord at C4 is a more severe model of SCI that has been used in previous studies to evaluate 
transplants of fetal spinal cord tissue or PSC-derived NSCs [148, 149]. Thus, this was the first 
model of choice for the present study (Figures 4.3, 4.4.1 and 4.4.2). Inspired by the publications 
by Lu et al., a cocktail of calpain inhibitor and nine growth factors, as well as fibrinogen and 
thrombin, were used to support the survival of HUES6-derived neurospheres (Figure 4.4.1). 
Despite the possibility to directly compare injured and healthy fibers within the same animal, 
hemisection models are not reflecting human SCI. As an example, to perform a hemisection of 
the spinal cord, the integrity of the dura mater is disrupted but a longitudinal cut of several 
millimeters, whereas the dura mater usually remains intact in human SCI. Other possible models 
of SCI are contusion, compression, distraction, dislocation, full or partial transection and 
chemical models [430]. Although contusion would have been a model that is well established in 
our laboratory and closest to human SCI, wire knife transection of the dorsal column, i.e. 
transection of CST projections, was chosen for this study (figures 4.3, 4.5, 4.15, 4.16 and 
appendix table 2). In this animal model, the dura mater is not disrupted during the injury, cysts 
typical of contusive SCI models develop, a well-characterized neuronal tract is transected, a 
feature which is useful to address regeneration, and spinal cord injured rats do not exhibit 
drastic loss of neurological function, which makes post-surgical animal care easier. A big 
disadvantage of this animal model is that it is more difficult to assess neurological 
improvements due to the small functional deficits. Nevertheless, since survival and 
differentiation in the lesioned spinal cord was a first parameter to analyze, the use of a 
neurologically relevant model of SCI was not a priority.  
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5.3.2. Survival of pluripotent stem cells derived neural stem cells and 
astrocytes in the spinal cord  
 
Survival of grafted cells is one of the major issues leading to the current low efficacy of cell 
transplantation studies in SCI. Although they are robust, proliferative and expandable in vitro, 
once transplanted into the lesioned spinal cord, NSCs or their more differentiated progeny are 
exposed to a multiplicity of challenging environmental cues (Paragraph 2.2.1.), which they do 
not have to cope with in vitro. These stressful conditions severely reduce their survival rate. To 
promote survival of PSC-derived NSCs, we therefore provided two additional factors. On one 
side, cells were resuspended in a solution containing thrombin or fibrinogen immediately prior 
to injection and delivered separately; known from studies on blood coagulation, thrombin 
cleaves fibrinogen to fibrin monomers and fibrinopeptides A and B; fibrin protein chains then 
polymerize and crosslink to establish the framework of a thrombus or blood clot [433]. The 
consequent gelation provides a physical substrate for the transplanted cells, impeding their 
dispersion. On the other side, based on studies published by Lu et al. [148, 149], cells were 
resuspended in a solution containing calpain inhibitor, which counteracts calpain-induced cell 
injury and death [434, 435], and nine additional growth- and neurotrophic factors. 
Indeed, survival of HUES6-derived neurospheres was qualitatively higher if the cells were 
resuspended in the full growth factor cocktail prior to transplantation (Figure 4.4.1), whereby 
cells generally did not survive at the lesion epicenter but rather at the edge of the lesion (Figure 
4.4.1 and 4.5). After transplantation into the wire knife lesioned spinal cord without additional 
growth factors, HUES6-derived neurospheres were not able to fill the cyst(s), but survived at the 
lesion edge or within areas of spared tissue proximal to it, where they could provide a growth-
promoting substrate for regenerating or sprouting projections (Figure 4.5). The effects of the 
growth factor cocktail did not seem to lead to a qualitative improvement in cell survival in later 
experiments: iPSC #1-derived NSCs cultured as monolayers in the presence of 1% FBS and then 
transplanted with or without fibroblasts, respectively, or with or without growth factor cocktail 
were not able to survive in the wire knife-lesioned spinal cord, and qualitative differences in cell 
survival were not striking (Figure 4.15). In contrast, iPSC #1-derived NSCs differentiated as 
monolayers in the presence of 1% FBS plus CNTF, BMP2/4 or FGF1 and then resuspended in a 
solution containing calpain inhibitor and their respective differentiation factor exhibited a much 
better survival: CNTF- and BMP2/4-treated iPSC #1-derived cells survived at the lesion epicenter 
and reduced cyst size compared to all other conditions within the same experiment (Figure 4.16 
versus 4.15), suggesting that the use of the full growth factor cocktail does not necessarily play a 
major role.  
Transplantation into the intact spinal cord led to some unexpected observations. First, survival 
of HUES6- and iPSC #2-derived astrocytes was generally low although the host environment was 
less challenging (Figure 4.18.1), and hNUC+ cells were detected only in 50-75% of the animals 
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(Appendix Table 2). Second, while hNUC+ iPSC #1-derived NSCs differentiated for two weeks the 
factors indicated were observed in 75-100% of all wire knife injured animals, they were 
detected in only 33-50% of the intact animals (Appendix Table 2). When detected, they led to 
tumor-like colony formation. One possible explanation is that the host environment is rather 
capable to reject the xenograft while intact, and that iPSC #1-derived NSCs, which survive this 
rejection are robust enough to form a tumor via clonal expansion.  
Generally, survival of grafted cells in one big issue, which needs to be addressed to improve 
therapeutical approaches based on cell transplantation. Several options are available, of which 
few were adopted in this study: (1) delivery of ECM molecules such has fibrin, (2) delivery of 
inhibitors of cell death, (3) delivery of growth- and neurotrophic factors, (4) co-transplantation 
with cells which are more robust, such as fibroblasts or BMSCs, (5) inclusion in a stable 
biomaterial. However, these aspects need to be fine-tailored. For instance, delivery of 
fibrinogen and thrombin is useful to provide an initial physical substrate for the transplanted 
cells, but does not provide the supportive signals of CNS ECM. Accordingly, specific CNS ECM 
compositions could be identified and co-delivered to specifically enhance the survival of 
transplanted cells or to enhance regeneration of injured projections. Recent studies have 
started to address this issue by comparing the effect of selected ECM molecules on NSC survival 
and differentiation [436] and on neurite outgrowth [437, 438]. Although only recently this issue 
has been addressed in the context of CNS nerve injury [437], ECM-engineering seems worth-
while pursuing. However, delivery of ECM molecules and soluble factors is challenged by the 
rapid degradation in vivo, which does not affect biomaterials to the same extent. Co-
transplantation of non-CNS cells (fibroblasts), on the other side, did not seem to have a positive 
effect on the survival of our cells.  
In conclusion, survival of grafted cells is a high-priority, which needs to be extensively addressed 
in order to enhance the efficacy of cell-based therapeutical approaches for SCI.   
  
5.3.3. Differentiation of pluripotent stem cells derived neural stem cells 
and astrocytes in the spinal cord  
 
When PSC-derived NSCs are transplanted into the injured spinal cord they give rise to mixed 
populations of mainly neurons and astrocytes - only rarely oligodendrocytes - which vary from 
batch to batch, from animal model to animal model, as well as from laboratory to laboratory, 
strongly depending on the experimental paradigm. For instance, Nori et al. in 2011 [230] and Lu 
et al. in 2014 [148] reported that hiPSC-derived NSCs transplanted into mice and into rats gave 
rise to 50% and 70% neurons after two and three months, respectively, whereby in the first 
study only 22% of the total transplanted cells were NeuN+ after two months and in the second 
study all neurons (70%) were NeuN+ after three months. In both studies ~17% of the 
transplanted cells gave rise to GFAP+ astrocytes. Although this last finding is consistent, the two 
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studies are generally hardly comparable: (1) Nori et al. transplanted human iPSC-derived 
neurospheres into NOD/SCID mice which received a thoracic contusive lesion of the spinal cord 
without additional factors and analyzed the outcome after two months, whereas (2) Lu et al. 
transplanted human iPSC-derived NSCs cultured on PLO/laminin into athymic nude rats which 
received a cervical hemisection with a full growth factor cocktail and analyzed the outcome 
after three months. In the study by Nori et al., neurons were mostly GABAergic, whereas Lu et 
al. hardly detected transmitter associated markers and, if so, GABAergic markers were absent. 
If such experimental variability exists across laboratories and studies, the phenotype of the 
transplanted PSC-derived progeny will be as well highly variable and it will be therefore difficult 
to dissect out the mechanisms, which lead to functional improvement. In contrast, if a specific 
cell population is transplanted, for instance GRPs / astrocytes [222, 387, 388], genetically 
modified astrocytes [392] or specific populations of neurons, it is possible to address specific 
aspects or tissue repair, such as restoration of tissue integrity (astrocytes) or replacement of lost 
neuronal connections (neurons).  
Based on this, the present study aimed at generating specific and well-characterized astrocytic 
populations with a stable phenotype to provide a favorable substrate for axonal regeneration 
after SCI. While PSC-derived neurospheres retained the ability to generate neurons in vitro and 
in vivo (Figures 4.2.2, 4.2.3, 4.4.2 and 4.5), PSC-derived NSCs treated with 1% FBS led to neuron-
free cultures in vitro (figure 4.6) and to nearly pure astrocytic populations in vivo (figures 4.18.1 
and 4.18.2).  
The host environment had a clear effect on the differentiation of HUES6-derived neurospheres: 
within the lesion hNUC+ cells homogeneously expressed vimentin, suggesting that they are 
either less mature or reactive, whereas they expressed only GFAP once they migrated into the 
surrounding host tissue (Figure 4.4.2). On the other hand, pre-differentiated PSC-derived 
astrocytes maintained their intrinsic capacity to produce a low or a high amount of laminin in 
the host environment (Figures 4.18.1 and 4.18.2), suggesting that some phenotypical 
characteristics acquired during in vitro specification can be maintained in vivo. This makes it 
possible, for instance, to directly compare the pro-regenerative effect of astrocytes, which 
produce laminin versus astrocytes which produce less laminin, thus allowing (1) the 
identification specific mechanisms which promote axonal outgrowth and (2) the selection of a 
specific cell population for transplantation experiments. Accordingly, while HUES6 neurosphere-
derived astrocytes were generally not growth-repulsive and co-localized with NFH+ host 
projections (figure 4.4.2), laminin expressing astrocytes pre-differentiated with CNTF might be 
more growth-promoting.  On the other side, undesired differentiation patterns in vitro or in vivo 
can be used as an exclusion criterion.  
While this study applied this principle to astrocytes, it is worthwhile to pursue experiments in a 
similar way with neurons: to form a functional “relay” it is reasonable to transplant neurons or 
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neuronal precursors which will acquire a glutamatergic phenotype. A mix of undefined, 
glutamatergic, GABAergic, serotonergic and cholinergic neurons might not be equally effective.  
 
5.4. Safety of induced pluripotent stem cells  
 
5.4.1. Tumor formation of grafted pluripotent stem cells derived neural 
stem cells 
 
Based on the fact that survival of PSC-derived NSCs is generally limited in the injured spinal cord 
(Figures 4.4.1 and 4.5), highly proliferative iPSC #1-derived NSCs were chosen for 
transplantation experiments due to their robustness. 
Transplanted iPSC #1-derived NSCs treated with CNTF and BMP2/4 showed promising survival in 
the wire knife lesioned spinal cord (Figure 4.16), but most hNUC+ cells did not express GFAP. In 
addition, in some animals small tightly-packed colonies of GFAP- cells were observed (Figure 
4.15). These alarming findings led to the hypothesis that iPSC #1-derived cells might give rise to 
tumor-like tissue, which was confirmed once the cells were transplanted into the intact spinal 
cord (Figure 4.17). Because iPSC #1-derived NSCs differentiated into other lineages (neuronal, 
oligodendroglial) did not give origin to tumors both in the wire knife lesioned and in the intact 
spinal cord (data not shown, n = 21 animals), this outcome was actually unexpected. It 
pinpoints, however, that a simple pre-evaluation of tumorigenicity [229, 439] is not necessarily 
sufficient to exclude tumor-formation by iPSC-derived progeny. The genetic and epigenetic 
background of specific iPSC-lines might confer a predisposition to give rise to a tumor, however 
this ability might be generally “invisible” and only be “waken up” by a specific treatment, for 
instance incubation with 1% FBS.  
This study provides to some extent “predictive” or inclusion/exclusion criteria for 
transplantation of PSC-derived NSCs/progeny. In almost all parameters analyzed, iPSC #1-
derived precursors significantly differed from the other two PSC-lines: they (1) were not 
responsive to ATP stimulation (Figure 4.7), (2) less responsive to BMP2/4-mediated maturation 
(Figure 4.8 and 4.9), (3) significantly more proliferative (figure 4.10), (4) hardly produced ECM 
molecules (Figures 4.11 and 4.12), resulting in (5) low support of axon outgrowth in co-cultures 
with astrocytes (Figure 4.14). As a consequence, although the fact that they were able to fill 
cysts resulting from wire knife lesion of the DC, they did not acquire the desired astrocytic 
phenotype.  
The above mentioned observations are likely not universal predictive criteria, but represent 
exclusion criteria, which can be used in future studies to better select astrocytic populations for 
transplantation after SCI.   
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5.4.2. Safe methods for the generation of induced pluripotent stem cells 
 
Despite the major effort which has been made within the past decade to establish 
reprogramming methods which do not modify the genome of de-differentiated somatic cells, 
virus mediated reprogramming is still quite commonly used. As an example, in the previously 
mentioned study by Lu et al., reprogramming was achieved via retroviral delivery of the 
Yamanaka factors [148], and the same method adopted in the laboratory of our collaborator, 
Prof. Dr. Beate Winner, Friedrich-Alexander Universität Erlangen-Nürnberg. This is the oldest 
reprogramming method and is not considered to be safe due to integration into the genomic 
DNA, which can result in one or more genetic mutations during the integration process. In 
addition, although retrovirally transduced genes are subject to epigenetic silencing during the 
reprogramming process, they can be reactivated in vivo by an unknown/unpredictable stimulus 
and enhance predisposition of iPSC-derived progeny to form tumors [440]. Indeed, one of two 
human iPSC lines we used gave origin to tumors once in vivo.  
As mentioned in paragraph 2.4.1.1., the safest methods for reprogramming somatic cells are 
delivery of the reprogramming factors via (1) RNA delivery and (2) protein delivery. Since these 
techniques were developed only recently, most laboratories might be resilient to adopt them 
due to concerns arising from lack of experience and of tools. In addition, in most cell 
transplantation studies, including this study, the scope is not to establish safe iPSC-lines. Thus, 
the fastest and more convenient iPSC source is chosen. As this study shows, this leads to 
undesired outcome, which considerably slows down the progress towards the set goals – in this 
case the generation of astrocytes for transplantation after SCI.  
Therefore, it is worthwhile to fully take into account risks associated with the reprogramming 
method of choice and to consider alternatives and preventive solutions. In fact, virus-free 
reprogramming kits are already commercially available:  Merck-Millipore recently launched the 
SimpliconTM RNA Reprogramming Technology, where a single RNA molecule encoding for four 
transcription factors allows for efficient reprogramming bypassing genomic integration.  
 
6. Conclusions 
 
The present study focused on the generation of astrocytes from human PSCs for transplantation 
after SCI. Neuron-free astrocytic cultures were successfully generated from two human PSC 
lines and their morphological as well as functional properties were extensively analyzed to (1) 
determine if generated astrocytes exhibit features of authentic/mature astrocytes and (2) to 
estimate their in vivo pro-regenerative potential. In particular, potential inclusion/exclusion 
criteria were defined, which may facilitate the choice of the astrocytic subtype for 
transplantation studies. The present study also sheds light on the necessity to use iPSC lines 
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obtained by means of non-integrative reprogramming methods in order to minimize or 
completely eliminate the risk for tumor formation.      
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